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Impacts of trogocytosis-mediated intracellular signaling on CD4+ T cell effector cytokine
production and differentiation
Chairperson: Scott Wetzel
Trogocytosis is the direct intercellular transfer of membrane and membrane
associated molecules. Unlike other passive-membrane transfer events, trogocytosed
molecules may remain fully functional and become re-expressed on the surface of the
trogocytosis-positive (trog+) recipient. This phenomenon commonly occurs between
various cell types, including those of the immune system. CD4+ T cell trogocytosis
occurs during their activation by antigen presenting cells (APC). Consequently, the
acquired molecules include ligands for signaling receptors on the T cell.
The impacts of CD4+ trogocytosis on the immune response are largely unknown.
While it has been demonstrated that trog+ cells can present trogocytosed peptide:MHC
(pMHC), and costimulatory molecules to activate other T cells, the consequences of
trogocytosis on the individual trog+ CD4+ T cell have not been studied in-depth. We
previously reported that trog+ cells perform cell-autonomous signaling by trogocytosed
ligands engaging surface receptors, referred here to as trogocytosis-mediated signaling.
This signaling led to the enhanced survival of trog+ cells in vitro compared to trog– cells
after APC removal. Because the duration of T cell signaling influences the activation,
lineage determination, and effector functionality of CD4+ T cells; trogocytosis-mediated
signaling has the potential to uniquely modulate the effector-cytokine production and
differentiation of trog+ CD4+ T cell after separation from APC.
Examining this possibility is the foundation for this dissertation. Here, I will report
my findings that: 1. Between 0-72 hrs post-separation from APC, trogocytosis-mediated
signaling drives IL-4 and GATA-3 expression, consistent with T helper type-2 (TH2)
differentiation; 3. Extended trogocytosis-mediated signaling (>72 hrs) leads to the
expression of Bcl-6, PD-1, CXCR5, and IL-21, consistent with T follicular helper (TFH)
differentiation; 4. In absence of exogenous antigen (Ag), trogocytosis-mediated
signaling is critical for the survival of the activated CD4+ T cells with high memorypotential.
Despite the critical role for CD4+ T cells in generating protective immunity in the
host, much remains unknown about the differentiation of CD4 + T cell effector subsets.
The findings here present a novel mechanism for CD4+ T cell activation and
differentiation via trogocytosis-mediated signaling, demonstrating the broad implications
for such signaling in matters of public health.
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Chapter 1
Introduction
Part I
Brief overview of the immune response
The immune system provides protection against infection from a multitude
of pathogens in a series of events orchestrated by various leukocytes (white
blood cells). The immune response is broadly broken down into three major
stages, the first being the innate immune response, followed by adaptive
immunity, and finally, long-lasting protective memory. As suggested by its title,
the innate immune response occurs rapidly (minutes to hours), and
independently of specific antigens (Ag). Cells of the innate immune system
consist of those derived from common myeloid progenitors including: neutrophils,
mast cells, basophils, and dendritic cells (DC); as well as natural killer (NK) cells,
NK T cells, γδ T cells, and innate-like lymphocyte (ILC) derived from common
lymphoid progenitors. A portion of innate cells reside in mucosal and epidermal
layers to increase detection of pathogens by proximity, while others are found in
circulation. Innate cells are activated by signaling through pattern recognition
receptors (PRR) which include toll-like receptors (TLRs), rig-like receptors (RLR)
and nod-like receptors (NLRs). These receptors detect conserved, pathogen
associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), viral
CpG DNA and RNAs, and flagellin. Signaling through PRRs triggers a rapid
inflammatory response that recruits other immune cells to the site of infection [11

3]. During this stage of the immune response, activated PAMP-stimulated
antigen-presenting phagocytes, primarily DC, mature and migrate to secondary
lymphoid organs, such as the lymph nodes. In these tissues they present peptide
fragments of phagocytosed pathogens loaded into major histocompatibility
complexes (MHC) to T cells, which are key mediators of the adaptive immune
response [4].

The Adaptive Immune Response
Unlike the innate immune response, cells of the adaptive response respond to
specific antigenic epitopes. Adaptive immunity is established by two primary
types of lymphocytes; T cells, named after the location of their development in
the thymus, and B cells which develop in the bone marrow. T cells make up the
largest proportion (40-75%) of the peripheral blood mononuclear cell population
and are broken down further into two major subsets determined by CD4 (CD4 +)
and CD8 (CD8+) surface antigens. Cytotoxic CD8+ T cells are associated with
cell-mediated immunity and the killing of infected cells, whereas the primary role
of CD4+ “helper” T cells is to mediate the activity of other cells of the immune
system through contact-dependent stimulation and cytokine secretion. B cells
secrete protective antibodies (Abs) against Ags on pathogens leading to their
neutralization, opsonization, or lysis through initiating the classical complement
cascade and antibody-dependent cellular cytotoxicity (ADCC). An important
hallmark of the adaptive immune response is the rapid clonal expansion of
responding lymphocytes resulting in an increase of several orders of magnitude
2

in the number of Ag-specific lymphocytes within days after initiation. This
expansion typically peaks 5-7 days post-infection and is followed by a rapid
contraction phase, which coincides with clearance of Ag. Once Ag has been
cleared, ~90-95% of activated lymphocytes die within a matter of days. The
remaining cells survive as long-lived memory cells, which are maintained at
relatively stable numbers for years after infection. In addition to increasing the
pool of antigen-specific cells, memory cells respond more quickly, and cells are
pre-differentiated to generate the appropriate type of response for the given
pathogen. The difference in memory responses vs primary responses is quite
significant, and the generation of stable memory populations is the basis of
modern-day vaccines.

Part II
CD4+ T cell Activation, Differentiation, and
Functions in the Immune Response
CD4+ T cell Activation
CD4+ T lymphocytes play a central role in generating protective immunity against
infection. The importance of CD4+ cells has been exemplified through the HIV
epidemic of recent decades, in which viral-depletion of CD4+ cells leads to AIDS
progression. While low CD4+ levels result in impaired immunity against infection,
aberrant CD4+ T cell responses can lead to, or exacerbate, autoimmune
diseases such as asthma [5, 6], allergy [6], multiple sclerosis [7-9], [10-12],
systemic lupus erythematosus (SLE) [13], psoriasis [14], irritable bowel disease

3

(IBD) [10, 15-20], and tumor persistence, amongst others [21]. Despite the clear
implications of T cells in modulating the immune response, the mechanisms
behind T cell activation and subsequent differentiation are still being elucidated.
Thus, additional research is necessary to develop a comprehensive
understanding of the mechanisms which govern these events and have farreaching implications in human health.

T cell Maturation and Central Tolerance
Due to the profound impact T cells have on the generation of
immune responses, T cell development is a highly regulated process. The model
for central tolerance involves two phases known as positive selection and
negative selection. Both CD4+ and CD8+ T cells arise from common progenitors
which express CD2 but are double-negative for CD4 and CD8. The majority of T
cells contain  TCR (while ~20% have  TCR). In early development, diversity
among the TCR repertoire is established through genetic recombination of DNA
encoding segments for TCR by RAG1 and RAG2 recombinases. This leads to
different variable (V) and common chain subunits to be expressed by each T cell
through recombination of V(D)J regions of the of TCR  chain, and VJ
recombination in the  chain. For a developing CD4+ T cell to progress through
primary selection, the rearranged TCR must be able to recognize self-MHCII.
This step, in positive selection is necessary due to the diversity of MHC proteins
between individuals. In fact, the Human MHC is locus (referred to as HLA, for
human leukocyte antigen) is the most polymorphic region in the human genome,
4

with >10,000 different alleles identified to-date [22, 23]. As a result, depending on
the number of different inherited alleles, an individual may express up to 6
different MHC I molecules, or haplotypes. MHC II are made up of two subunits (A
and B), and humans can express between 3 and 12 different MHC II molecules
[23]. In mice, there are three classical MHC I subclasses, (H2-K, D, L) and two
MHCII classes H-2A(I-A) and H-2E(I-E) with many haplotypes indicated by lower
case superscripts (such as I-Ek) seen later in this dissertation [24]. Endogenous
T cells in the periphery only recognize Ag presented by host MHC haplotypes,
but foreign MHC molecules have the potential to be antigenic as evident through
the large role these molecules have in transplant rejection [25, 26]. During
positive selection, if the re-arranged TCR cannot recognize self-MHC, the T cell
dies from lack of stimulation in the cortex of the thymus. Negative selection
subsequently serves to eliminate strongly self-reactive T cells which could lead to
autoimmunity. During negative selection, single-positive CD4+ T cells which have
survived the process of positive selection are exposed to a variety of self-Ag by
medullary thymic epithelial cells (mTECs), along with DCs and macrophages,
which present various self and non-self Ags. T cells that have high affinity TCR
for self-Ags are eliminated through APC-induced apoptosis, while some loweraffinity self-reactive T cells are programmed to become natural T regulatory
(nTreg). T cells that recognize self-Ag weakly, or not at all are able to exit as
mature, naïve T cells and circulate throughout the periphery. Central tolerance
results in a population of mature T cells that display, each of which displays
unique T cell receptor (TCR) specificity for a single peptide epitope (Ag). Thus,
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the population of T cells can recognize a diverse array of Ags, while limiting the
risk of unwanted immune responses by maintaining high Ag specificity.
The peptides presented to CD4+T cells are typically 12-25 amino acids
in length, and alterations in the sequence may alter the T cell response
significantly. While each TCR has a precise sequence for optimal Ag-recognition,
TCR may recognize similar peptide sequences (with ~1-3 amino-acid
substitutions) with varying affinity. Lower affinity interactions typically lead to a
weaker TCR ligation, and subsequent TCR signaling. Therefore, a single amino
acid replacement could be the difference between a T cell becoming activated or
not [27]. Due to the immense diversity among TCRs, and physiological
limitations of an organism, the frequency of circulating naïve T cells which
recognize a particular epitope is approximately 0.01%, or roughly 100 cells in a
WT mouse [28]. Peripheral naïve CD4+ T cells circulate throughout the lymphatic
system where in lymph nodes (LN), they scan 160-200 DC per hour in search of
cognate peptide:major histocompatibility complexes (p:MHC) complexes [29].

Regulation of T cell Activation
T cell activation requires TCR recognition of antigenic peptide presented
by MHC on the surface of an APC. However, recognition of cognate p:MHC and
subsequent TCR signaling alone is insufficient to drive complete activation. In
order to become fully activated, naïve CD4+ T cells require concurrent
costimulatory receptor engagement including CD28, ICOS, and CD27 [30, 31].
The critical role of costimulatory signaling in T cell activation is apparent, as in
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models where costimulatory molecules were knocked out, ~8000 TCR:pMHC
contacts were required to induce T cell activation and proliferation. In the
presence of CD28 signaling, this number was reduced to only ~1500 contacts
[32]. In typical immune settings, insufficient costimulatory signaling following Ag
recognition results in the T cell becoming hyporesponsive, or “anergic” [33].
This checkpoint limits the activation of CD4+ T cells in absence of
infection, as T cell costimulatory ligands such as CD80/CD86 (ligands for CD28),
ICOS-L, and OX40L are not highly expressed on resting APC, but become
upregulated following PRR stimulation [34]. Initial priming and activation of naïve
T cells primarily occurs through interaction with DC [35], however B cells are also
potent APC later in the response after many Ag-bearing DC have died, and Agspecific B cells have become abundant following clonal expansion [36].
Activated T cells, and memory cells have been observed to respond
more quickly to stimuli compared to naïve T cells [37], although the exact
mechanism for these differences is unclear. One study has proposed that it may
be attributed to differential signaling through Erk pathways in naïve vs previously
activated cells [38]. Other studies have found that memory cells have higher
levels of ZAP-70, thus may more readily form TCR signaling complexes than
naïve cells [39]. In addition, activated cells are significantly larger than naïve
cells, so the number of initial TCR:pMHC contact points is likely greater on
activated cells. These results suggest that CD4+ T cells that have passed through
the initial activation checkpoints and undergone clonal expansion require less
stimuli compared to naïve T cells.
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T cell:APC Interactions
The Immune Synapse
A single T cell expresses ~30,000 TCR, while an APC typically displays ~100
cognate ligands spread across the cell surface [40, 41]. In the case of naïve
CD4+ T cells, interaction between a single TCR:pMHC is insufficient for complete
activation. In order to obtain sufficient levels of TCR and costimulatory signaling
required for activation, engagement of TCR with cognate p:MHC complexes
leads to the formation of the immunological synapse [42-49]. Initiation of the
immunological synapse may be triggered by a single TCR:pMHC interaction, but
an elegant study by Irvine et al., visualized labeled peptide bound to MHC, and
found 10 or more TCR:pMHC ligands are necessary to produce a functional
immunological synapse [50]. The formation of the immunological synapse
involves the spatio-temporal rearrangement of the TCR, costimulatory molecules,
and adhesion molecules into distinct, spatially-segregated supra-molecular
activation complexes (SMACs) [48, 51-54]. This rearrangement is actindependent [55, 56], and is initiated by a rapid calcium influx initiated upon
TCR:pMHC ligation. In effector cells, TCR and costimulatory molecules such as
CD28 and ICOS, as well as the regulatory molecule CTLA-4, form connections at
multiple points of T cell:APC contact and rapidly migrate towards the center of
the SMAC forming the central SMAC (c-SMAC) [45, 57, 58]. Exclusion of
adhesion molecules from the c-SMAC leads to the formation of a proximal ring
(p-SMAC) of adhesion molecules such as LFA1-ICAM1, talin, and CD4 around
the c-SMAC, stabilizing the interaction. Surrounding the p-SMAC are larger
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molecules not directly involved in the immune synapse including CD43, CD44,
and CD45, which form a distal SMAC (d-SMAC) [42, 47].
This entire process of rearrangement typically occurs within 2-3
minutes of initial Ag recognition [31, 59]. As TCR reach the center of the cSMAC, they lose signaling capacity and become internalized by the T cell and
are either recycled to the surface or are ubiquitinated, leading to their
degradation [60]. The loss of TCR signaling and surface expression have been
proposed as a mechanism for dissociation from APC [61], though the exact
events which initiate the termination of the immunological synapse remain
unknown. The inhibitory molecule CTLA-4 which shares the APC ligands CD80
and CD86 with the T cell costimulatory molecule CD28 may also be involved in
dissociation of the immune synapse by outcompeting CD28 for shared ligands on
APC [62]. Dissociation from APC generally occurs within 15-60 minutes in
activated CD4+ cells [31]. Naive CD4+ T cells tend to maintain longer synapses
and have been commonly observed to maintain contact with APC for hours [63].
One study found that at the immunological synapse, as many as 20,000 TCRs
could be triggered by only 100 p:MHC complexes [64], showing the great
efficiency of the immunological synapse in T cell activation. Depictions of the
formation of the immunological synapse, and molecules involved are seen in
figure 1 below.
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Kinapses, and Microvessicles and the Distal Pole
Complex

Immune Kinapses
Immune synapses are not the only mechanism for T cells to receive stimulation.
Shorter-lived interactions between highly motile T cells and APC also occur and
have termed kinapses [46, 57]. Similar to the immunological synapse, kinapses
typically have a focal point of contact between the T cell and APC. However,
unlike synapses that are stable structures, with kinapses the T cell does not
arrest upon TCR signaling thus, these are unstable structures and signaling is
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intermittent [65]. From imaging experiments, signaling molecules that are found
in the cSMAC of a classical synapse appear to be localized to the trailing edge
(uropod) the migrating T cell (Fig. 1.2B).

It has been proposed that kinapses may form as opposed to a classical synapse
due to the high mobility of the T cell, or in cases where chemokine receptor
signaling is greater than signaling triggered by APC molecules [57]. Recently, an
elegant study by Akkaya et al., proposed a model for kinapse morphology
involving T cell microvilli, (small protrusions containing TCR/costimulatory
molecules on the surface of T cells) that form the main points of contact during
synapses [66].
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Kinapses are not generally associated with the activation of naïve T cells,
though it has been found multiple kinapses can result in the accumulation of
sufficient signaling to drive T cell activation [67]. Kinapses also serve as a
mechanism to maintain the activation state of already activated T cells [67].
These findings, combined with the proposed model for kinapse formation via
microvilli [66], suggest that microvilli may play a larger role than previously
thought in the context of active TCR signaling.

Microclusters
A third physically distinct signaling mechanism that has been
observed between T cell and APC involves small clusters of TCR and
costimulatory molecules such as CD28 termed microclusters. The initiation of
both the immune synapse and formation of microclusters involve filamentous like
protrusions on the T cells known as microvilli [66, 68]. Microvilli have high
concentrations of TCR, thus enabling T cells to efficiently scan the surface of
APC for pMHC complexes. Microvilli also contain costimulatory molecules such
as CD28. Microclusters form outside of the dSMAC upon microvilli binding pMHC
and costimulatory molecules on APC. These microcluster signaling complexes
provide a major source of TCR/costimulatory molecule signaling. The synaptic
microcluster morphology commonly occurs in synapses formed with DC [45],
while the classical “bulls-eye” centrally focused synapses are predominantly
formed during Ag presentation by B cells [45, 69]. Because DC play a primary
role in the activation of naïve T cells, this is a notable observation.
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One particularly interesting aspect of TCR microclusters is their unique migration
patterns. Signaling via microclusters precedes the formation of the immunological
synapse, and rapidly initiates (0-30 seconds) following engagement of TCR and
MHC and CD28:CD80/86. Microclusters generally migrate towards the cSMAC,
but also have been observed to migrate away from the immunological synapse
and localize at the distal pole of the T cell [70]. In contrast to some of the original
models of the immune synapse, where maximal signaling was predicted to occur
in the cSMAC, more recent models suggest that TCR signaling primarily occurs
in microclusters outside of the SMAC [69, 71-73]. It has been proposed that
while active signaling is occurring in the microclusters, the cSMAC mainly serves
as the location where TCR that are no longer actively signaling are endocytosed
and either recycled to the surface or ubiquinated, leading to their destruction [69,
74, 75].
Curiously, microclusters migrating away from the immune synapse have
been shown to retain active TCR signaling, despite their apparent lack of APC
contact [70, 76]. An interesting study by Hashimoto et al., observed that TCR
microclusters form a surrounding ring of adhesion molecules, and on a microscale are similar in structure to the immunological synapse [71] (Fig. 1.3).
Microclusters outside of the cSMAC have also been observed to exclude the
phosphatase protein CD45 [74]. CD45 can act to enhance TCR signaling through
the dephosphorylation of autoinhibitory tyrosine in clusters of Lck [77]. On the
other hand, CD45 also plays an important role in regulating TCR signaling by
dephosphorylating ITAMs and TCR in the sMAC, leading to the termination of the
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TCR signaling [78, 79]. The formation of the ring surrounding TCR microclusters
has been thought to aid in their exclusion of CD45, permitting TCR signaling to
be maintained in absence of APC contact.

The Distal Pole Complex
During the formation of the immunological synapse, cytoskeletal rearrangements
and establishment of an active signaling location leads to distinct polarity within
the T cell. This axis of polarity is established as TCR and costimulatory
molecules migrate towards the T cell:APC interface to form the proximal pole,
which is the location of the highest active signaling. Concurrent with the
formation of the synapse, surface molecules not involved in the immune synapse
such as CD43, SHP-1, PI3K, scribble (PKCζ), Numb, Par3/6, and Disks Large
(hDLG) [80], migrate to the side of the T cell directly opposite the immune
synapse. Together these molecules form the distal pole complex (DPC) [70].
While the DPC contains negative-regulators of T cell activation,
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surprisingly, active signaling of molecules including ZAP-70, have also been
observed to occur at the DPC [76, 81]. Although the mechanism is unknown, the
presence of active TCR signaling at the DPC has been observed to precede the
formation of the immune synapse in a TCR-independent, but contact-dependent
manner [70]. Randriamampita et al. have termed active signaling at the DPC the
“antisynapse”. [76]. Upon formation of a stable immunolocigal synapse, activelysignaling TCR at the antisynapse are recruited to the proximal pole until
eventually signaling localized to the distal pole is no longer detectable [70]. The
mechanisms behind active TCR signaling at the distal pole have not yet been
characterized [76]. However, it is likely that the antisynapse is formed by
microclusters which retain active signaling outside of the cSMAC [74, 76].

Additional Variables That Influence Synapse
Morphology
While it has been suggested that T cell activation via microclusters vs
classical synapse are dependent on APC cell type, factors such as Ag dose, or T
cell subset also have been shown to influence the morphology of the T cell:APC
interaction [31, 82]. For example, Thauland et al., found that the majority of prepolarized TH2 cells formed multifocal synapses with low doses of Ag, while high
doses lead to the majority of synapses forming the classical “bull’s-eye”
morphology [83]. Meanwhile, polarized TH1 cells formed canonical synapses
under both low and high Ag dose [83] (Fig. 1.4).
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The existing models of T cell activation, requires the ligation of many TCR
by pMHC, CD28 ligation with CD80/CD80, and the interaction of adhesion
molecules. Thus, regardless of the physical location of these interactions,
synaptic or microclusters, a period of stable signaling molecule ligation is
necessary to achieve full CD4+ T cell activation.
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T cell Signaling: Pathways, Consequences, and
Regulation
T cell activation
Following TCR and costimulatory receptor engagement, downstream signaling
leads to the activation of three canonical transcription factors which play the
primary roles in T cell activation, proliferation, and differentiation. These
transcription factors are; nuclear factor-κB (NF-κB) (required for proliferation and
differentiation), activator protein 1 (AP-1) (involved in IL-2 production and
activation), and nuclear factor of activated T cells (NFAT) (drives IL-2 and IL-2Rα
expression, and important in effector functions and differentiation) [84]. An
overview of T cell signaling events is shown in figure 1.5.
Following recognition of p:MHC by TCR formed by αβ heterodimers, the
Src-family kinase p56Lck (Lck), which is non-covalently associated with CD4
molecules, is recruited to the TCR signaling complex [85]. Lck is recruited to the
early synapse, upon CD4 binding to the non-polymorphic β2 domain of MHCII
[86]. CD4 is therefore often categorized as part of the TCR signaling complex,
and also acts as a coreceptor because it enhances the sensitivity of TCR by up
to 100-fold [87-90]. Upon removal of an autoinhibitory phosphate by CD45, and
phosphorylation of Tyr 505, activated Lck phosphorylates immunoreceptor
tyrosine-based activation motifs (ITAMs) on the CD3 and TCR ζ chains, which
then become binding sites for the SH2 domains of the Syk-family kinase zeta
associated protein 70 kDa (ZAP-70) [91]. Lck phosphorylates and activates
recruits ZAP-70. Phosphorylated Ltk/ZAP-70 stabilize the TCR signal [92] and
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phosphorylate four major tyrosine sites on the adaptor protein linker of activated
T cells (LAT). The proximity of LAT to TCR-signaling complexes is maintained via
its single transmembrane domain, and the multiple cytoplasmic binding domains
of LAT serve as scaffold for multiple signaling molecules. The recruitment of
these signaling molecules to activated LAT forms the proximal signaling complex
which plays a central role in the initiation of the multiple signaling pathways
downstream of TCR signaling [93]. The formation of this complex promotes
interaction with recruited proteins including the adaptor Grb2-related adaptor
protein-2 (GRAP2/Gads), SLP-76, IL-2 inducible T cell kinase (ITK), Grb2, p85
PI-3 kinase, and phosphoinositide-specific phospholipase C1 (PLCγ1) [94]. Here
the signal diverges through signaling of GRB2/SOS and SLP-76, as well as
PLCγ1, to act on different transcription factors involved in T cell activation.
Grb2 and Gads are adaptor proteins which bind Son of Sevenless
(SOS) and SLP-76, leading to Ras and subsequent MAP kinase cascade. This
signaling cascades leads to ERK1/2 activation, which acts in the nucleus to
regulate c-Jun and c-Fos, which form the AP-1 transcription factor. AP-1 plays
roles in IL-2 production by binding to the IL-2 promotor to induce gene
expression and also stabilizes IL-2 mRNA [95]. Its activation also promotes
survival by indusing expression of the anti-apoptotic gene Bcl-xL [96].
Downstream of AP-1, NF-κB activation occurs, which drives T cell proliferation
and differentiation through IL-2 expression, enhancing translation of subsetspecific transcription factors, increased effector functions, and upregulation of
surface activation and costimulatory markers [93, 97-99].
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PLCγ1 hydrolyzes PIP2 to generate the secondary messengers inositol
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which activate different
downstream pathways. IP3 diffuses in the cytoplasm and becomes bound by its
receptor (IP3R) on the endoplasmic reticulum (ER). This causes the release of
Ca2+ stores from the ER leading to the subsequent influx of extracellular calcium
through channels in the plasma membrane. Elevated levels of cytosolic
Ca2+ activate various proteins, including the phosphatase calcineurin. Calcineurin
dephosphorylates the transcription factor nuclear factor of activated T cells
(NFAT), allowing it to traffic into the nucleus. In the nucleus, NFAT is involved in
stabilization and induction of lineage-specific transcription factors T-bet (TH1),
Gata3 (TH2), RORγt (TH17), and Foxp3 (iTreg) [100]. The specific transcription
factor NFAT promotes is dependent on the convergence of other signaling
pathways such as cytokine receptor signaling to activate respective STAT
signaling pathways. NFAT also is critical for the expression of IL-2 and IL-2Rα
(CD25), which enable T cell proliferation [101].
Activated DAG initiates signaling in two pathways. The first pathway
involves the calcium independent activation of protein kinase Cθ (PKCθ). DAG
binding to PKCθ leads to conformational changes in PKCθ to form an open,
active state. Activated PKCθ can phosphorylate cytoplasmic IkB kinase (IKK),
leads to NF-κB translocation to the nucleus where it acts as a transcription factor
driving T cell proliferation and differentiation [102]. The second role for DAG is to
initiate the RAS – MAPK cascade ending with the activation of kinases ERK1/2
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which, as described above, leads to the nuclear translocation and activation of
AP-1.
At the immunological synapse, costimulatory signaling primarily involves
the costimulatory receptor CD28. CD28 ligation activates phosphoinositide 3kinase (PI3k) which subsequently phosphorylates phosphatidylinositol 4,5bisphosphate (PIP2) to yield phosphatidylinositol (3,4,5)-trisphosphate (PIP3).
PIP3 recruits proteins to the inner leaflet of the plasma membrane, such as ITK
kinase [103]. ITK binds to PIP3 and SLP-76, which localize it to the plasma
membrane and cause its activation. Activated ITK can then phosphorylate
PLCγ1, thus CD28 signaling pathways converge with TCR signaling to amplify
RAS/MAPK and PCKθ signaling. CD28 signaling also increases expression of
the costimulatory CD40L to aid in the maintenance of T cell activation [104].
Signaling through CD28 alone can enhance the survival of activated T cells.
Importantly, TCR + CD28 activation of PI3k also activates the protein
kinase B (Akt) / mammalian target of rapamycin (mTOR) signaling pathway.
mTOR includes two unique signaling complexes mTORC1 and mTORC2.
Through inhibition of STAT signaling, mTORC1 has been found to play a role in
TH1, TH2, and TH17 differentiation, while a role for mTORC2 has only been found
in the differentiation of TH1, and TH2 [105]. While early studies suggested the
absence of mTOR signaling in the presence of TCR signaling led to anergy [106],
more recent studies have found that absence of mTOR signaling leads to
induction of Treg [107]. mTORC1 signaling leads to glycolysis, and trafficking of
the glucose transporter Glut1 to the cell membrane [108].The induction of
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mTORC glycolic metabolism is associated with CD4+ effector function. It also is
directly involved in protein synthesis through inhibition of eukaryotic initiation
factor 4E binding protein (4EBP1) (which inhibits protein translation), and
activation of p70 S6K ribosomal protein [109, 110]. In addition, mTORC1
increases lipid metabolism and synthesis, as well as mitochondrial biogenesis
which aids in T cell effector functionality and clonal expansion [111]. mTORC2
acts by phosphorylating other proteins including Akt, which forms a positive
feedback loop [112], leading to increased cell survival, cytoskeletal organization
and migration [113]. mTOR signaling can lead to increased effector functionality
by promoting the production of effector cytokines [114]. Collectively, the mTOR
signaling complex integrates multiple cell signaling events to regulate cell
proliferation, differentiation, effector functionality, and survival.
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Regulation of T cell signaling
Proximal signaling through ZAP-70 is negatively regulated by the binding of the
E3-ubiquitin ligases Cbl c-Cbl and Cbl-b. Cbl ubiquinates lysine residues on ZAP70 targeting it for proteasomal degradation [115]. Excessive Cbl-recruitment can
lead to insufficient signaling for activation and is largely associated with T cell
anergy. While anergic T cells are able to form mature immunological synapses, it
was found by Doherty et al., that anergic synapses showed higher recruitment of
Cbl-b to the cSMAC compared to control cells, leading to decreased pERK
signaling [116]. Cytoplasmic phosphatases have also been shown to reduce
ZAP-70 activity through removal of activating tyrosine phosphate [117].
Dysregulation of ZAP-70 signaling can lead to cell exhaustion, or excessive
responses implicated with autoimmune diseases. Along these lines, inhibitors of
ZAP-70 signaling have been proposed for use in treatment of autoimmune
diseases and organ transplant rejection [118, 119].
The Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), which is
expressed after T cell activation, binds to the same ligands as CD28
(CD80/CD86), but rather than providing positive costimulation, CTLA-4 signaling
inhibits T cell activation [120]. CTLA-4 resides in intracellular vesicles and upon
strong TCR ligation, these vesicles move to and fuse with the plasma membrane
delivering CTLA-4 into the immunological synapse [121, 122]. Although
expressed at much lower levels than CD28, CTLA-4 binds to CD80/86 with
significantly higher affinity than CD28. CTLA-4 ligation provides competitive
inhibition of costimulatory signaling, as well as inducing unique signals that inhibit
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IL-2 production [120]. The immunoregulatory effects CTLA-4 comes from studies
using antibody-mediated blockade of CTLA-4 signaling, which has become a
promising component in anti-tumor therapies [123, 124]. However, the absence
of CTLA-4 has also been shown to lead to CD28-mediated autoimmunity in mice
and humans [62, 125]. In these particular cases, it is likely that CTLA-4 blockade
not only increased costimulatory signaling through CD28, but also decreased the
function of Treg. The high expression levels of CTLA-4 by Treg plays an important
role in peripheral tolerance, and are discussed in greater detail in later sections.

Events Following T-cell Activation
T cell Clonal Expansion
Following activation, naive CD4+ T cells rapidly proliferate, resulting in clonal
expansion of up to 100,000-fold within 3-4 days [126]. Despite early contradictory
findings [127], continued Ag signaling is not required during the expansion phase
[128, 129]. This allows for rapid T cell proliferation without the requirement for
daughter cells to scan APC for Ag. Clonal expansion leads to a massive increase
in Ag-specific lymphocytes which can then rapidly clear an infection. It also
underscores the necessity for the regulation of T cell activation through activation
checkpoints and Treg, in order to conserve physiological resources and prevent
unwanted inflammation and autoimmunity due to potential self-reactive T cells
that have escaped negative selection.
Following expansion, activated CD4+ effector cells provide “help” to other
cells of the immune system through effector-cytokine secretion and contact
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dependent mechanisms [130]. Effector T cells undergo a genetic reprogramming
into specialized lineages of T helper TH subsets. Each TH subset exhibits effector
functions associated with protection against a given type of pathogen, or
interacts with a specific type of cell, such as TFH help for B cells. This
reprogramming from undifferentiated precursors is known as T cell differentiation.

CD4+ T Helper Differentiation
The immune system must be highly adaptable in order to provide protection
against a diverse array of pathogens with various modes of infection. For
example, a cell-mediated response is optimal for combating intracellular
pathogens, while a humoral response leading to the production of antibodies is
more effective at neutralizing extracellular infections. Typically, a fine balance is
required to provide optimal protection. CD4+ T cells play a central role in directing
the type of immune response generated. They are differentiated from naïve,
undifferentiated precursors, into specialized subsets upon activation. While some
T cell lineages such as natural T regulatory (nT Reg) [131], and NK T cells [132]
are predetermined during maturation in the thymus, the majority of naïve CD4 + T
cells in the periphery are undifferentiated.
The first insights into TFH differentiation came from the work of Mossmann
and Coffman in the late 1980s when they observed two distinct subsets of CD4+
T cells that produced either IFNγ (TH1), or IL-4 (TH2) [133, 134]. In the years
since, new subsets with specialized functions have been discovered including
TH17, TH9, TH22, induced T regulatory (iTreg/ Treg), T follicular helper (TFH), and
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cytotoxic CD4+ T cell (CD4+ CTL) [135-137]. The primary model for naïve TH
differentiation, known as the three-step model, proposes that TCR signaling
primes the T cell (step 1), while costimulatory signaling is required for T cell
activation (step 2). The effector subset differentiation is driven by cytokine
signaling concomitant with, or shortly after, activation (step 3). This differentiation
is ultimately controlled by PRR signaling in APCs, which leads to the expression
of cytokines associated with protection against the encountered pathogen. In this
way, CD4+ T cells differentiate into lineages which promote the most effective
immune response against the pathogen at hand [138] (Fig. 1.6).
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While this model holds true for the majority of TH differentiation cases,
recent evidence has found this process to be more complex than initially thought.
One example comes from findings that the strength of TCR signaling may
override cytokine signaling in the context of TH2 differentiation. Weak TCR
signaling has been found to drive cells to differentiate towards T H2 even when
cells are in a TH1 -polarizing environment [139]. In contrast, strong TCR signaling
has been shown to favor TH1 differentiation [82, 140, 141]. The duration, or
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persistence, of TCR and costimulatory signaling also impacts TH differentiation,
with short-lived interactions favoring a TH2 phenotype and longer synapses
promoting TH1 differentiation [82]. In the case of TFH cells, repeated cognate
interactions with cognate APC are required for their differentiation [142, 143]. To
add to the complexity, under opposing polarizing conditions, there is plasticity
between differentiated TH subsets, and concurrent expression of two or more
subset-characteristic cytokines and/or transcription factors in the same TH cell is
possible [144-149] (Fig. 1.7B)
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Functions of CD4+ TH Subsets
As described above, while TH differentiation is a complex process, the cytokines
present at the time of activation play a major role in TH-subset differentiation.
Through the activation of specific STAT proteins, cytokine signaling is able to
activate transcription factors that act as master regulators of differentiation, and
the expression of cytokines which further drive TH differentiation, or by inhibiting
the expression of transcription factors associated with other T H subsets. The
cytokines, transcription factors, and primary functions associated with known
effector subsets is shown in table 1 below.
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TH1: Cell-mediated immunity against intracellular pathogens
TH1 differentiation is driven primarily by the polarizing cytokine IL-12, while IL-18,
IL-23, and IL-27 also favor TH1 differentiation [150]. Meanwhile opposing signals
from IL-4 can inhibit TH1 differentiation and effector functionality [151]. Although
other APC are capable of driving TH1 differentiation, CD8α+ dendritic cells (DC)
localized in lymphoid organs [152] secrete IL-12, thus are effective promoters of
promoting TH1 differentiation [153]. The master transcriptional regulator T-bet
inhibits GATA3 expression [154], and is a defining marker for TH1 lineage [150].
Strong TCR and costimulatory signaling through high Ag dose [155-157], and
extended T:DC interactions also favors TH1 differentiation [157]. TH1 cells aid in
cellular-mediated immunity through secretion of IFNγ, IL-2, TNFα and TNFβ,
which activate cytotoxic CD8+ T cells (CTL) and NK cells to kill infected cells
[158], or tumors [159, 160]. These cytokine also induce nitric oxide production in
macrophages to enhance pathogen killing [161, 162]. IFNγ induces B cell class
switching towards IgG2 Ab production which are highly effective in activating the
classical complement pathway [163, 164]. Aberrant TH1 responses contribute to
pathogenicity of organ-specific autoimmune diseases including type 1 diabetes,
psoriasis, Crohn’s disease, and multiple sclerosis [7, 153, 165]
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TH2: Humoral-Mediated Immunity and Protection Against
Extracellular Pathogens
TH2 differentiation cells are identified by the master regulator transcription factor
GATA3 [166, 167], and produce effector cytokines IL-4, IL-5, IL-6, and IL-13. The
presence of IL-4 following activation drives GATA3 expression via STAT6
signaling [168], while IL-12 negatively regulates TH2 differentiation [169]. IL-4R
signaling not only prevents TH1 differentiation, but also negatively regulates IFNγ
expression [170], following a clear pattern for TH1/TH2 negative regulation. In
addition, IL-2-induced STAT5 has been found to be required for TH2
differentiation [171]. Lower signal strength or short interactions with APC favor
TH2 differentiation [139, 156, 172], thought to be due to weaker signaling leading
to early IL-4 production [173]. Some contrasting reports have found high signal
strength to drive TH2 differentiation [174, 175], and the consensus is that either
low, or high signal strength can drive TH2 differentiation, while medium to high
signal strength drives TH1 [155-157].
These cells specialize in providing B cell help through directed cytokine
secretion upon recognition of cognate Ag displayed by the B cell. The cytokines
IL-4 and IL-6 in particular are important in driving B cell class switching and
proliferation in the germinal center response, with IL-4 favoring class switching
towards IgE and IgG1 isotypes [6, 176]. TH2 cells activate eosinophils [177] and
play a role in airway inflammation. TH2 responses are also associated with
protection against large extracellular pathogens such as helminths [178].
Dysregulation in the activation of TH2 cells can lead to increased allergic
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inflammation, ulcerative colitis, atopic dermatitis, chronic rhinosinusitis, as well as
airway inflammation and asthma [6, 165, 179].

TH17: Mucosal and Surface-Barrier Immunity
The third effector subset of CD4+ T cell to be identified were TH17 cells, induced
by a combination of TGFβ + IL-6 or IL-23 signaling leading to the expression of
transcription factors STAT3, RORγt, and RORα [180]. While TNFα, IL-21, and IL23 can enhance TH17 differentiation, IL-4, IFNγ, IL-12, and IL-27 inhibit their
differentiation. TH17 cells secrete IL-17A, IL-17F, IL-21, IL-22, and granulocytemacrophage colony-stimulating factor (GM-CSF) [181, 182]. These cells are
associated with inflammation and mucosal immunity, primarily act at barrier
tissues, and provide protection against extracellular bacteria, fungi, and enteric
parasites such as Giardia [183, 184]. IL-17 in combination with IL-22 has been
found to induce expression of β-defensin 2 and other antimicrobial peptides,
suggesting that TH17 cells play a role in skin immunity [185]. Cytokines produced
by TH17 cells can induce neutrophil production, and lead to recruitment of other
immune cells to sites of inflammation. TH17 cells are also able to regulate the B
cell Pigr gene, which is crucial for the expression of the poly Ig receptor for IgA,
pIgR. The pIgR enables IgA molecules to cross luminal membranes [183], again,
demonstrating the important role TH17 cells play in mucosal immunity. As TH17
cells are associated with inflammation, excessive T H17 responses have been
found to play a role in exacerbation of diseases in a manner similar to T H1 cells.
Excessive numbers of TH17 likely increases pathology of psoriasis [14], as drugs
which neutralize IL-17A have been effective in reducing the symptoms of
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psoriasis [186]. IL-17A has also been associated with rheumatoid arthritis,
multiple sclerosis, airway inflammation and COPD, asthma, atopic dermatitis,
and irritable bowel disease [10, 15-20].

TH22: Surface barrier immunity
TH22 cells are a more recently described subset of cells, which are related T H17
cells. it has been found that TH22 cells are identified by expression of the
transcriptional regulator, the Aryl Hydrocarbon Receptor (AhR) and they produce
TGFα and IL-22, but not IFNγ, IL-4, or IL-17 [187]. It has been proposed that IL22 differentiation is driven by IL-6, IL-23, IL-1β, and FICZ [188]. While originally
considered to be identical to TH 7 [185] these cells have roles in immune function
distinct from TH17 cells [189]. High numbers of TH22 localize to the epidermis and
TH22-produced IL-22 has been found to play important roles in protection against
enteropathogenic bacteria [190]. The impact of IL-22 differs between locations,
as pathogens may enter through the skin, gut, and respiratory tract [191, 192].
However, the end result is production of antimicrobial peptides on surface
barriers, and mucus-associated glycoproteins at mucosal barriers, both which
provide defense against bacterial infection [193]. IL-22 also exhibits epithelial
reparative and regenerative properties [194]. Interestingly, the depletion of TH22
cells during HIV infection led to the epithelial barrier becoming compromised due
to decreased IL-22 levels, suggesting IL-22 may play a role in protection from
HIV, among other viral infections, at mucosal membranes [194]. Excessive TH22
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responses can exacerbate symptoms of rheumatoid arthritis [10, 19], skin allergy
[195] and atopic dermatitis, psoriasis, irritable bowel syndrome, and potentially
systemic lupus erythematosus (SLE) [13].

TH9: Type-2 Associated extracellular Pathogen, (and anti-tumor?) Immunity
The recently discovered TH9 subset [196] is induced by IL-2 and IL-4 + TGFβ
[197] and is typically associated with a type 2 Immune response. T H9 cells
require transcription factors STAT6, IRF4, GATA3, and are identified by
expression of PU.1 [198]. While the redundancy of TH9 cells with TH2 has led to
uncertainty whether they play an indispensable role in immune protection, T H9
cells have been found to uniquely produce IL-10, IL-21, and IL-9 [137]. IL-9
stimulates growth, proliferation and survival of T cells and mast cells, increases
secretion of mucus, and enhances IgE production by B cells [199-202].
suggesting a protective role for TH9 cells in mucosal immunity. Results have
found TH9 cells drive immunity against helminth infection [203] through
increasing IL-5 and IL-13 production in T cells, and basophil and eosinophil
numbers at the site of infection [204]. IL-9-secreting cells have also recently been
found to play a role in anti-tumor immunity in melanoma models [205, 206]. While
the mechanism for IL-9 driven anti-tumor activity is unclear, it was proposed that
IL-9 induced recruitment of mast cells [205], DC and cytotoxic CD8+ cells to the
site of the tumor through increasing expression of the chemoattractant CCL20
[206]. The impacts of TH9 cells on autoimmunity are still undetermined, though
transfer of TH9 cells in a colitis model led to increased inflammation [197]. It was
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unclear however, if this was a result of IL-9 production, as transferred cells were
observed to increase IFNγ expression, thus the results may have been due to a
TH9-TH 1 effector transition [197].

T follicular helper cells: Key Players in the Humoral Response
T follicular helper cells (TFH) play an essential role in providing B cell help in the
germinal center (GC) reaction. Their proximity to B cells, secretion of IL-21 and
IL-6, maintained expression of the C-X-C chemokine receptor type 5 (CXCR5)
along with inducible T-cell costimulatory (ICOS) and programmed cell death
protein-1 (PD-1) [207-211], sets them apart from the TH 2 subset. Unlike other
CD4+ T cell effector subsets, TFH differentiation does not occur following initial
priming of naïve TH0 cells by antigen-bearing DC, but requires subsequent
interaction with APC for full differentiation [142, 212-215]. The current model of
TFH differentiation seen in Fig. 1.8, holds that pre-TFH are primed by DC through
IL-6 and ICOS signaling which leads to the upregulation CXCR5. As activated T
cells downregulate CCR7 (which keeps cells in T cell zones), the expression of
CXCR5 enables them to chemotax in response to the CXCL13 chemokine
gradient present in B cell zones [212, 216-218]. At the edge of the B cell follicle,
pre-TFH interact with antigen-bearing, cognate B cells and these repeated
interactions in combination with either IL-6 or IL-21 induce STAT3 signaling [219,
220]. STAT3 signaling leads to upregulation of the transcription factor Bcl-6 to
drive full TFH differentiation (in the absence of the transcription factors Blimp-1
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and KLF2) [209, 213, 215, 219, 221-225]. Bcl-6 acts as a transcriptional
repressor for GATA3 and inhibits the activity of T-bet and RORγt, thus inhibiting
TH2, TH1, and TH17 differentiation, respectively [226]. The transcription factor
Tcf1 has also been found to be necessary for full differentiation in the context of
viral infection [227].

The proposed requirement for B cells in TFH differentiation is potentially
due to the fact that pre-TFH are much more likely to encounter antigen-bearing B
cells than DC upon their CXCR5-driven migration to the B cell follicles. In
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addition, about 3 days following the initiation of the immune response, the
majority of APC are Ag-specific B cells. This possibility is supported by the fact
that continual stimulation by repeated immunizations in the absence of B cells
was found to produce TFH [213]. This, combined with results from other studies
[228], suggests that B cells do not provide unique signals which drives T FH
differentiation, but simply serve to prolong Ag stimulation that is required for T FH
differentiation.
Upon full TFH differentiation, high Bcl-6 expression leads to loss of EpsteinBarr virus-induced G-protein coupled receptor 2 (EBI2). EBI2 is present in the B
cell follicle, but not the germinal center (GC) where the majority of B cell class
switching and somatic hypermutation occurs. The high expression of CXCR5 and
CXCR4, in combination with low surface expression of CCR7 and sphingosine 1phosphate 1 receptor (S1P1R) displayed by TFH allows them to migrate into the
GC [229, 230]. Once in the GC, TFH provide B cell help through contactdependent co-stimulation and secretion of high levels of IL-21 and IL-6, which
induce B cell maturation, proliferation, and class switching [208, 231-233]. TFH
cells in mice have also been found to produce intermediate amounts of IL-4
[234], and low amounts of IL-5, IFNγ, and IL-17 [235, 236]. The diverse cytokine
profile of TFH is in part, due to the fact that differentiated TH1 [237], TH2 [238],
TH17 [148], and possibly Treg [239], cells have the ability to convert to TFH. The
differentiation of these cells is driven in the same manner as un-differentiated T
cells, through repeat cognate interactions. These effector-TFH retain the
expression of their lineage-associated cytokines in addition to TFH-associated
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markers and are classified by their co-localization with B cells in the GC. Less
evidence exists for the differentiation of Treg to TFH TFH-regulatory (TFR), and it has
been speculated that these cells may arise from naïve precursors, or transition
from TFH to TFR [239-241]. TFR regulate the GC reaction and play an important
role in preventing excessive humoral responses which could lead to Ab-mediated
autoimmune disease. Interestingly, CXCR4-expressing cells that otherwise
resemble TFH in surface phenotype and function, have been detected outside of B
cell follicles and can induce class switching in extrafollicular B cells [242]. The
exact mechanisms that drive this phenotype have yet to be elucidated.
Due to the heterogenicity of the TFH pool, the Ig subclasses produced
generally correlate with the effector-like phenotype of the TFH themselves (i.e. TH
2-like TFH) [243]. Since their identification as a distinct subset of TH cells, TFH cells
have been found to be crucial in GC formation and effective antibody-mediated
protection [244]. Dysregulation of TFH function is a major cause of systemic Abmediated autoimmunity such as SLE [245], and has been implicated in human
diseases including myasthenia gravis (MG), autoimmune thyroiditis, Sjögren’s
syndrome (SS), rheumatoid arthritis (RA), multiple sclerosis (MS), ulcerative
colitis, Crohn's disease, ankylosing spondylitis (spinal arthritis), and type 1
diabetes [245, 246].

Cytotoxic CD4+ (CD4+ CTL): MHCII-Restricted Killers
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CD4+ CTL secrete granzyme B and perforin to kill infected cells in a similar
fashion to CD8+ T cells [247, 248]. IL-2 is required for their differentiation through
upregulation of the transcription factor EOMES which leads to IFNγ expression
and perforin [249, 250]. It also appears that there is an inverse correlation
between CD4+ CTL and TFH differentiation, as CD4+ CTL express high levels of
Blimp-1, which inhibits Bcl-6 expression [251]. These cells are thought to be
related to TH1 cells as they most often occur in viral infection models, express Tbet, and secrete IFNγ [252]. Although they have also been found to develop from
TH0 [253, 254], TH2 [255], TH17 [256], and Treg [257]. Class I-restricted T cellassociated molecule (CRTAM) has been identified as a likely early marker for
identification of CD4+ CTL [258]. The majority of CD4+ CTL are found in
peripheral tissues, such as in the lung, but this is likely due, at least in part, to
their increased presence in viral infection models of the lung. CD4+ CTL have
been found to have a major role in late-onset EAE with implications for
exacerbation of multiple sclerosis in humans [259]. It is also possible that these
cells play a major role in the onset of colitis [257].

Regulatory T cells (Treg): Preventing Excessive, and Undesirable
Immune Responses
Regulatory T cells (Treg) function to suppress the activities of the other effector
subsets and play a role in tolerance to non-self Ags [260, 261]. While nTreg exit
the thymus pre-differentiated, inducible Treg (iTreg) are differentiated by a
combination of TGF-β and IL-10. Treg express the transcription factor Foxp3 [262,
263], and often display the surface marker CD25. Foxp3 acts as a transcriptional
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regulator which suppresses the activation of T cells by inhibiting NFAT and NFκB [264]. Foxp3+ Treg regulate peripheral tolerance through multiple inhibitory
mechanisms and are a critical component in preventing the activation of cells
reactive to self or allergy-associated Ags, as well as limiting infection-induced
organ pathology, fetal and transplant rejection, and graft versus host disease
(GvHD) [265-271]. The immunosuppressive roles by Treg are carried out both in a
contact-dependent manner and through secretion of inhibitory cytokines and
other glycoproteins. Unlike conventional CD4+ effector cells, Treg constitutively
express the inhibitory molecule CTLA-4 which binds costimulatory CD80 and
CD86 on APC. CTLA-4 binds these ligands with a significantly higher affinity than
CD28 and can inhibit the activation of conventional T cells via competitive ligation
[272-274]. Interestingly, in addition to limiting conventional TH access to
costimulatory molecules through the binding of CD80/CD86, T reg have been
observed to physically remove CD80/CD86 from DC in a process which has
been termed transendocytosis [275, 276]. While studies have proposed this
acquisition resembles trogocytosis [277], transendocytosis by Treg differs slightly
from trogocytosis [278, 279] in that acquired molecules are degraded within the
Trreg rather than expressed on the surface as they are after trogocytosis [275,
280-287]. In addition to the physical removal or engagement of CD80/86 from
APC, ligation with CTLA-4 itself drives signaling through CD80/86 on the DC
which lead to the nuclear translocation of Foxo3, which then inhibits the
expression of IL-6 and TNFα [288]. It has also been observed that ligation with
CTLA-4 induces production of the immunosuppressive tryptophan catabolizing
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enzyme IDO by DC [289], which would further inhibit T cell activation. It has been
speculated that the high expression of CD25 (IL-2Rα) by Treg may also act as a
sink for IL-2, limiting the amount of IL-2 available to effector T cells and thus
hampering their proliferation and activation
Treg can also directly influence the activation of conventional T cells by
secreting the cytokines TGF-β, IL-10 and IL-35, as well as Granzyme-B, perforin,
cAMP, Galectin, and Neutropilin. [290, 291]. In an immunosuppressive context,
TGF-β inhibits T cell proliferation. While TGF-β + IL-6 can drive TH17
differentiation [292]. Treg can limit TH17 differentiation through CTLA-4:CD80/86mediated downregulation of IL-6 by DC. IL-10 can inhibit TH1 and TH2 responses
through activation of STAT3, while enhancing the differentiation of Treg in a
positive-feedback loop [293]. The immunosuppresive cytokine IL-35 is produced
almost exclusively by regulatory cells, and reduces the activation of naïve T cells,
and inhibits proliferation in activated cells [290].
Treg have been observed to release cyclic-AMP (cAMP) onto effector cells
through gap-junctions between Treg and effector T cells [294]. Granzyme B and
perforin secreted by Treg has been shown to kill effector T cells and activated B
cells in vitro [295-297]. Treg have been found to generate high levels of the β galactoside–binding protein galectin-1 which is secreted as well as found on the
surface membrane. Galectin-1 binds to surface glycoproteins on effector T cells,
such as CD7, CD43, and CD45, leading to cell-cycle arrest, apoptosis, and the
inhibition of inflammatory cytokines such as IL-2 and IFNγ [298-301].
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Through the mechanisms mentioned above, Treg play a critical role in
peripheral tolerance. Thus, excessive Treg responses may hamper an immune
response leading to insufficient protection, and decrease anti-tumor immunity
[266, 302, 303]. On the other hand, insufficient Treg presence can result in
excessive immune responses associated with all TH subsets and therefore has
been associated with numerous autoimmune diseases, allergy, and asthma [8,
304-307].
In addition to conventional Treg, other regulatory T cell subsets that can
conditionally express Foxp3 include Tr1 and TH3 cells. Tr1 secrete IL-10 and
TGFβ which inhibit proinflammatory TH1 responses [308]. TH 3 cells share many
similarities with conventional Treg, and Tr1 cells, but can also secrete IL-4 [309311]. Both Tr1 and TH3 cells are important for oral tolerance, as secreted TGFβ
increases IgA production by B cells plays a large role in mucosal immunity [309,
312]. Further contributing to Treg diversity is the ability for naive nTreg to
differentiate into effector Treg (eTreg) in the context of the current immune
response [313]. eTreg occurs concurrently with effector T cell activation, and by
receiving similar stimuli from APC, eTreg differentiate similarly to T effector cells.
This allows the eTreg to display similar homing patterns to the effector T cells,
enhancing their ability to regulate the activation of effector T cells in the periphery
[313, 314]. The multiple pathways for Treg development, and high diversity of
regulatory mechanisms show the high diversity of the T reg pool and emphasizes
the broad implications in Treg-mediated immunological tolerance and
homeostasis.
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Memory CD4+ T cells: Providing Long-Term Immunity
Following Ag clearance, the vast majority of activated T cells die within days
while ~ 5 -10% persist as long-lived memory cells, which maintain stable
populations for years. Due to the ability of multiple CD4+ effector subsets to
become memory cells, memory CD4+ T cells are comprised of a heterogenous
population [315]. Therefore, memory cells are largely defined by the ability to
survive for extended periods of time in absence of Ag [316], and exhibit rapid
recall responses upon re-encountering their cognate Ag [39].
The exact mechanisms which drive activated CD4+ T cells to become
memory remain unclear. Studies have found that T cells that receive weaker
signals upon activation, along with late cognate interactions are more likely to
become memory cells [317-320]. A proposed mechanism for the survival of
previously activated CD4+ T cells is through the permanent upregulation of the
IL-7 receptor alpha chain (CD127) [321-323]. IL-7 is secreted throughout the
body by multiple cell types, including epithelial cells [324], stromal cells [325],
skeletal muscle cells [326], and follicular DCs [327]. CD127 ligation signals
through Jak3/1 - STAT5 promotes cell survival by inducing expression of the antiapoptotic genes Mcl-1 and Bcl-2 [328]. CD127 is highly expressed on naïve cells,
but is downregulated on activated cells, facilitating their clearance during the
contraction of the immune response. While the mechanisms which allow
memory-fated cells to survive during the contraction phase are unknown, it has
been suggested that autocrine IL-2/CD25 (IL-2Rα) signaling induced by TCR
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signaling late in the immune response may be required, by driving constitutive
CD127 (IL-7Rα) expression [317, 319].
A second path to becoming memory cells is through asymmetrical cell
division, where one daughter cell becomes a memory-precursor or maintains a
quiescent memory phenotype, and the other displays effector functionality [329331] (Fig. 1.9). Existing memory T cells have also been observed to
asymmetrically divide upon restimulation to produce effector cell progeny and a
daughter cell which retains memory-like capacity [331].
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CD4+ Memory Subsets
Memory CD4+ cells are categorized into various subsets based on their
physiologic locations and recall responses. Variable expression of CD44 and
CD62L was the basis for the initial characterization of two distinct CD4 + memory
populations. Cells expressing both CD62L and CD44 are classified as T central
memory (TCM), while CD44+ CD62L- are classified as T effector memory (TEM)
[332]. Additional subsets of CD4+ memory cells have been identified in recent
years, including Tissue-resident memory (TRM) T cells, and stem cell-like memory
T cells (TSCM). These subsets are largely defined by their physiological location
that is dictated by expression of the chemokine receptor CCR7, and CD62L (L
selectin), (Fig. 1.9). The ligands for CCR7, CCL19 and CCL21, are highly
expressed by stromal cells in T cell zones of the lymph node [333], mature DCs,
and on the luminal side of HEVs [334, 335]. Thus, expression of CCR7 by naïve,
and memory subsets allow these cells to exit the periphery and home to T
cell/DC rich areas in the LNs. CD62L is a member of the selectin family of
adhesion molecules. Expression of CD62L contributes to the tethering and rolling
action of lymphocytes along luminal surfaces of venules through interactions with
P-selectin glycoprotein ligand 1 (PSGL1) [336, 337]. Therefore, CD62L
expression permits T cells to cross endothelial barriers and enter lymphoid
organs from the periphery.
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Another marker commonly used to identify memory T cells is CD44. This
surface protein is not expressed by naïve T cells but is upregulated following
activation. Thus, expression of CD44 indicates that T cells have been previously
activated. After contraction of cells during the effector phase, its presence can be
used to identify Ag-experienced cells. The primary receptor for CD44 is
hyaluronic acid (HA) which is a component of the extracellular matrix, and is also

46

expressed by some by endothelial cells [338-340]. It has been speculated that
CD44 may aid in lymphocyte trafficking through the extracellular matrix, through
HEV, and aid in the retention of T cells to luminal barriers. CD44 has been found
to also act as costimulatory molecule [341-343].

T central memory (TCM)
TCM cells account for a large percentage of CD4+ memory cells and may arise
from undifferentiated precursors, or from differentiated effector cells [344, 345].
TCM are identified by surface expression of both CD44+ and CD62L+, while also
commonly expressing CCR7 [346]. The expression of CD62L and CCR7 allows
these cells to circulate in blood, cross through high endothelial venules (HEVs),
and traffic through lymphoid organs [332]. As a result, TCM are the primary CD4+
memory population found in lymphoid tissue and upon restimulation, rapidly
produce IL-2 and proliferate to produce effector cell progeny, and can serve to
stimulate Ag-presenting DCs to increase costimulatory molecule expression [332,
347].

T effector memory (TEM)
TEM cells share a similar phenotype to activated effector cells and are thought to
arise primarily from effector cells which have transitioned to memory. This is
supported through the observations that TEM show less plasticity between TH
subset phenotypes compared to TCM [348]. As mentioned above, these cells
express CD44, but not CD62L or CCR7. As a result, TEM continually scan
47

peripheral tissue and circulate in blood, and are able to rapidly migrate to sites of
inflammation. Upon re-activation, TEM quickly exert effector functions, but do not
rapidly proliferate compared to TCM. [332, 349, 350] However, there has been
some debate whether TEM are simply effector cells that arise from TCM upon
reactivation and subsequent proliferation.

Tissue resident memory (TRM)
During infection, activated CD4+ T cells migrate to peripheral tissue to induce
local responses and clear pathogens. Among the memory cells that survive after
Ag clearance include a subset of cells that take up residence in tissues such as
the lung, small intestine, and skin [351-353]. Upon Ag-reencounter, localized TRM
induce rapid localized inflammation to recruit other immune cells [354]. These
cells are retained in peripheral tissue through constitutive expression of CD69
[355], and many maintain expression of CD103. While CD69 is commonly used
as an early activation marker, one of its biological roles is to suppress the
function of sphingosine 1-phosphate receptor-1 (S1P1) [356]. As high
concentrations of S1P are found in blood and lymph, CD69 expression prevents
the egress of CD69+ cells into these fluids [357]. Different migration patterns
have been observed between CD8+ and CD4+ TRM. While CD8+ migrate and
localize at sites of infection, CD4+ cells were more mobile and continually
scanned through skin [358]. One study using mice, as well as mice bearing
human skin xenografts, found that human skin TRM were able to downregulate
CD69 expression and enter circulation [353]. These cells then took up residency
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in secondary skin sites where they resumed a TRM phenotype [353]. As such, TRM
may not be as strictly compartmentalized as previously thought, and TRM that
develop early may downregulate CD69 to become more evenly distributed
throughout the body. Although the mechanism for TRM re-entry into circulation
remains unknown, it is possible that this could also play a role in recruitment of
TRM to sites of subsequent infection.

T stem cell-like memory (TSCM)
Human TSCM are identified by the surface expression pattern CD45RO−, CCR7+,
CD45RA+ CD62L+, CD27+, CD28+ and IL-7Rα+ [359]. In mice, the surface
phenotype of TSCM largely resembles that of a naïve T cell (CD62L+ CD44-).
Similar to TCM, the expression of CD62L and CCR7 allows these cells to circulate
in blood, cross through high endothelial venules (HEVs), and traffic through
lymphoid organs. TSCM cells are Ag-specific, but retain sTEM cell-like properties in
that they are able to undergo homeostatic proliferation and replenish the memory
pool of Ag-specific cells of both TEM and TCM [359, 360]. Human TSCM have also
been found to rapidly proliferate, to a greater extent than T CM or TEM [359]. TSCM
were produced upon Mycobacterium tuberculosis infection [361], however the
exact mechanisms that drive TSCM differentiation have yet to be elucidated.
In all, the rapid recall responses of the various populations of memory
CD4+ T cells provide long-lived Ag-specific immunity. This is accomplished by
TCM in the LN rapidly proliferating to produce effector cells and stimulating the
activation of other responding cells; TEM and TRM residing in surface and
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peripheral organs to rapidly exert effector functions upon encountering Ag in the
periphery; and TSCM performing homeostatic proliferation to replenish the memory
pool.

Part III
Trogocytosis
Trogocytosis, stemming from the Greek words trogo, or “to gnaw” and
cyto meaning cells, is the direct, intercellular transfer of membrane and
membrane-associated molecules in a contact-dependent manner. Trogocytosis
occurs rapidly and between live cells, and therefore is not a simply a result of
phagocytosis of apoptotic vesicles. In addition, unlike endocytosis of CD80/CD86
by Treg where acquired molecules become degraded [275, 276], a defining feature
of trogocytosis is that acquired molecules remain functional, and may become reexpressed on the surface of the trogocytosis-positive (trog+) T cell. Images of a
live-cell experiment showing trogocytosis by CD4+ T cells is shown in Fig. 1.11
The first report of trogocytosis came from the research of Cone, Sprent,
and colleagues in 1972, where they detected donor B cell MHCII molecules on
adoptively transferred T cells in mice [362]. They concluded that the MHC
molecules were integrated into the T cell surface, and similar in composition to the
membrane-bound form on B cells. While the mechanism was unknown at the
time, mouse T cells do not endogenously express MHCII [363], thus these
molecules were acquired from the host B cells. One year later, Bona et al were
the first to detect the transfer of Ag from APC to lymphocytes using B cells that
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acquired LPS from macrophages in a B cell receptor-dependent manner [364].
Several years later, Hudson and Sprent became the first to report the transfer of
surface molecules between APC and T cells when they found B cell-derived IgM
on the surface of activated T cells that had been transferred into irradiated
allogenic (MHC-mismatched) mice [365]. This discovery provided an explanation
for the earlier findings by Cone and Sprent, as well as other instances where
signaling molecules were detected on cells in which they are not endogenously
expressed (as determined by the absence of mRNA for these molecules). Shortly
after two, separate groups observed MHC transferred to T cells in donor
thymocytes cells from host splenic cells [366], and in cultures of proliferating T
cells [367]. In the years since, this phenomenon has been observed in CD4+ [81,
285, 287, 368-372], CD8+ [370, 373-376], and  [377] T cells, B cells [378, 379],
NK cells [380-382], basophils [283], macrophages [383, 384], neutrophils [385387], dendritic cells [388, 389], and between tumor cells [390]. Despite the
widespread occurrence and immunomodulatory potential of trogocytosis by
immune cells, the biological impacts of trogocytosis remain largely unknown.
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Mechanisms for Trogocytosis
Contributions of T cell Signaling and Activation State on
Trogocytosis
Although significant work over the past decade has been conducted in
deciphering the mechanism of T cell trogocytosis, the exact details of this event
remain unknown. This is in part, due to multiple factors which appear to influence
trogocytosis such as the activation state of the T cell [391-396] and APC [383];
Ag-dose [287, 373, 397] and affinity [397, 398]; and costimulatory molecule
signaling [394]. In contrast to B cells, Natural killer (NK) cells [399], and DCs that
may passively perform trogocytosis [370, 400, 401], evidence suggests that active
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signaling is required for T cell trogocytosis. We, and others, have previously
shown that trogocytosis by CD4+ T cells occurs at the immunological synapse
formed between Ag-specific CD4+ T cells and APC (Fig 1.11) [287, 392, 394, 397,
402]. This is consistent with the vast majority of reports which have found Agspecificity to be a requirement for T cell trogocytosis [285, 287, 375, 399, 403]. In
fact, the presence of trogocytosed molecules has been used as an identifying
marker for tumor- [399, 403], and viral-, reactive cells [404]. In addition, this
method has recently been described as a method to identify antigen-epitopes for
specific T cells in vivo [399].
The strength of TCR signaling by Ag-dose positively correlates with the
trogocytosis [287, 373, 397]. The activation state of T cells impacts the efficiency
in which cells perform trogocytosis, as activated T cell blasts perform trogocytosis
to a greater extent than naïve T cells [391-396]. This could be due, in part, to the
larger size of activated T cells compared to naïve cells, which have increased
surface area contact with APC. It has also been hypothesized that increased
avidity of the activated T cells due to their increased expression of adhesion and
costimulatory molecules, such as CD28 and LFA-1, and CD44, stabilizes the
immune synapse to facilitate trogocytosis [394, 405]. Costimulatory molecule
ligation such as CD28:CD80/CD86 can also lead to acquisition of CD80 and
CD86 [394], thus increasing the amount of total material trogocytosed by the T
cell.
Similar to the effect of adhesion molecules in stabilizing the immune
synapse and promoting trogocytosis, T cell microvilli (as mentioned under

53

kinapses and microclusters) are also central factors in trogocytosis. These
filamentous like protrusions concentrated with TCR form multiple contact points
with APC and enhance signaling in both the T cell and APC [68]. In a recent
study, Akkaya et al., found that microvilli stabilize T:APC interactions and
correlate with the acquisition of MHCII by the T cell [66]. iTreg had the highest level
of microvilli, formed the most stable contacts, and showed the highest acquisition
of MHCII, compared to activated effector T cells which had higher levels of
microvilli compared to naïve t cells (Fig. 1.12). They also found that microvilli
acquired MHCII with cognate, but not irrelevant peptide, suggesting that the
acquisition of MHCII occurred in an Ag-specific manner.

Further insight into the mechanism of trogocytosis comes from studies
showing that treatment of cells with latrunculin or cytochalasin D to inhibit actin
polymerization severely limited trogocytosis [370, 405]. Blocking proximal TCR
signaling through ZAP-70 has also been found to significantly reduce the rate of
trogocytosis [373]. Intriguingly, trogocytosis of CD80 and CD86 may occur
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independently of CTLA-4, or CD28-signaling in Treg [277]. Studies with
conventional effector cells found that antibody blockade of CD80 had minimal on
trogocytosis of GFP-tagged MHCII, while blocking MHCII or CD3 significantly
reduced the amount of trogocytosed MHCII [287].
Collectively, the above data suggests that trogocytosis is an active
process in T cells that occurs predominantly in an Ag-specific manner and
requires stable-T cell:APC interactions.

Proposed Physical Mechanisms of Trogocytosis
The possibility that more than one pathway exists for the acquisition of APC
molecules by T cells has contributed to the elusiveness in defining the underlying
mechanisms. While it is understood that trogocytosis requires stable, cognate
interactions and trogocytosed molecules may be re-expressed on the T cell
surface, the pathways leading to this end-result may differ. For example, CD8+
CTL have been observed to acquire membrane and associated proteins from
target cells through small regions of fused membrane termed membrane bridges
(Fig. 1.13A) [406]. These membrane bridges are distinct from the significantly
longer nanotubules formed between T cell and APC (Fig. 1.13B) that are thought
to extend cell communication [407].
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However, the presence of T cell:APC membrane bridges in CD4+ T cells has not
been reported. Live-cell imaging data from Wetzel et al., showed that GFPtagged MHCII was removed from APC during spontaneous dissociation from the
immune synapse [287] (Fig. 1.11). As the immune synapse is comprised of a
multitude of ligated molecules, the strength of these interactions is greater than
the integrity of the APC membrane. Spontaneous dissociation during the
immunological synapse results in the stripping of APC molecules by the
migrating T cell.
Multiple proposed models for trogocytosis suggest that APC-derived
molecules become internalized by the T cell through endocytosis. These models
diverge from one another in how the APC molecules arrive on the surface of T
cell. In one theory, APC-derived exosomes containing various molecules are
taken up by the T cells and then re-expressed on the surface [408]. It has been
observed that strong MHCII:TCR interactions leads to the migration of late
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endosomal compartments containing MHCII towards the immunological synapse,
thus TCR signaling may increase the release of APC exosomes directed towards
the T cell [409]. In a separate study, electron microscopy revealed that MHCII
was transferred to T cells in T cell:DC conjugates via exosomes which were
concentrated at the immunological synapse [408]. Here, the authors proposed
that the exosomes were endocytosed by the T cell during TCR recycling, then
were re-expressed on the T cell. Similar results were observed by Huang et al.,
in a model using Drosophila APC transfected with mouse MHC and costimulatory
molecules, where they observed small packets containing MHCII localized
between T:DC synapses [397]. The authors in this study observed that acquired
MHCII were co-internalized with recycling TCR and were found to be present in
both endosomes and lysosomes. Thus, they concluded that TCR-endocytosis
was driving the internalization and subsequent acquisition of APC-derived
signaling molecules [397]. However, results from numerous studies suggest that
the acquisition of APC-derived molecules via exosomes is distinct from
trogocytosis. For example, the transfer of PD-L1 and MHC is blocked when cocultured T cells and APC are separated by a trans-well membrane [375, 410]. In
addition, blocking exosome formation by DC with the ATPase inhibitor CMA was
found to only slightly decrease the amount of trogocytosed material compared to
untreated controls [375].
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The most recent model for trogocytosis comes from studies by MartinezMartin et al., proposing that APC-derived membrane and membrane proteins
are internalized in tandem during TCR downmodulation. Consistent with much
of the published research, this model proposes that T cell trogocytosis is an
active event occurring in a TC21/RhoG dependent manner. Once internalized by
the T cell, recycling endosomes containing acquired APC fragments fuse with
the T cell plasma membrane resulting in APC-derived molecules being
displayed on the T cell surface in their native topological orientation (Fig. 1.14,
above) [278, 411] This model is consistent with the majority of published data
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including results of Sprent and colleagues that found trogocytosed GFP-tagged
MHCI is internalized by CD8+ T cells before surface re-expression [397]. Finally,
pre-treatment of T cells with the vacuolar ATPase CMA to inhibit endosomal
formation and trafficking led to a significant decrease in trogocytosis [375],
strengthening a model for endocytosis-dependent trogocytosis.
Our live-cell imaging experiments also show that GFP-labeled p:MHC
found on the surface of the T cell moves from the immunological synapse and
localizes at the distal pole region (Fig. 1.15). We also observed that in fixed
T:APC conjugates, >82% of T cells with detectable trogocytosed molecules had
p:MHCII localized to the distal pole [81]. Similar distal pole localization of
trogocytosed MHCI was reported by Huang et al., using CD8+ T cells and
Drosophila APC [397]. Regardless of the mechanisms in which the molecules are
acquired from APC, true trogocytosis results in the expression, or re-expression,
of the acquired molecules on the T cell surface.

Biological Consequences of T cell Trogocytosis
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While the intracellular exchange of proteins is common among various cell types,
the outcome of trogocytosis has distinct biological implications in that; 1. the
molecules acquired may be involved in active signaling; and 2. these signaling
molecules become re-expressed in the native topological orientation on the
surface of recipient cell. As mentioned above, molecules trogocytosed from APC
by T cells include molecules that can trigger active signaling within the T cells
including pMHCI/MHCII complexes [66, 81, 282, 285, 287, 376, 399, 412],
CD80/CD86 [277, 281, 282, 284], OX40-L [368], and PDL-1 [375], as well as
adhesion molecules such as ICAM-1 [400]. Due to the nature, and accessibility of
these trogocytosed molecules, this event has numerous biological implications.
Elevated levels of trogocytosis have been documented in sites of autoimmune
inflammation [391], viral and parasitic infections [282, 413, 414], rheumatoid
arthritis [11], and in tumor environments [284, 403]. While the function of
trogocytosis in these cases is not yet established, this widely-observed event has
been proposed to play a role in the modulation of immune responses [277, 388,
415-419].

Antigen Presentation by Trog+ T cells
The potential for trog+ cells to act as APC themselves has inspired significant
research focused on the ability of the trogocytosis-positive (trog+) T cells to
present antigen, in the context of other acquired molecules, to responding T cells
[369, 371, 372, 415, 420-426]. The outcome of such presentation appears to
correlate with the nature of the acquired molecules and phenotype of the trog+
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cell. For example, trog+ CD4+ cells displaying acquired costimulatory molecules
such as CD80, along with MHC:peptide can activate responding naïve T cells
both in vitro, and in vivo [371, 410, 420, 424]. One such example comes from the
work of Zhou et al., who found that FACS-sorted hemagglutinin (HA)-specific
trog+ T cells induced proliferation of naïve HA-specific T cells in vitro [406].
Through bystander acquisition of MHCI from DC, OVA-specific trog+ CD4+ T cells
have been found to activate naïve CD8+ T cells both in vitro, and in vivo after
adoptive transfer of trog+ cells [421]. In a study using human T cells, Game et al.
showed that in an allogenic response, trog+ cells can stimulate both naïve and
allogenic and autologous T cells to proliferate [410]. The antibody blockade of
CD80/86 limited these responses, suggesting that, similar to Ag-specific
responses, the presence of allogenic MHC alone on T cells is insufficient to
induce a response in other allogenic T cells.
A separate study compared the effects of trogocytosed CD80 in both an
allogenic and Ag-specific response. Similar to the results above, they found that
the trog+ cells could induce activation of other cells in both types of responses.
However, the trog+ cells only were shown to have significant effects on
stimulating naive T cells in the first 48 hours of their activation [427]. In the case
of allogenic responses they proposed that T cells expressing CD80 could act to
as a mechanism to boost the costimulatory presence for responding naïve T
cells. Interestingly they also noticed a difference in the chemokine receptor
pattern between allogenic and Ag-specific responses. T cells that performed
antigen-independent acquisition of CD80 retained expression of CCR7 and low
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levels of CCR5, thus were more likely to remain in the T cell zones of the lymph
node after activation. On the other hand, CD80+ cells which were stimulated with
cognate Ag-presenting DCs downregulated CCR7 and increased expression of
CCR5, thus, they would be more likely to exit the lymph node and act on
peripheral sites to modulate the response of peripheral T cells. Finally, it was
observed in samples from human donors with either malignant ascites or
autoimmune thyroiditis, circulating T cells had increased levels of CD86
compared to healthy controls, suggesting that these cells may play a role in
augmenting these autoimmune disorders [428].
While T:T Ag-presentation has been shown to augment an immune
response, numerous studies have also found it may play a role in suppressing
the immune function of other cells. In an in vivo study, Helft et al., found that Ag
presentation by trog+ cells to activated T cells induced responder cell death, but it
stimulated naïve T cells to proliferate. The authors proposed that this was likely
due to insufficient levels of costimulatory molecules upon p:MHC presentation by
trog+ cells [429]. The authors speculated that T cell Ag-presentation may play a
role in preventing peripheral memory, but not naïve T cells, from entering
activated lymph nodes by interacting with T cells in the periphery.
Attenuation of the immune response via presentation of trogocytosed
molecules to T cells has also been observed in T cells from donors with multiple
myeloma. In vitro incubation of patient cells with myeloma cell lines led to
trogocytosis of CD86 and the immunosuppressive molecule HLA-G by T cells
[284]. These HLA-G+ trog+ cells were functionally comparable to nTreg in
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proliferation of trog- cells. In samples directly from patients, a significantly higher
frequency of circulating T cells had detectable HLA-G and CD86 compared to
healthy controls, and the increase in the frequency of these trog+ cells was
associated with poor prognosis [284].
In addition to conferring regulatory functions to non-Treg cells [277, 375,
415, 417, 430-432], Treg themselves display high-rates of Ag-specific trogocytosis
[66]. CD80 and CD86 have been detected on the surface of both nTreg and iTreg
[277], and has been proposed that these trog+ Treg use trogocytosed molecules to
form connections with activated T cells, thus enhancing their suppressive
[431,432].
Trogocytosis itself also has been found to suppress the immune
response in a manner similar to Treg, where pMHC complexes and costimulatory
molecules are removed via trogocytosis rendering APC inefficient stimulators of
other responding T cells, or inhibiting the detection and killing of tumor cells [284,
433-436]
Another means of immune suppression is the killing of Agpresenting T cells by CTL through fratricide. This phenomenon is most widelyassociated with viral infection, but CD8+ T cells with trogocytosed PD-L1 can
induce fratricide of neighboring T cells expressing PD-1. In addition, trog+
themselves may be targeted by cytotoxic cells through displaying trogocytosed
pMHC [434].
Collectively, the studies described underscore the biological significance of
trogocytosis and subsequent Ag presentation by trog+ T cells
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Trogocytosis-Mediated Signaling
While the ability of trog+ T cells to present trogocytosed molecules to
other T cells has been fairly well-documented, much less is known about the
biological consequences of trogocytosis on an individual trog+ cell. Trogocytosed
molecules are retained in punctate areas on the CD4+ T cell surface and colocalize with their receptors and signaling molecules [81, 287]. This raises the
possibility that trogocytosed molecules may drive intracellular signaling within the
T cell. It has been observed that trog+ cells are more activated compared to their
trog- counterparts, as indicated by expression of CD44, CD69, and/or CD25
[277, 417, 420, 422, 432, 437, 438], and, in some cases, express higher levels of
effector cytokines compared to similarly-stimulated trog- cells [81, 282, 412, 439].
One possible explanation for these observations is that highly activated cells are
more efficient at performing trogocytosis. Another possibility is that the
trogocytosed molecules induce intracellular signaling and are playing a role in
augmenting the activation state and effector functions of the trog+ cells.
In our previous studies, TCR signaling was detected in trog+, but not
trog–, CD4+ T cells up to 72 hours after separation from APC. This sustained
signaling was mediated by trogocytosed molecules engaging their cognate
receptors on the trog+ T cell, resulting in autopresentation, referred to here as
trogocytosis-mediated signaling. This signaling led to the enhanced survival of
trog+ cells compared to trog– cells, up to five days after APC removal [81]. This
was not due to residual signaling from the T-APC interaction, as treatment with

64

the Src-family kinase inhibitor PP2 was used to halt signaling after APC removal.
Signaling, as measured by ZAP-70 and ERK 1/2 phosphorylation resumed only
in trog+ cells. Consistent with these findings, Zhou et al. found that trog+ CD4+ T
cells displayed sustained activation of NFB and AP1, 24 hours after removal
from APC. Interestingly, the trog+ cells also developed a unique cytokine profile
[439]. This suggests that a qualitative difference may exist between trogocytosismediated signaling and signals received from APC, raising the possibility that this
non-canonical signaling has the potential to modulate the immune response.
Trogocytosis-mediated signaling, by altering the activation state, survival,
and effector cytokine production has the potential to significantly impact the
physiology and subset differentiation of the trog+ cell, and by extension, an
immune response. This paradigm-shifting event may play a significant role in the
generation and control of protective immune responses, cancer immunotherapy,
and vaccine efficacy. However, we have a very limited knowledge of
trogocytosis-mediated signaling, and more work is necessary to improve our
understanding of this underappreciated phenomenon and the role it plays in
modulating the immune response.
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Rationale for the Current Study
While the ability of CD4+ T cells to differentiate into specific subsets with
specialized roles is a defining feature of the adaptive immune response, the
mechanisms behind their differentiation are not fully understood. While canonical
T cell activation is dependent on APC, trog+ CD4+ cells can sustain active TCR
signaling through engaging trogocytosed molecules with their surface receptors
(trogocytosis-meidated signaling) [81]. This signaling was observed up to 72 hrs
after APC removal, and despite being similarly activated by APC, the trog+ cells
displayed enhanced survival compared to trog- cells in the absence of exogenous
stimulation [81]. These findings strongly suggest that trogocytosis-mediated
signaling in the trog+ T cells can modulate their survival.
The overall objective of this study was to determine the biological effects
of trogocytosis-mediated signaling on CD4+ T cell activation, effector cytokine
production, and differentiation. Due to the demonstrated ability for trog+ cells to
retain active signaling and maintain a heightened state of activation, I
hypothesized that trogocytosis-mediated signaling would drive sustained
effector cytokine production and influence the differentiation of the
recipient trog+ cell.
This was examined through the following three aims:
Aim 1. Determine the activation state, effector cytokine production, and TH subset differentiation of trog+ and trog- cells after APC removal, and the
contribution of trogocytosis-mediated signaling to the observed phenotype
Rationale and supporting data: Sustained T cell signaling is not only required for
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effector T cell and survival, but also mediates T cell activation state and effector
cytokine production. In addition, trog+ cells display higher levels of activation and
increased effector functionality in vitro and in vivo. Whether trogocytosis is a
result, plays a causative role in these phenotypes has yet to be determined.
Because variations in signaling events, including the frequency, and
duration, of TCR signaling, can significantly impact the differentiation of CD4 +
cells [82, 139-143], it is plausible that sustained trogocytosis-mediated signaling
may also impact these aspects in the trog+ cell.

Aim 2. Ascertain the impacts of trogocytosis-mediated signaling in the
differentiation of trog+ CD4+ T cells towards TFH
Rationale and supporting data.
While events during initial T cell activation are sufficient to drive CD4+ cells to
differentiate into common effector subsets including TH1, TH2, and TH17, the
differentiation of T follicular helper (TFH) requires prolonged, and/or repeated
TCR and costimulatory signaling [142, 143]. Multiple studies have suggested that
following T cell activation, subsequent interactions with B cells presenting
cognate Ag are required for full TFH-differentiation, [209, 221-224]. However,
signaling from DC in absence of B cells is capable of driving T FH differentiation
[213]. Thus, the key factor in TFH differentiation is likely sustained T cell signaling,
and not a signal uniquely attained through B cell interactions. It is possible that
sustained trogocytosis-mediated signaling may promote TFH differentiation after
separation from APC.
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Aim 3. Determine the impact of trogocytosis-mediated signaling in the
generation of memory-precursor CD4+ T cells.
Rationale and supporting data: Though the exact requirements for driving CD4+ T
cells to become long-lived memory cells are unknown, sustained and/or repeated
TCR and costimulatory signaling from APC promote CD4+ transition to memory.
It is possible that by emulating T:APC interactions, trogocytosis-mediated
signaling may satisfy signaling requirements to transition into memory cells. One
of the defining criteria for memory cells is the ability to survive in the absence of
Ag. We previously found that sustained trogocytosis-mediated signaling leads to
enhanced survival of trog+ cells compared to trog- cells after APC removal,
suggesting that such signaling could play a role in the survival of
memory/memory-precursor cells.
Results from aim 1 showed that trog+, but not trog- cells produced IL-4
and IL-21, both of which have been shown to aid in CD4+ survival. In addition, IL21 has also been found to be critical for CD4+ and CD8+ memory cell generation
[440]. Therefore, it is possible that autocrine signaling through IL-4 and IL-21
produced by the trog+ cells would enhance their survival, as well as promote
transition to memory.
In addition to effector-to-memory transition, T cells may be fated to
become memory cells during initial T cell activation and subsequent asymmetric
division. In our previous study, during T:APC synapses, it was found that over
83% of these cells had trogocytosed molecules at the distal pole, and these
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molecules were driving TCR signaling. Thus, it is possible that the commonly
observed TCR signaling at the distal pole is due to TCR engagement with
trogocytosed pMHC complexes. If trog+ cells undergo asymmetric division and
trogocytosed molecules are retained on the distal daughter cell, this would
implicate that trogocytosis-mediated signaling may play a role in the survival of
memory cells that are generated through asymmetric division.

These aims were addressed primarily using our well-established standard in-vitro
trogocytosis-assay using fibroblast cell line and peptide-loaded mouse BMDC
cells as APC. Briefly, naïve or non-polarized resting CD4+ T Cell blasts were
incubated with fibroblasts which constitutively express covalently-attached MCC
to the I-Ek -chain, or MCC-loaded BMDC, for 90’ at 37 oC. T cells are removed
from APC from T cell cultures and are analyzed immediately, or cultured at low
density to limit potential T:T interactions. In addition, in vivo experiments were
conducted using MCC-specific TCR-transgenic mice, and wild-type (WT) mouse
models. These experiments involved immunization of whole protein to examine
the phenotype of cells which have performed in vivo trogocytosis. Studies on
memory T cell survival included the adoptive transfer of CD4+ T cells recovered
from an in vitro trogocytosis assay into naïve animals. Full details of these
experiments are described in the materials and methods section.
Results from this study provide insight into both, the biological
consequences of trogocytosis, as well as the mechanisms behind CD4+
activation and differentiation. Due to the common occurrence of trogocytosis by
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CD4+ T cells upon activation, and the central role of CD4+ T cells in immune
responses, these findings are of significance in advancing our current knowledge
of basic cell biology while also providing insight into better understanding the
pathology of infectious and autoimmune diseases, allergies, along with future
drug or vaccine design.
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Chapter 2
Materials and Methods

Animals
B10.A and C57BL/6 CD45.1 mice were purchased from The Jackson Laboratory
(Sacramento, CA). 5C.C7 TCR (V3+) transgenic Rag-1-/- mice specific for pigeon
cytochrome c fragment 88–104 and reactive against moth cytochrome c (MCC)
fragment 88–103 [441] were purchased from Taconic (Rensselaer, NY). For
some experiments, 5C.C7 mice were crossed with B10.A mice and the
splenocytes from F1 generation animals were used. Both male and female mice
were used in this study, and no differences were observed between male and
female T cell phenotypes. Mice were housed in the University of Montana
Laboratory Animal Resources facility and were allowed food and water ad
libitum. All procedures were supervised and in accordance with the University of
Montana Institutional Animal Care and Use Committee.

Antibodies and Reagents
The following conjugated or unconjugated antibodies were purchased from:
Biolegend (San Diego, CA): anti-CD3 (145-2C11), anti-CD4 (RM4-5), anti-CD69
(H1.2F3), anti-CD80 (16-10A1), anti-Foxp3 (150D), anti-I-Ek (17-3-3), anti-IA/IE
(M5/114.15.2), anti-IFN (XMG1.2), anti-IL-2 (JES6-5H4), anti-IL-4 (11B11), antiIL-6 (MP5-20F3), anti-IL-9 (RM9A4), anti-IL-17A (TC11-18H10.1), anti-IL-21
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(FFA21), anti-Bcl-6 (IG19E/A8), anti-T-bet (4B10), anti-PD-1 (29F.A12), antiCCR7 (4B12), anti-Ki-67 (16A8), anti-CD25 (3C7) anti-CD62L (MEL-14), antiCD127 (A7R34), anti-ICOS-L (HK.53), anti-CD44 (IM7), anti-GATA-3
(16E10A23), Streptavidin (PE-Dazzle594). Conjugated or unconjugated
antibodies were also purchased from BD Biosciences (Franklin Lakes, NJ): antipZAP-70 (17A/P-ZAP-70), anti-V3 (KJ25), anti-IL-12 (C15.6), anti-CD80 (1610A1), anti-CD86 (GL1), anti-CD90.2 (30-H12)], and eBiosciences (San Diego,
CA): anti-IL-5 (TRFK5), anti-IL-10 (JES5-16E3), anti-RORt (AFKJS-9), antiTcf1/Tcf7 (S33-966). AlexaFluor 488- and AlexaFluor 647-conjugated
Streptavidin were purchased from Jackson ImmunoResearch Laboratories (West
Grove, PA).

Whole pigeon cytochrome c (PCC) and Ovalbumin (Ova) proteins were obtained
from Sigma-Aldrich (St. Louis, MO) and moth cytochrome C fragment 88-103
(MCC88-103) peptide was obtained from Genscript (Piscataway, NJ). Peptides
were dissolved in sterile nano-pure water at 500 µM and aliquots were stored at 80 °C until used.

Culture Media
Fibroblast APC were cultured in DMEM (Life Technologies, Carlsbad, CA)
supplemented with 10% FBS (Atlanta Biologicals, Atlanta, GA), 1 mM Lglutamine, 100 mg/ml sodium pyruvate, 50 mM 2-ME, essential and nonessential
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amino acids (Life Technologies), 100 U/ml penicillin G, 100 U/ml streptomycin,
and 50 mg/ml gentamicin (Sigma-Aldrich).

Primary splenocytes, T lymphocytes, and bone marrow-derived dendritic cells
(BMDC) were maintained in complete RPMI which consisted of RPMI 1640
medium (Life Technologies) supplemented with 10% FBS (Atlanta Biologicals,
Flowery Branch, GA), 1 mM L-glutamine, 100 mg/ml sodium pyruvate, 50 mM 2ME, essential and nonessential amino acids (Life Technologies), 100 U/ml
penicillin G, 100 U/ml streptomycin, and 50 mg/ml gentamicin (Sigma-Aldrich).

Antigen Presenting Cells
In in vitro trogocytosis experiments, peptide-pulsed B10.A BMDC or the
previously described MCC:FKBP cell line [287] were used as APC. The
MCC:FKBP is a CD80high Ltk– fibroblast cell line that has been transfected with
ICAM-1, I-Ek α-chain, and an I-Ek -chain with covalently attached antigenic
MCC88–103 peptide via a flexible linker, and a cytoplasmic tail containing 3 copies
of FK506-binding protein (Ariad Pharmaceuticals, Cambridge, MA). This cell line
expresses levels of CD80 and ICAM-1 comparable to B10.BR splenocyte APC
[287].

Surface-Labeling of APC
MCC:FKBP APC or BMDC APC cells were surface biotinylated using EZ-Link
Sulfo-NHS-Biotin (Thermo Scientific, Waltham, MA), or in some cases surface
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labeled with BODIPY™ FL NHS Ester (Succinimidyl Ester) conjugated to
AlexaFluor 647 (ThermoFisher), in PBS pH 8.0 for 20 min at RT. Following
surface labeling, excess biotin or BODIPY dye was quenched with 15x volume of
PBS pH 7.4 containing 100mM glycine, followed by an additional 3 washes with
PBS + 100 mM glycine. Cells were then resuspended in cRPMI prior to counting
and plating for use in the trogocytosis assay.

Generation of BMDCs
Bone marrow cells were isolated from femurs and tibiae of B10.A mice and
cultured for 6 days in sterile non-tissue culture grade petri dishes at 105 cells/ml
in complete RPMI medium containing 30 ng/ml recombinant murine granulocyte
macrophage-colony stimulating factor (GM-CSF) (PeproTech, Rocky Hill, NJ) at
37 °C and 5% CO2. Fresh culture media and GM-CSF were added on day 3, and
non-adherent cells were harvested on day 6. Cells were activated by plating on
tissue culture-coated 6-well plates with addition of Sigma adjuvant sysTEM at 125
ng/ml 18 hours prior to use. Adherent cells were surface biotinylated and
exogenously loaded with MCC88–103 peptide at a final concentration of 2.5 µM for
2 hours prior to use. Purity was verified via flow cytometry to be >90% CD11c+.

In vitro T cell priming
Non-polarized TCR-transgenic CD4+ T cell blasts were generated in vitro to
increase the potential for trogocytosis relative to naïve CD4+ T cells [392]. Singlecell suspensions of splenocytes from 6- to 12-week-old 5C.C7 or 5C.C7 x B10.A
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F1 transgenic mice were depleted of erythrocytes by hypotonic lysis using Gey’s
balanced salt solution (155 mM NH4Cl, 10mM KHCO3) and resuspended in
complete RPMI 1640. Splenocytes from 5C.C7 x B10.A F1 mice were activated
in vitro for 6 days by addition of 2.5 µM MCC88–103 peptide to splenic cell

suspensions. 5C.C7 splenocytes were stimulated for 48 hours on pre-coated
anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) plates followed by a 2-day incubation
after removal from antibody-coated plates prior to use. Viable lymphocytes were
isolated from priming cultures by density centrifugation using Lympholyte M
(Cedarlane Labs, Burlington, NC). When culturing B10.A x 5C.C7 F1 or C57BL/6
cells, B cells were depleted from cultures by incubating cells for 30 min with
biotin-labeled anti-B220 (BioLegend), followed by 3 washes in PBS. Cells were
then incubated for 20 min with 3.75 µm streptavidin-coated magnetic particles
(Spherotech) followed by removal of B220+ cells by magnetic separation.
Cultures of cells from peptide T cell blast cultures were 90-95% CD4+
immediately prior to use in the trogocytosis-assay.

In vitro TH1 and TH2 polarization to induce TH1 or TH2 effector subset
differentiation
Primary T cells were stimulated directly ex vivo on anti-CD3 (1 µg/ml) and antiCD28 (1 µg/ml) coated plates, as described above, with either T H1 (5 ng/ml IL-12
and 20 µg/ml anti-IL-4 (11B11), or TH2 (10 ng/ml rmIL-4 and 20 µg/ml anti-IFN)
differentiation cocktails [83]. On day 2, 5 U/ml rmIL-2 was added to all cultures.
The exogenous cytokines were obtained from Peprotech, (Rocky Hill, NJ) and
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neutralizing antibodies were purchased from Biolegend. Cells were removed
from Ab-coated plates on day 4. Polarization was confirmed through flow
cytometry analysis of transcription factor and cytokine staining for GATA-3, TBet, IL-4 and IFN. Immediately prior to use in the trogocytosis assay, >95% of
CD4+ blasts generated under TH1-polarizing conditions were T-bet+, and >60% of
CD4+ blasts generated under TH2-polarizing conditions were GATA-3+.

Standard in vitro trogocytosis assay
To assess trogocytosis by the CD4+ 5C.C7 T cells, we used our previously
described standard in vitro trogocytosis assay ([81] Fig. S3.1A). Briefly, 0.5 x 106
surface biotinylated or BODIPY labeled MCC:FKBP fibroblast or 1 x 10 6 similarly
labeled BMDC APC were plated into individual wells of a 6-well tissue culture
plate (Greiner, Monroe, NC) and incubated overnight at 37 °C. The MCC:FKBP
cell line doubling time is approximately 12 hours, so following the overnight
incubation wells contained 106 APC at the time T cells were added. To facilitate
magnetic depletion of APC from recovered T cells, iron-containing polystyrene
2.22 µm beads (Spherotech, Green Oaks, IL) were added to the overnight
cultures at a final concentration of 0.01% w/v. Twelve to 18 hours later, free
magnetic beads were removed from cultures by rinsing, and 2.5 x 10 6 in vitroprimed T cells, (for a final 2.5:1 T:APC ratio), were added to each well and
subsequently incubated for 90 min at 37 °C. For experiments using naïve CD4+ T
cells, B220 negative selection was performed as described in in vitro T cell
priming, and the same 2.5:1 T:APC ratio was used, but T cells were incubated
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with APC for 18 h at 37 °C. After the co-incubation, T cells were recovered from
the cultures by rinsing with cold PBS pH 7.4. Greater than 95% of residual APC
were removed by magnetic separation and greater than 70% of the input T cells
were routinely recovered from the culture at 90 min after the PBS wash. After two
additional PBS washes, recovered T cells (containing both trog+ and trog– cells)
were analyzed immediately by flow cytometry, or were resuspended in complete
RPMI 1640 medium at low density (104 /ml) to minimize T:T contact, and cultured
for 60 min in 6-well plates or petri dishes to allow for residual APC to settle and
bind to the surface of the 6-well plate. Cells were then gently aspirated and
placed into unused 6-well plates with 2 mL/well at 104 cells/ml additional time
periods. These cultures of recovered cells contained >95% CD4+ cells, and
<0.1% residual APC (Fig. S3.1B).

Inhibition of TCR Signaling
To confirm the role of trogocytosis-mediated signaling in effector function, TCR
signaling was extinguished using the reversible Src family tyrosine kinase
inhibitor PP2 (Life Technologies), as previously reported [81, 442]. Immediately
post-trogocytosis assay, recovered T cells were incubated for 20 min in 20 µ
PP2, followed by three washes in PBS to remove the PP2. Cells were then
assessed immediately to confirm the treatment halted all TCR-signaling, or were
cultured as described above and assessed for TCR-downmodulation,
transcription factor, and intracellular cytokine expression via flow cytometry.
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CFSE / CellTrace Violet Labeling of T cells
Primary mouse splenocytes were washed twice with CFSE loading buffer ( 0.1%
FBS in PBS pH 7.4). Cells were then resuspended at 107 cells/ml in pre-warmed
CFSE loading buffer containing 5 µM CFSE (Sigma-Aldrich), or 5 µM CellTrace
Violet (ThermoFisher) and incubated at 37 °C for 10 minutes. The reaction was
stopped by addition of an equal volume of complete RPMI 1640 medium
containing 10% FBS, followed by two additional washes in complete RPMI.

In vivo Trogocytosis Experiments
In adoptive transfer experiments, B10.A mice were immunized via subcutaneous
injection (s.c.) (base of tail) with either 300 µg pigeon cytochrome c (PCC)
protein (Sigma-Aldrich) in 100 µl of Sigma Adjuvant System (SAS) or with 100 µl
of PBS as a negative control. 24 hours later, 2 x 106 CFSE labeled 5C.C7
primary splenocytes in PBS were injected i.v. Draining inguinal lymph nodes
were collected five days post-adoptive transfer and analyzed using flow
cytometry. Donor 5C.C7 cells were identified as being V3+ and CFSE+. Of these
transferred donor cells, trog+ cells were identified as CD3+ CD4+ CD80+ I-Ek+ (Fig.
S.31D).

To generate in vivo trog+ cells in a non-transgenic setting, C57Bl/6 CD45.1 mice
were subcutaneously immunized at the base of tail with 300 µg of chicken egg
white albumin (OVA) (Sigma-Aldrich) in 100 µl SAS, or 100 µl SAS alone as a
control. 14 days later, OVA-immunized mice were boosted s.c. with 300 µg OVA
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in 100 µl of PBS, control mice were injected with 100 µl PBS alone. Five days
post-boost, draining inguinal lymph nodes and spleens were harvested and
analyzed via flow cytometry. Trog+ cells were identified as CD3+ CD4+ CD80/86+ IA/E+ (Fig. S3.5). To confine analysis of cytokine and transcription factor
expression to cells with similar activation states, CD4+ CD69High cells were gated
on prior to identification of trog+ and trog– populations.

Flow cytometry
Cells were recovered from cultures and resuspended at 106 /ml in FACS buffer
(PBS pH 7.4 containing 2% BSA Fraction V (Sigma-Aldrich), 2.5 mM EDTA, and
0.1% NaN3). To assess viability of cells, cells were stained for 10 min at RT with
Zombie NIR fixable viability dye (Biolegend) diluted in PBS then washed 3x with
PBS. Cells were then stained for surface markers with the indicated reagents for
30 min on ice in FACS buffer. After three additional washes in FACS buffer, cells
were stained for 20 min with secondary reagents in FACS buffer, when
necessary. Following a final set of three washes in FACS buffer, cells were
resuspended in 400 µl of FACS buffer and stored on ice until being analyzed
within 2 hours of staining. Alternatively, cells were fixed in ice-cold fixative (4%
paraformaldehyde and 0.5% glutaraldehyde), or Biolegend Fixation Buffer, for 30
min at 4 °C followed by 3 washes in FACS buffer. Fixed cells were resuspended
in 400 µl of FACS buffer and stored in the dark at 4 °C until being analyzed the
following day.
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For the detection of antigen-specific cells, an MCC:I-Ek (88–103) MHC class-II
tetramer was obtained through the NIH tetramer core facility (Emory University,
Atlanta, GA). Prior to surface staining, tetramer was diluted 1:100 in FACS buffer,
and spun down at 1000 x g for 10 minutes to remove aggregates. Cells were
blocked with FC receptor-block, then stained with recovered tetramer in
suspension, for 30 min at 37 °C, or with an irrelevant isotype control tetramer.
For detection of previously-activated cells gating included selection of CD44+
cells (Fig. S4.3)

Intracellular Cytokine Staining
To enhance detection of intracellular cytokines, in Figs. 3.2, 3.4A-C, 3.6, 3.7,
3.8, 4.4, 4.8, 4.12, 4.16-18, 4.29, and 4.35B, cells were re-stimulated at for 5
hours 37 °C with 500 ng/ml PMA (Phorbol 12-myristate 13-acetate) (SigmaAldrich), 1 µg/ml Ionomycin (Sigma-Aldrich), in the presence of 5 µg/ml brefeldin
A (BioLegend). After staining surface molecules on live cells, as described
above, cells were fixed for 30 min in BD Bioscience cytofix/cytoperm followed by
three washes in 1x Biolegend permeabilization/wash buffer (PWB). Cells were
then stained for intracellular targets for 60 min on ice or overnight at 4 °C with
staining reagents diluted in 1x PWB. Following intracellular staining, cells were
washed three times in PWB and were either analyzed immediately, or were
stored in FACS buffer in the dark at 4 °C and analyzed the following day.

Transcription Factor Staining
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For transcription factor staining, live cells were stained for surface molecules, as
described above, then fixed in Biolegend True-Nuclear transcription factor
fixation buffer for 60 min at room temperature. Following 3 washes in TrueNuclear Perm Buffer, intercellular targets cells were stained with antibodies
diluted in True-Nuclear Perm Buffer for 60 minutes on ice, or overnight at 4 °C.
After a final set of 3 washes in Perm Buffer, cells were resuspended in 300 µl
FACS buffer and analyzed immediately via flow cytometry.

Cells were analyzed on a FACSAria (BD Bio-sciences) in the University of
Montana Fluorescence Cytometry Core, or an LSRII (BD Bio-sciences) in the
University of Montana Center for Translational Medicine. Data were analyzed
with FlowJo 8.8.7 and FlowJo 10 software (Tree Star, Ashland, OR). Geometric
mean flourescence intensity (MFI) values were determined, where indicated.

Gating Strategies
Identification of trog+ cells was done by gating on lymphocyte population (SSC-A
vs. FSC-A) followed by rigorous doublet exclusion (FSC-W vs. FSC-H, and SSCW vs. SSC-A). Live CD3+ CD4+ cells were identified by the absence of fixable
live/dead staining, and trog+ cells were identified by the presence of trogocytosed
biotinylated-APC membrane protein (greater than stained, anti-CD3/CD28stimulated, or unstimulated controls), or the presence of CD80/CD86 + I-Ek for
experiments using 5C.C7 TCR transgenic mice, or presence of CD80/CD86 +
MHCII I-A/E for experiments using C57BL6/J mice (Fig. S3.5). Ag-specific
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staining was confirmed by comparison to respective isotype controls of matched
populations confirmed by background levels on unstimulated CD4 + T cells (Fig.
S3.5).

Intracellular cytokines and transcription factor gating was established using
matched-isotype control Ab staining for respective populations. trog+ and trogisotype control intensities were nearly identical, and vertical lines in histogram
data depict fluorescence intensity greater than 99% of cells stained with isotype
controls.

Removal of Peptide from Trogocytosed-MHCII
Recovered T cells were washed in PBS at RT and 5 x 106 cells/ml were
incubated at RT for 2.5 min with citric acid buffer (0.1M sodium citrate (Sigma),
0.1M citric acid (Sigma) in PBS pH 4.5 to induce reversible-conformational
changes in MHCII [443]. The reaction was neutralized by adding 15x volume of
cRPMI, followed by two additional washes in cRPMI. Following washing of
unbound peptide, aliquots of cells were supplemented with 10 mM hemoglobin
(Hb) peptide, or MCC peptide. When MCC-loaded BMDC were exposed to the
same treatment, then used in a trogocytosis-assay, in cultures with
supplemented Hb the rate of trogocytosis, and activation (as measured by CD69
expression) of CD4+ T cells recovered from the trogocytosis-assay were reduced
by >80% relative to cells recovered from BMDC cultures supplemented with
MCC-peptide. Trog+ cells recovered from cultures where peptide was stripped
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and replenished with Hb showed a substantial reduction in pZAP-70 signaling
compared to untreated, or peptide-stripped cultures where MCC was replenished
(Fig. S4.2). Acid treatment did not have a significant effect on activation state of
cells as determined by CD69 expression (data not shown).

Antibody-Neutralization of Trogocytosed MHCII/CD80
Following recovery from the trogocytosis-assay and removal of contaminating
APC, 20 µg/ml of purified anti-I-Ek (17-3-3) (BioLegend) and anti-CD80 (Clone)
(BioLegend) were added to an aliquot of recovered cells, and replenished 3d
post-recovery. In experiments involving neutralizing antibodies, trogocytosis was
measured by the presence of trogocytosed biotin-labeled APC membrane
proteins. trog+ cells recovered from cultures containing neutralizing antibodies
showed a substantial decrease in pZAP-70 compared to trog+ cells from
untreated cultures (Fig. S4.2)

In vitro Cytokine Supplementation
Immediately following recovery from the trogocytosis assay, an aliquot of
recovered T cells was supplemented with recombinant mouse IL-2 to a final
concentration of 100 iU/mL. Cultures were re-supplemented with IL-2 at 24, and
48 hrs post-recovery.

Isolating Lymphocytes from Blood
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Blood was collected into tubes containing 0.2 mM EDTA followed by RBC lysis
with Gey’s solution then stained as described above.

Isolation of lymphocytes from skin
Prior to immunization mouse hair was trimmed in a ~2 cm2 patch around the
injection site. At the time of harvest, ~1.5 cm 2 skin was collected from the
injection site and minced into 3-5mm pieces. Tissue was incubated with 2.5 mM
HBSS for 30 min at 37 °C degrees followed by an additional 60 min digestion at
37 °C after the addition of collagenase D (Sigma) to a final concentration of 100
U/ml. Skin was washed in cRPMI and tissue was dissociated with glass slides,
and filtered through a 70 µm filter prior to staining for flow cytometric analysis.

Treatment of T cells with Cytochalasin D
Prior to imaging of proliferating naïve cells, cytochalasin D (Sigma), was added to
cultures for a final concentration of 10 µM, followed by a 4 hr incubation at 37 °C
before collection and staining.

Edu Incorporation Assays
Twenty-four hours prior to collection and analysis, 2 mM 5-Ethynyl-2´deoxyuridine (EdU) was added aliquots of recovered cells. After collection, cells
were stained for surface molecules, with the exception of PE-conjugated Abs.
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Cells were fixed with 4% PFA for 20 min at RT and permeabilized with 0.2%
Triton-x 100. Edu staining was conducted according to manufacturer’s protocol,
followed by 3 washes and when applicable, staining with PE-conjugated Abs.

Detection of Extracellular Cytokines
The detection of secreted cytokines in culture medium was performed using
BioLegend LEGENDplex beads according to the manufacturer’s directions.
Briefly, culture medium from cells was centrifuged to remove contaminating cells
and debris, and immediately stored at -80 °C until used. Samples and known
standards for each cytokine analyzed were subsequently incubated with
cytokine-capture beads and biotinylated-detection antibodies in polypropylene
microfuge tubes shaking at 1000 rpm at room temperature for 2 hours. Following
this incubation, SA-PE was added, followed by a 30 min incubation while shaking
at 1000 rpm. Beads were washed and immediately analyzed via flow cytometry.

LEGENDplex beads were analyzed on a LSRII (BD Bio-sciences). Standard
curves were generated, and data were analyzed with LEGENDplex software
(Biolegend/ VigeneTech). Cytokine levels in samples were confirmed using
BioLegend LEGEND MAX sandwich cytokine-capture ELISA kits according to
manufacturer’s protocol.

85

Cell Staining and Image Collection for Microscopic Analysis

T cells recovered and isolated from the standard trogocytosis assay were
cultured at low density (104 cells/ml) for three days in complete RPMI at 37 °C.
Live cells were isolated using Lympholyte M density centrifugation prior to
detection of trogocytosed molecules with fluorochrome-conjugated streptavidin
and anti-I-Ek antibodies diluted in FACS buffer for 30 min on ice. Cells were then
washed 3x in PBS and ~106 recovered T cells were placed in 0.01% poly-Llysine (Sigma) precoated #1.5 LabTek II eight-chambered coverslips (Nunc) for
10 min at 37 °C in PBS. Cells were fixed with ice-cold fixative (4%
paraformaldehyde and 0.5% glutaraldehyde in PBS) in a dark, a humidified
chamber for 20 min at room temperature, followed by permeabilization with 0.2%
Triton X-100 in PBS for 10 min. Intracellular cytokine and phospho-ZAP70
staining was performed for 1 hour at room temperature in a dark humidified
chamber followed by washing with PBS and addition of SlowFade Gold anti-fade
reagent (Thermo Fisher, Eugene, OR). 0.3 µm optical sections were collected, on
an Olympus Fluoview FV1000 laser scanning confocal mounted on an inverted
IX81 microscope using a Nikon 60x objective with 1.4 N.A, housed in the UM
Molecular Histology and Fluorescent Imaging core facility.

Image analysis
Constrained, iterative deconvolution was performed using the Applied Precision
SoftWorx software package (GE Healthcare, Issaquah, WA). The integrated
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intensity of streptavidin, which is a measure of the amount of fluorescently
labeled molecules trogocytosed, was obtained for areas ≥ six-times above
background fluorescence. For analysis of phosphorylated ZAP-70, the integrated
intensity and mean fluorescent intensity was obtained for areas 6-fold above
background. Between 25 and 55 trog+ cells were imaged in each of five
independent experiments. Cells were selected for analysis by the presence of
streptavidin or I-Ek (6-fold above background intensity). Unstimulated cells were
also stained and examined to establish levels of background and non-specific
staining. To determine IL-4 or IL-21 polarization towards trogocytosed molecules,
cells were divided into 4 quadrants using the ImageJ quadrant picker plugin, with
trogocytosed molecules in the center of one radian along the circumference of
the cell. The presence of IL-4 staining in the same quadrant as trogocytosed
molecules was defined as specific accumulation. Images presented are
maximum intensity projections of three consecutive 0.3 µm-thick Z-axis optical
sections centered around the highest intensity staining of trogocytosed molecules
on the cells surface were created by stacking images in ImageJ. IL-21 and Tcf-1
images in chapter 4, and the additional images presented in Fig. S3.4, are single
0.3 µm-thick optical sections

Statistical Analysis and Graphing
Statistical analysis was determined by student’s t test, and one-way ANOVA
followed by Tukey’s multiple comparison test when more than two samples were
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compared, using Prism 4 (GraphPad Software, La Jolla, CA). Significance was
defined as * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, and **** p≤ 0.0001.

Chapter 3
Trogocytosis-mediated Intracellular Signaling in
CD4+ T cells Drives TH2-associated Effector
Cytokine Production and Differentiation
The following are results as presented in the Journal of Immunology, 2019,
minus the materials and methods section which has been consolidated into
chapter II, and references which have been consolidated in the bibliography of
this dissertation.
Trogocytosis-mediated Intracellular Signaling in CD4+ T cells Drives TH2associated Effector Cytokine Production and Differentiation1,2
Jim Reed† and Scott Wetzel*†,§
† Program in Cellular, Molecular and Microbial Biology, Division of Biological

Sciences, University of Montana, Missoula, MT 59812, USA
§Center for Environmental Health Sciences, University of Montana, Missoula, MT
59812, USA

1. Work funded by R03AI122167 (to S.A.W). Fluorescence Cytometry and
Molecular Histology and Florescence imaging core facilities used to perform
studies are supported by P30RR033379.

2. Abbreviations used:
BMDC, bone marrow-derived dendritic cells; FKBP, FK506-binding protein; ICS,
Intracellular cytokine staining; Lck, P56Lck; MFI, mean fluorescence intensity;
MCC, moth cytochrome-c; OVA, ovalbumin; pZAP-70, phosphotylated ZAP-70;
Trog (+), trogocytosis-(positive); Trog (–), trogocytosis-(negative)
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Abstract
CD4+ T cells have been observed to acquire APC-derived membrane and
membrane-associated molecules through trogocytosis in diverse immune
settings. Despite this, the consequences of trogocytosis on the recipient T cell
remain largely unknown. We previously reported that trogocytosed molecules on
CD4+ T cells engage their respective surface receptors, leading to sustained
TCR signaling and survival after APC removal. Using peptide-pulsed BMDC and
transfected murine fibroblasts expressing antigenic MHC:peptide complexes as
APC, we show that trogocytosis-positive CD4+ T cells display effector cytokines
and transcription factor expression consistent with a TH2 phenotype. In vitro
polarized TH2 cells were found to be more efficient at performing trogocytosis
than TH1 or non-polarized CD4+ cells, while subsequent trogocytosis-mediated
signaling induced TH2 differentiation in polarized TH1 and non-polarized cells.
Trogocytosis-positive CD4+ T cells generated in vivo also display a TH2
phenotype, in both TCR-transgenic and wild type models. These novel findings
suggest that trogocytosis-mediated signaling impacts CD4+ T cell differentiation
and effector cytokine production, and may play a role in augmenting or shaping a
TH2-dominant immune response.
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Introduction
T lymphocytes acquire lipids and membrane-bound molecules directly from the
surface of antigen presenting cells (APC) in a phenomenon termed trogocytosis
[279, 373]. This event has been frequently observed in CD4+ T-helper (TH) [81,
285, 287, 368-372], CD8+ [370, 373-376], and  [377] T cells. Though the
consequences of trogocytosis on recipient cells are not completely understood, it
has been described as “an inherent feature in CD4+ T cell activation” [420]. This
phenomenon is not exclusive to T cells, as B cells [378, 379], NK cells [380-382],
basophils [283], macrophages [383, 384], neutrophils [385-387], and dendritic
cells [388, 389], have all been reported to perform trogocytosis. With elevated
levels of trogocytosis documented in sites of autoimmune inflammation [391],
viral and parasitic infections [282, 413, 414], rheumatoid arthritis [11], and in
tumor environments [284, 403], this widely observed event has been proposed to
play a role in the modulation of immune responses [277, 388, 415-419].
Work over the past decade has begun to decipher the mechanism of T
cell trogocytosis. We, and others, have previously shown that trogocytosis by
CD4+ T cells occurs at the immunological synapse formed between Ag-specific
CD4+ T cells and APC [287, 392, 394, 397, 402]. The formation of the
immunological synapse involves the spatio-temporal rearrangement of the TCR,
costimulatory molecules, and adhesion molecules, into distinct, spatiallysegregated supramolecular activation complexes (SMACs) [51-54]. Upon binding
MHC:peptide complexes, TCRs migrate towards the center of the SMAC where
they become internalized by the T cell and are either recycled to the surface, or
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ubiquitinated leading to their degradation [60]. Martinez-Martin et al., have
proposed a model of trogocytosis in which APC-derived membrane and
membrane proteins are internalized in tandem with TCR via T-cell phagocytosis.
Recycling endosomes containing acquired APC fragments then fuse with the T
cell plasma membrane resulting in APC-derived molecules being displayed on
the T cell surface in their native topological orientation [278, 411]. Trogocytosed
molecules are retained in a focused spot on the CD4+ T cell surface [81, 287]
and remain fully functional, as demonstrated by the ability for trogocytosispositive (trog+) T cells to present antigen, in the context of other acquired
molecules, to responding T cells [369, 371, 372, 415, 420-426]. The
consequences of such presentation appear to correlate with the nature of the
acquired molecules and phenotype of the trog+ cell. While trog+ CD4+ cells
displaying acquired CD80 and MHC:peptide have been shown to activate
responding naïve T cells [371, 410, 420, 424], presentation of Ag to activated
cells has been reported to induce responder cell death [429]. In a regulatory
context, trog+ T regulatory (Treg), or TH cells displaying trogocytosed molecules
associated with immune-suppression, such as HLA-G, show enhanced
suppressive capabilities [417, 420, 422, 432, 437, 438]. Collectively, the above
findings underscore that CD4+ T cell trogocytosis, and the subsequent
presentation of acquired molecules, are biologically significant events in the
context of regulating immune responses.
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While the ability of trog+ T cells to act as APC has been fairly well documented,
much less is known about the biological consequences of trogocytosis on an
individual trog+ cell. In our previous studies, we detected TCR signaling in trog+,
but not trog–, CD4+ T cells up to 72 hours after separation from APC. This
sustained signaling was mediated by trogocytosed molecules engaging their
cognate receptors on the trog+ T cell, resulting in “autopresentation”, referred to
here as “trogocytosis-mediated signaling”. This signaling led to the enhanced
survival of trog+ cells compared to trog– cells, up to five days after APC removal
[81]. Consistent with these findings, Zhou et al. found that trog+ CD4+ T cells
displayed sustained activation of NFB and AP1, 24 hours after removal from
APC. Interestingly, the trog+ cells also developed a unique cytokine profile [439],
raising the possibility that a difference exists between trogocytosis-mediated
signaling and signals received from APC. Taken together, the above results
suggest that trogocytosis-mediated signaling has the potential to uniquely impact
the survival, activation state, and effector cytokine production and/or
maintenance of the trog+ CD4+ T cell after separation from APC.
In this study, we examined whether trogocytosis-mediated signaling
impacted T cell effector cytokine production and differentiation in the context of
the individual trog+ cell. Using non-polarized in vitro CD4+ T cell blasts, we found
that shortly after APC removal, a high frequency of trog– cells expressed IFN,
consistent with a T helper 1 (TH1) phenotype. The trog– cells did not maintain
IFN expression over a subsequent 72-hour incubation, and by 72 hours only
minimal levels of any effector cytokine examined were detected. In contrast, 5
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hours after APC removal the frequency of IFN+ trog+ cells was significantly lower
than IFN+ trog– cells. Interestingly, over the subsequent 72-hour incubation, IL-4
expression was significantly increased in the trog+ cells, consistent with a TH2
phenotype. Because trogocytosis-mediated signaling induces preferential
survival of trog+ cells [81], the appearance of the TH2 phenotype by trog+ cells
could be due to differences in the ability of TH1 and TH2 cells to perform
trogocytosis. Consistent with this possibility, in vitro polarized TH2
cells were more efficient at performing trogocytosis than TH1 or non-polarized
CD4+ cells. However, further investigation revealed that trogocytosis-mediated
signaling was directly contributing to the TH2-associated effector cytokine and
transcription factor expression in non-polarized trog+ CD4+ cells. In addition, in
vitro TH 1-polarized trog+ cells lost expression of IFN and T-bet, and began
expressing IL-4 and GATA-3, suggesting that trogocytosis-mediated signaling
was inducing TH 1 to TH2 conversion. Finally, using both TCR-transgenic and
non-transgenic models, and distinct Ag systems, we show that in vivo, a
significantly higher frequency of trog+ CD4+ T cells display a TH2
phenotype when compared to trog– cells from the same animal. Cumulatively,
these findings suggest that trogocytosis-mediated signaling has the potential to
significantly impact CD4+ T cell effector cytokine production and differentiation,
and subsequently may play a role in sustaining, augmenting, or shaping, TH2dominant immune responses.
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Results
Intracellular TCR signaling and elevated activation is maintained in trog+,
but not trog– CD4+ T cells after APC removal.
At sites of inflammation and immune activation, there is a correlation between
CD4+ trogocytosis and a heightened activation state [397]. This is consistent with
data showing that highly activated cells display enhanced trogocytic activity [287,
391]. An additional explanation for the heightened activation observed in
trogocytosis-positive (trog+) cells is that that trogocytosed molecules could
engage their receptors on the trog+ CD4+ T cell and sustain intracellular
signaling. Such trogocytosis-mediated signaling may be playing an important and
unappreciated role in driving and/or maintaining T cell activation, effector
functions, and differentiation. We have previously shown that that after APC
removal, there is selective survival of trog+ cells over 5 days in vitro compared to
trog– cells [81]. In addition, both TCR-proximal (ZAP-70 phosphorylation) and
distal signaling (ERK 1/2 phosphorylation) was detectable in trog+, but not trog–
cells 72 hours after APC removal. This sustained-signaling occurred
independently of APC, and was driven by the engagement of trogocytosed
molecules and their receptors on T cells (i.e. trogocytosis-mediated signaling)
[81].

To extend on our previous study, we began by comparing the activation state
and TCR-proximal signaling in trog+ and trog– cells up to 72 hours after recovery
from a 90-minute in vitro trogocytosis assay. Recovered T cells were analyzed
immediately, or cultured for 3 days at low density (104 cells/ml) to minimize T:T
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interactions, and samples were collected daily. At indicated time-points (Fig. 3.1),
cells were analyzed via flow cytometry, and trog+ cells were identified by the
presence of trogocytosed, biotin-labeled APC-derived molecules (Fig. S3.1C).
Consistent with our previous findings, both trog+ and trog– cells showed similar
levels of TCR downmodulation immediately after the trogocytosis-assay,
indicating that both populations had recognized antigen (Fig. 3.11A, B). In
agreement with the TCR downmodulation data, both trog+ and trog– cells also
displayed elevated levels of the activation marker CD69, compared to
unstimulated cells (Figs. 3.11C-E). However, after APC were removed from the
system, only the trog+ cells maintained TCR downmodulation and an activated
(CD69High) phenotype throughout the 72-hour incubation. In contrast, at the 48
and 72-hour time points, the trog– cells displayed significantly lower TCR
downmodulation levels compared to the trog+ cells (Fig. 3.1B), and surface TCR
levels were similar to unstimulated T cell blasts (Figs. 3.11A, B). The loss of TCR
downmodulation coincided with a decrease in CD69 expression by the trog– cells
to levels similar to unstimulated T cell blasts (Figs. 3.1C, D), and at the 48 and
72-hour time points, the trog+ cells displayed significantly increased levels of
CD69 compared to trog– cells (Fig. 3.1D). This marked difference was not only
due to the loss of CD69 expression by trog– cells, but also a result of trog+ cells
enhancing CD69 expression, and the loss of CD69Low trog+ cells (Figs. 3.1C-E).
In agreement with our previous study [81], the trog+ cells displayed enhanced
survival compared to the trog– cells, as seen by the increase in trog+ frequencies,
and decrease in trog– frequencies after APC removal (Fig. 3.1C). While the
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phenotype of the trog+ cells is consistent with active-TCR signaling, the
phenotype displayed by the trog– cells is consistent with published data showing
that CD69 expression peaks between 18-48 hours after removal of in vitro TCR
stimulation [444].

To confirm that the TCR engagement displayed by trog+ cells resulted in TCRproximal signaling, the levels of phosphorylated ZAP-70 (pZAP-70) were
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assessed [445, 446]. In support of the data in Figs. 3.1A and B, and consistent
with our previous studies [81], the trog+, but not trog– cells, maintained pZAP-70
levels after APC removal (Fig. 3.1E). At each observed time-point, the trog+ cells
had significantly higher levels of pZAP-70, as determined by MFI, compared to
the trog– cells (Fig. 3.1F). Because nearly no APC were present in the cultures of
CD4+ T cells following the trogocytosis-assay (Fig. S3.1B), the increased CD69
expression, TCR downmodulation, and elevated pZAP-70 maintained in trog+,
but not trog–, cells over the 72-hour incubation suggests that cell-autonomous,
trogocytosis-mediated signaling sustained the T cell activation.

Trog+ CD4+ T cells express elevated levels of IL-4 and IL-5, whereas trog–
cells express high levels of IFN+ and little IL-4 or IL-5.
The sustained activation and TCR proximal signaling in trog+ cells after removal
from APC raised the possibility that trogocytosis-mediated signaling may impact

98

effector cytokine production within these cells. To examine this, culture
supernatants from T cells recovered from the trogocytosis assay were analyzed
for cytokines characteristic of various TH subsets using cytokine-capture beads.
Five hours after recovery from the in vitro trogocytosis-assay, T cell supernatants
contained high levels of IFN and IL-2, but negligible amounts of IL-4, IL-6, IL-21
or IL-13 (Fig. 3.2A). Interestingly, by 72 hours IFN levels were significantly
decreased, while IL-4 levels had increased significantly (Fig. 3.2A). To examine a
potential correlation between trogocytosis and the observed cytokine production,
intracellular cytokine staining (ICS) was performed on recovered cells at 24-hour
intervals over a 72-hour incubation after APC removal. The fold-difference in MFI
for TH subset-characteristic cytokine expression of trog+ and trog– cells compared
to T cell blasts which did not undergo the trogocytosis-assay (unstimulated cells)
is shown in Fig. 3.2B. Five hours post-recovery, neither the trog+ nor trog– cells
showed increased levels of IL-4, IL-5, IL-12, IL-6, IL-9, or IL-17, and the only
cytokine showing substantially increased expression compared to unstimulated
controls was IFN (Fig. 3.2B). Interestingly, at 5 hours IFN levels were increased
in the trog– cells significantly more than in the trog+ cells (Fig. 3.2D). By 72 hours,
there were still minimal expression of IL-12, IL-6, IL-9, or IL-17 by both
populations. The robust IFN expression seen in trog– cells at 5 hours was no
longer apparent and had decreased to levels only marginally higher than that of
unstimulated cells, while IFN levels remained minimal in trog+ cells. However,
the trog+ cells had developed a striking 2.2-fold increase for IL-4 and 1.85-fold
increase for IL-5, and 0.89-fold increase for IL-2, all of which were found to be
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significantly higher in the trog+ cells compared to the trog– cells (Fig. 3.2B).
Representative histograms for IFN and IL-4 expression by trog+, trog–, and
unstimulated cells are presented in Fig. 3.2C. Enhanced IL-4 expression was
also observed in trog+ cells from parallel experiments using MCC peptide-pulsed
BMDCs as APC (Fig. S3.2). Because the only significant differences in subsetcharacteristic cytokines detected between trog+ and trog– cells were TH1 and
TH2-associated, the subsequent experiments focused on these subsets.

Further assessment of the IFN and IL-4 production on a per-cell basis showed
that the frequency of IL-4+ cells increased exclusively in the trog+ cells, from an
average of 12.5% at 5 hours to an average of 73% by 72 hours (Fig. 3.2D). By
comparison, the frequency of trog– IL-4+ cells remained below 5% at all timepoints. This resulted in significantly more trog+ IL-4+ cells than trog– IL-4+ cells at
24, 48, and 72 hours (Fig. 3.2D left). In contrast, on average, 34% of the trog–
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cells, but only 10% of trog+ cells were IFN+ at 5 hours. Unlike IL-4, IFN
expression was not maintained in trog+ cells. Despite a dramatic loss of trog–
IFN+ cells, there was still a significantly lower frequency of trog+ IFN+ cells
compared to the trog– IFN+ cells at each observed time-point (Fig. 3.2D right).
The decrease in trog– IFN+ cells over the 72-hour incubation correlates with the
loss of TCR signaling and activation seen in Fig. 3.1, and the massive cell death
in this population as observed in Fig. 3.1C and our previous study [81].

The strong IFN+ expression in trog– cells at 5 hours further demonstrates that
both trog+ and trog– cells are fully activated by the initial APC encounter. Thus,
differences in the phenotype between trog+ and trog– cells do not simply reflect
whether T cells have recognized Ag. In addition, although trog+ cells displayed
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sustained signaling and activation (Fig. 3.1), IFN expression in these cells was
not maintained. Combined with the increase in IL-4 expression by trog+ cells after
removal from APC, these results are consistent with the possibility that
trogocytosis-mediated signaling was impacting the effector cytokine production of
the trog+ cells, in a manner consistent with a TH2 phenotype.
TH2 cells are more efficient than TH1 or non-polarized CD4+ T cells at
performing trogocytosis.
One potential explanation for the increased IL-4 expression and frequency
observed in trog+ cells is that pre-TH2 or TH2-like cells had performed
trogocytosis more efficiently than pre-TH1 / TH1-like cells. Thus, the increase in
IL-4+ trog+ cells may simply reflect the superior survival displayed by trog+ cells
after removal from APC [81]. To compare the trogocytic potential of differentiated
TH1 and TH2 cells, in vitro-polarized TH1 and TH2 blasts were used in an in vitro
trogocytosis assay (Figs. 3.3A, B). Representative histograms in Fig. 3C and D
show that GATA-3+ TH2 blasts were highly efficient at performing trogocytosis,
with an average of 71.5% displaying biotin-labeled APC-membrane and 58.1%
having I-Ek on their surface. In contrast, T-bet+ TH1 cells were weakly trogocytic,
averaging only 14.2% of cells with detectable APC-membrane and 10.4% being
I-Ek+. For comparison, non-polarized blasts, which showed a predominant TH1
phenotype (Figs. 3.3A, B), averaged 26.8% of cells with detectable APCmembrane, and 16.8% with trogocytosed I-Ek. Thus, while non-polarized cells
had a significantly higher frequency of trog+ cells compared to polarized TH1
cells, the TH2 cells performed trogocytosis at significantly higher rates than both
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non-polarized, and TH1 cells (Fig. 3.3E). These results support the hypothesis
that the predominant TH2-associated cytokine production in the trog+ cells at 72
hours (Fig. 3.2) was, at least in part, due to the increased ability of TH2 cells to
perform trogocytosis and their subsequent enhanced survival, which was driven
by trogocytosis-mediated signaling.
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Trogocytosis-mediated signaling is sufficient, and effective, in driving IL-4
expression.
Based on the data in Fig. 3.3 showing that TH2 cells possess higher trogocytic
potential than TH1 or non-polarized cells, the increase in trog+ IL-4+ cells may
simply be due to trogocytosis-mediated signaling enhancing the survival of
predestined TH2 cells. If this were the case, then sustained-canonical TCR and
costimulatory signaling would be expected to augment the TH2 phenotype of preTH2 or TH2 cells. To examine this possibility, an aliquot of the same T cell blasts
to be used in a trogocytosis-assay were stimulated with plate-bound anti-CD3 +
anti-CD28 in parallel with T cells recovered from a standard in vitro trogocytosisassay. At 72 hours, on average, 77.4% of the trog+ cells were IL-4+, but only
3.5% of trog– cells and 1.8% of Ab-stimulated blasts were IL-4+ (Figs. 3.4A-C). In
contrast, Ab-stimulated blasts maintained a similar frequency of IFN+ cells over
the 72 hours (Fig. 3.4A), while the frequency of IFN+ trog+ cells dropped from an
average of 13.4% at 5 hours to 1.5% by 72 hours (Fig. 3.4C). The striking
difference between the IFN and IL-4 expression patterns between the trog+ and
Ab-stimulated blasts suggests that trogocytosis-mediated signaling provides
additional, potentially unique, signals that favor TH2-associated cytokine
expression, beyond the signaling induced by repeated CD3 + CD28 signaling.
These results further strengthen the association between trogocytosis-mediated
signaling, and a TH2 phenotype.
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As seen in Fig. 3.3, the majority of non-polarized T cells did not displayed a TH1
phenotype prior to the trogocytosis assay, yet the vast majority of trog+ cells
developed a TH2 phenotype after APC removal. While the data thus far is
suggestive that trogocytosis-mediated signaling was driving this phenotype, the
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possibility that residual signaling from the T:APC interaction was driving the
observed IL-4 expression in trog+ cells remained. To confirm that trogocytosismediated signaling alone was capable of driving IL-4 production in trog+ cells,
Lck signaling was interrupted in cells recovered from the trogocytosis assay with
the reversible Src family kinase inhibitor PP2. Using this technique, we previously
demonstrated that PP2 treatment terminated TCR signaling, however, after
removal of PP2, signaling was re-initiated in trog+, but not trog– cells [81]. Here,
we hypothesized that if trogocytosis-mediated signaling was driving IL-4
expression, then cytokine production would resume in trog+, but not trog– cells
after removal of PP2. If neither trog+ nor trog– cells re-initiated IL-4 expression
after PP2 was removed, it would indicate that trogocytosis-mediated signaling
alone was insufficient to drive the expression of IL-4. Immediately following the
trogocytosis assay, recovered cells were treated for 20 min with PP2 to halt TCR
signaling, and then incubated for an additional 2 hours after PP2 removal.
Results in Fig. 3.4D show that PP2 treatment did not alter the engagement of
TCR by trogocytosed MHC:peptide complexes, as nearly identical levels of TCR
downmodulation were observed in PP2-treated trog+ and untreated trog+ cells, at
2 (MFI reduced 2.9 fold or 2.81 fold vs. unstimulated controls, respectively) and
72 hours (1.7 fold vs. 1.3 fold reduction, respectively) (Fig. 3.4D). Treatment with
PP2 did however, reduce the frequencies of trog+ IL-4+ cells at 2 hours by an
average of 83.5% (from 11% to 1%). However, 72 hours after PP2 removal, the
frequency of IL-4+ trog+ cells had rebounded from 1% at 2 hours, to nearly 60%
at 72 hours (Fig. 3.4D, right). PP2 treatment also decreased the modest IL-4
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expression of trog– cells at 2 hours, and, as expected, neither the PP2-treated or
untreated populations of trog– cells expressed IL-4 at 72 hours (Fig. S3.3C). The
ability of trog+ cells to resume IL-4 production in absence of APC provides
compelling evidence that trogocytosis-mediated signaling was sufficient to drive
IL-4 expression in trog+ cells.

Treatment with PP2 reduced the frequency of trog+ IFN+ cells by 72%, and trog–
IFN+ cells by 80% at 2 hours (Fig. S3). However, consistent with the hypothesis
that trogocytosis-mediated signaling was driving IL-4, but not IFN expression,
the expression of IL-4, had rebounded in trog+ cells 24 hours after PP2
treatment, while IFN expression was significantly lower in PP2-treated cells
compared to untreated cells (Fig. 4E). This suggests that IFN expression was
due to signaling occurring at the immunological synapse, and that trogocytosismediated signaling was insufficient to maintain IFN production in these cells.

Intracellular IL-4 is polarized towards trogocytosed molecules
The sustained expression of IL-4 by trog+ cells up to 72 hours after removal from
APC (Fig. 3.2) suggested that trogocytosis-mediated signaling may be
contributing to the maintenance of TH2-associated cytokine production in these
cells. As a major function of TH2 cells is to provide contact-dependent help to
cognate B cells upon Ag recognition through B cell directed cytokine secretion,
we hypothesized that trogocytosis-mediated signaling may mimic these T:B
interactions. If so, intracellular IL-4 would likely be polarized towards areas of
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trogocytosis-mediated TCR-signaling. Three days after recovery from a standard
in vitro trogocytosis assay, recovered cells were stained for trogocytosed
molecules, intracellular IL-4, and pZAP-70, and analyzed by confocal
microscopy. Consistent with the flow-cytometry data (Fig. 3.2), IL-4 was only
detected in 5% of trog– cells in which polarization of IL-4 towards any distinct
region was only observed in 8% of trog– IL-4+ cells (Figs. 3.5C, S4). In contrast,
the trog+ IL-4+ cells had significantly higher frequencies of polarized IL-4
compared to the trog– IL-4+ cells, and 86% of these cells had IL-4 polarized
towards trogocytosed molecules on the T cell membrane (Fig. 3.5C).
Representative images illustrate that IL-4 was polarized towards trogocytosed
molecules (Fig. 3.5A), and that proximal TCR-signaling was occurring at the
trogocytosed molecules, as indicated by pZAP-70 staining (Fig. 3.5B). Additional
images are presented in Fig. S3.4. These images are reminiscent of
observations made by Kupfer et al., who revealed that during TH2 help for B
cells, IL-4 delivery was localized to the TH2:B cell interface [447]. Thus, data in
Fig. 3.5 are supportive of a model where trogocytosis-mediated signaling was
stimulating polarized IL-4 secretion, and also further reinforce the TH2 phenotype
displayed by trog+ cells.
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Trog+ cells develop a TH2 phenotype while trog– cells maintain a TH1
phenotype after separation from APC.
Although IL-4 is widely accepted as the representative TH2 effector-cytokine,
other T cell subsets, such as TFH, also express IL-4 [448]. Therefore, expression
of IL-4 alone does not indicate TH2-differentiation. To determine whether trog+
cells were differentiated to TH2, the expression of subset-characteristic
transcription factors was examined. The data in Fig. 3.6A show no detectable
differences in expression of GATA-3 (TH2), T-bet (TH1), Foxp3 (Treg), Bcl-6 (TFH)
or RORt (TH17) between trog+ and trog– cells, 5 hours post-recovery from an in
vitro trogocytosis-assay. This further supported that the unstimulated blasts
consisted of a homogenous population prior to use in the trogocytosis-assay. By
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72 hours however, the trog+ cells displayed a 1.7-fold increase for GATA-3, and
90% lower levels of T-bet compared to trog– cells, while only minimal differences
were detected for Foxp3, Bcl-6, or RORt (Fig. 3.6A). In agreement with the
cytokine profiles observed in Fig. 3.2, over the 72-hour incubation, T-bet
expression in trog+ cells decreased to a level below unstimulated bulk T cell
blasts, while trog– cells maintained elevated T-bet expression (Fig. 3.6B). In
contrast, at 72 hours, the majority of the trog+ cells were GATA-3+, and GATA-3
expression was negligible in the trog– cell population (Fig. 3.6B). While trog+ and
trog– displayed similar levels of T-bet and GATA-3 five hours after recovery, by
72 hours the trog+ cells displayed significantly increased GATA-3 expression,
and significantly decreased T-bet expression compared to trog– cells (Fig. 3.6C).
These results confirmed that the IL-4+ trog+ cells were consistent with a TH2
phenotype, and support the hypothesis that trogocytosis-mediated signaling was
driving TH2 differentiation rather than simply enhancing the survival of TH2commited cells.
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Trogocytosis-mediated signaling, rather than IL-4 availability, is required
for GATA-3 upregulation after APC removal.
While IL-4 is a major product of TH2 cells, it is also an inducer of this subset, as
IL-4R-signaling significantly contributes to TH2 differentiation [449]. Because the
trog+ cells produced significantly higher amounts of IL-4 than trog– cells (Fig. 3.2),
it was possible that the TH2 phenotype displayed by the trog+ cells was simply
the result of IL-4 availability. To examine whether IL-4R signaling was playing the
central role in the TH2-phenotype observed in trog+ cells, exogenous IL-4 (20
µg/ml) was added to cultures of cells immediately after recovery from the
trogocytosis assay, and replenished at 24 hours. As seen in Fig. 3.6D, at 72
hours, the addition of IL-4 had minimal effects on GATA-3 expression in
unstimulated cells. Similarly, the trog– cells from cultures containing
supplemented IL-4, showed only an 8.6% average increase in GATA-3
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expression, while trog+ cells from the same cultures had increased GATA-3
expression by an average of 25.5%, as determined by MFI (Fig. 3.6E). However,
the addition of IL-4 had little impact on the frequency of GATA-3+ trog– or trog+
cells, as no significant differences between cells from untreated cultures, and
cultures with supplemented IL-4, were detected in either population (Fig. 3.6F).
Thus, IL-4R signaling was not playing the central role in the increase in GATA-3+
expression by the trog+ cells. These results confirm that trogocytosis-mediated
signaling, and not simply the availability of IL-4, was essential for the observed
TH2 phenotype developed in trog+ cells, consistent with the finding that GATA-3
translation is dependent on TCR signaling [450].

Trogocytosis-mediated signaling drives TH1 cells to express IL-4 and
GATA-3
The results in Figs. 3.4 and 3.6 are consistent with the hypothesis that
trogocytosis-mediated signaling drives TH2 differentiation in trog+ cells. To
examine this hypothesis, we tested whether trogocytosis-mediated signaling
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could induce in vitro TH1 polarized trog+ cells to start producing TH2 characteristic
proteins. If such conversion was observed in trog+, but not trog–, polarized TH1
cells it would strongly support the hypothesis that sustained, trogocytosismediated signaling was inducing a TH2 phenotype. In vitro TH1 and TH2 polarized
blasts were generated and used in a standard in vitro trogocytosis assay. In
parallel, polarized TH1 and TH2 blasts were stimulated on anti-CD3 + anti-CD28
coated plates to provide sustained signaling throughout the 72-hour incubation.
Because plasticity between TH1 and TH2 subsets occurs only after days of
exposure to alternate polarizing conditions [144, 169, 451, 452], the 90 minutes
of exposure to APC during the trogocytosis-assay alone would not likely be
sufficient to induce TH1 to TH2 conversion. Cells were examined at 5 hours to
examine baseline conditions, and at 72 hours after APC removal, to assess
potential phenotypic changes.

The results in Fig. 3.7A show that sustained Ab-stimulation resulted in stable
IFN expression in polarized TH1 cells, with an average of 61% being IFN+ at 5
hours, and 57% being IFN+ at 72 hours. As anticipated, these TH1 polarized
cells did not express IL-4 at any time-point. The TH1 polarized trog+ cells showed
a phenotype similar to Ab-stimulated TH1 cells at 5 hours, with an average of
79% being IFN+, and only 8% expressing IL-4+ (Fig. 3.7B). However, unlike the
Ab-stimulated TH1 cells, the frequency of trog+ IFN+ cells decreased at each
successive time-point, and by 72 hours only ~5% remained IFN+. IFN
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expression was not detected in the trog+ TH2, or the Ab-stimulated TH2 blasts at
any time-point (Figs. 3.7 C, D).
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In contrast to the significant decrease in IFN expression, the frequency of trog+
TH1 polarized cells expressing IL-4 increased from 8% at 5 hours, to
approximately 70% at 72 hours (Fig. 3.7B). The presence of a unique population
(averaging 4.7%) of TH1 polarized trog+ cells which were IFN+ IL-4+ doublepositive cells at 72 hours (Fig. 3.7B) supported the idea that these cells
converted from TH1 towards a TH2 phenotype [178]. For comparison, while Abstimulation of the polarized TH1 maintained IFN expression, on average, less
than 0.2% of these cells were for IFN+ IL-4+ double-positive at 72 hours (Fig.
37A). Within the polarized TH2 cells, on average only 0.22% of trog+, and 0.31%
of Ab-stimulated cells were IFN+ IL-4+ (Fig. 3.7C, D).

While the TH2 polarized trog+ population displayed an average of 84.2% of cells
being IL-4+, somewhat unexpectedly, only 28% of Ab-stimulated cells were IL-4+
at 72 hours (Fig. 3.7C, D). These are similar to the results in Fig. 4, and further
support that trogocytosis-mediated signaling is favorable for driving and/or
augmenting a TH2 phenotype, while sustained anti-CD3 + anti-CD28 Abstimulation is not.

In addition to shutting down IFN expression and upregulating IL-4, the trog+ TH1
polarized cells also displayed a shift in transcription factor expression. These
cells were GATA-3 negative and expressed high levels of T-bet at 5 hours, but by
72 hours, the trog+ TH1 cells had upregulated GATA-3 expression, and
approximately half of the population lost T-bet expression (Fig. 3.7E). In contrast,
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the Ab-stimulated and trog– TH1 cells remained GATA-3– and maintained
expression of T-bet at 72 hours. While there were no significant differences in Tbet or GATA-3 expression between TH1 polarized trog+, trog–, and Ab-stimulated
cells 5 hours after recovery, by 72 hours the frequency of T-bet+ cells was
significantly lower in the trog+ population compared to trog– population. This was
concomitant with significantly more trog+ cells expressing GATA-3 compared to
trog– and Ab-stimulated cells (Fig. 3.7F). Consistent with the cytokine expression
data where the TH1 polarized trog+ cells expressed both IL-4 and IFN (Figs. 37A,
B), significantly more trog+ cells also expressed both T-bet and GATA-3
compared to trog– and Ab-stimulated cells (Fig. 3.7F). Taken together, the data in
figure 7 strongly suggest that trogocytosis-mediated signaling induced TH1 to TH2
conversion, strengthening the conclusion that trogocytosis-mediated signaling
drove the observed TH2 phenotype in trog+ cells.

Trogocytosis+ CD4+ T cells generated in vivo display a TH2 phenotype.
The results so far strongly support the hypothesis that trogocytosed molecules
engage cognate receptors on T cells to sustain intracellular signaling, leading to
TH2 biasing. To examine whether this in vitro phenotype was consistent with in
vivo immune responses, a protein immunization model in an adoptive transfer
system, using TCR-transgenic T cells transferred into wild type animals was
used, as well as the direct protein immunization of wild type animals. In the
adoptive transfer model, B10.A mice were immunized subcutaneously with whole
pigeon cytochrome-c (PCC) protein. Twenty-four hours later, naïve 5C.C7 TCR-
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transgenic T cells were adoptively transferred into the immunized animals (Fig.
3.8). Five days after the adoptive transfer, cells were harvested from draining
lymph nodes and analyzed. Of the recovered, adoptively transferred CD4 + T
cells, there was significantly higher rates of trogocytosis in the PCC-immunized
animals (averaging 19.4% trog+) compared to PBS-injected controls (averaging
0.28% trog+) (Fig. 3.8A). Based on CD69 upregulation and TCR
downmodulation, both trog+ and trog– adoptively transferred CD4+ T cells had
recognized Ag and were activated (Fig. 3.8B). Consistent with the in vitro results
in Fig. 3.1, the trog+ CD4+ T cells showed trends of higher activation and TCR
downmodulation compared to trog– CD4+ T cells from the same animal (Fig.
3.8B). Within the activated (CD69High) CD4+ T cells, there was a significantly
higher frequency of trog+ IL-4+ cells than trog– IL-4+ cells (Fig. 3.8C). On average,
15% of trog– cells and 11% of trog+ cells were IFN+ (Fig. 3.8C), resembling the
phenotypes observed at 48 hours following recovery from the in vitro trogocytosis
assay (Fig. 3.2D). Also, consistent with the phenotype of cells recovered from the
in vitro trogocytosis assays (Fig. 3.2C), the expression of IL-4 on a per-cell basis,
was higher in trog+ cells than similarly activated trog– cells (Fig. 3.8D).
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In a parallel set of experiments, non-transgenic C57BL/6 mice were immunized
with chicken ovalbumin (OVA), followed by a booster immunization 14 days later.
CD4+ T cells were recovered from draining lymph nodes five days after the
second immunization. These time-points were chosen to reintroduce antigen at
the end of the effector stage of the immune response, but before establishment
of a stable memory population. OVA-immunized animals had significantly higher
frequencies of trog+ CD4+ T cells compared to PBS-injected control mice (Fig.
3.8E). Consistent with our previous study [81], the trog+ cells displayed sustained
survival ex vivo, as the frequency of isolated trog+ CD4+ T cells from OVAimmunized mice increased from 8% on the day of harvest to nearly 60% after a
five-day in vitro incubation (Fig. 3.8D). Similar to the results with the TCR118

transgenic model, the trog+ CD4+ T cells were more activated than trog– CD4+ T
cells as determined by CD69 staining (Fig. 3.8F). Within the activated (CD69 High)
CD4+ cell populations, the trog+ cells displayed increased expression of GATA-3
and IL-4, whereas their expression in trog– cells from the same animal was nearly
identical to that of CD4+ T cells recovered from PBS-control animals (Fig. 3.8F).
Similar to results from in vitro and in vivo TCR-transgenic experiments (Figs. 3.2,
3.8C), the frequency of GATA-3+ CD4+ cells was significantly higher in the trog+
cells compared to the trog– cells (Fig. 3.8G). Consistent with these results, of
cells recovered from OVA-immunized mice, the frequency of IL-4+ cells was
significantly higher in CD69High trog+ cells, at nearly 50%, compared to the
CD69High trog– cells, of which 22.3% were IL-4+. (Fig. 3.8H). Collectively, the
results in Fig. 3.8 provide strong corroboration of the results obtained from the in
vitro experiments, as trog+ CD4+ T cells generated in vivo displayed enhanced
survival in vitro, and displayed greater activation, as well as increased GATA-3
and IL-4 expression, compared to trog– cells from the same animal. These results
support the hypothesis that trogocytosis-mediated signaling may play a role in
TH2 differentiation in vivo.
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Discussion
Trogocytosis by CD4+ T cells results in the presence of functional, APC-derived
molecules, including MHC:peptide complexes, on the surface of the trog+ T cell.
Many of these acquired molecules are not expressed endogenously by the T cell,
but they clearly have an impact on T cell biology. This has been demonstrated by
the ability of trog+ cells to impact the activation of other T cells through the
presentation of trogocytosed molecules [372, 420]. We have found that
trogocytosed molecules are also engaged by cognate receptors on the trog+ T
cell [81], however the biological implications of this phenomenon are largely
unknown. Because trogocytosis commonly occurs during the activation of CD4+
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T cells, it is important to develop a comprehensive understanding of the
biological consequences of this event.

In this study, we examined the impact of sustained, trogocytosis-mediated
signaling on the activation, effector cytokine production, and differentiation of the
trog+ T cell. trog+ cells have sustained TCR proximal signaling for at least 72
hours after APC removal, consistent with cell-autonomous signaling resulting
from engagement of the receptors on the T cell by trogocytosed molecules (Fig.
3.1). This sustained signaling was not due to T:T presentation or the presence of
contaminating APC, as only the trog+ cells maintained a phenotype consistent
with active TCR signaling and sustained activation, despite the cultures
containing both trog+ and trog– cells throughout the incubation period. This
conclusion is further supported by images showing that active TCR signaling
occurred proximal to trogocytosed molecules on the surface of trog+ cells, 72
hours after removal from APC (Fig. 3.5). Similar to our previous studies, the
sustained signaling led to preferential survival of the trog+ cells, as the frequency
of CD4+ cells that were trog+ increased from roughly 25% immediately after
recovery from the trogocytosis-assay, to nearly 80% 72 hours later (Fig. 3.1C,
[81].

Because the trog+ cells had sustained TCR signaling and remained activated 72
hours after APC removal, we investigated whether trogocytosis-mediated
signaling might impact the effector cytokine production of these cells. Intracellular
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cytokine staining of cells 5 hours after recovery from the trogocytosis-assay
showed that a significantly higher frequency of trog– cells were IFN+ compared
to trog+ cells. However, IFN levels decreased to resting levels in both trog– and
trog+ cells over a subsequent 72-hour incubation (Fig. 3.2B,C). While the
frequency of trog– IL-4+ cells remained at approximately 5% over the 72-hour
incubation, the average frequency of trog+ IL-4+ cells increased from 10% at 5
hours, to over 70% at 72 hours (Fig. 3.2D). Because the trog+ cells also
displayed enhanced survival after APC removal (Fig. 3.1C), the trog+ cells
accounted for over 98% of the total IL-4+ CD4+ cells at 72 hours. The increase in
the frequency of trog+ IL-4+ cells over the 72-hour incubation was likely not due to
increased proliferation of the trog+ cells, as the amount of trogocytosed
molecules on the trog+ cells remained constant and was not diluted, as would be
expected for dividing cells. In addition, our previous study showed no discernable
proliferation of trog+ cells, up to 5 days after removal from APC [81]. These
results are consistent with the observations that trogocytosed molecules are
retained in a punctate spot on the membrane of the trog+ cell (Fig. 4, [81, 287].
Thus, the data suggest that trogocytosis-mediated signaling led to sustained
survival of IL-4+ cells, and/or directly impacted the IL-4 expression in the trog+
cells.

If the trogocytosis-mediated signaling was simply sustaining the survival of IL-4expressing cells, the apparent increase in IL-4+ trog+ cells after APC removal
might be due to a difference in the ability of T H1 and TH2 cells to perform
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trogocytosis. We found that when in vitro polarized TH1 and TH2 cells and nonpolarized T cells were compared, the TH2 polarized cells were indeed more
efficient at performing trogocytosis (Fig. 3). However, the difference in the
efficiency of trogocytosis alone isn’t sufficient to account for the observed
phenotypes. While the frequency of trog+ IL-4+ cells increased, the frequency of
trog+ IFN producing cells decreased from 10% at 5 hours after recovery to 0.5%
at 72 hours, suggesting that trogocytosis-mediated signaling was not simply
boosting global intracellular signaling and enhancing the survival of all trog+ cells.
If that were the case, the frequency of IFN-expressing and IL-4-expressing cells
would be expected to remain relatively stable. Rather, our results suggested that
trog+ cells were differentiating into TH2 (GATA-3+ IL-4+) cells after the
trogocytosis-assay. While robust GATA-3 expression was detected in trog+ cells
by 72 hours (Fig. 6), anti-CD3 + anti-CD28 stimulation of an aliquot of the
unstimulated T cell blasts used in the trogocytosis-assay did not result in a
similar TH2 phenotype (Fig. 4A). Furthermore, T cell blasts immediately prior to
the trogocytosis assay displayed a relatively homogeneous TH 0/TH1 phenotype
(Figs. 3.2, 3.3, 3.6). This is consistent with the inherent bias towards a TH1
phenotype possessed by the 5C.C7 TCR transgenic mice used in our
experiments [453, 454], and may explain the rapid IFN production, and delay in
IL-4 expression, observed in the cells after recovery from the trogocytosis-assay.

To eliminate the possibility that the observed IL-4 production in the trog+ cells
was induced by residual signaling received from the T:APC interaction and

123

directly examine the role of trogocytosis-mediated signaling in the observed TH2
phenotype of trog+ cells, the reversible Lck inhibitor PP2 was used to halt TCR
signaling after APC removal, then washed out to allow trogocytosis-mediated
signaling to resume. We found that after PP2 removal, IFN expression did not
resume in either trog+ or trog– cells (Figs. 3.4D, 3.4E, S3.3), consistent with IFN
production being induced by interactions with APC, and not induced further by
trogocytosis-mediated signaling. In contrast to IFN, the frequency of trog+ IL-4+
cells from PP2-treated cultures rebounded to levels equal to untreated cells by
24 hours after PP2 removal (Fig. 3.4E), and robust IL-4 production was observed
in trog+ cells 72 hours after PP2 treatment (Figs. 3.4B, C). These significant
findings show that trogocytosis-mediated signaling was sufficient to drive IL-4
expression in trog+ cells. The results showing that in vitro TH1 polarized trog+
cells began expressing IL-4 and GATA-3, while at the same time decreasing
expression of IFN and T-bet (Fig. 3.7), further support that, at least in absence
of external stimuli, trogocytosis-mediated signaling promotes TH2 differentiation.
Although it is possible that a portion of the trog+ blasts generated under TH1polarizing conditions were not fully differentiated to TH1 prior to use in the
trogocytosis assay, the unique population of double-positive cells expressing
both IFN and IL-4 (Fig. 3.7B), and the transcription factors T-bet and GATA-3
(Fig. 3.7F), was only apparent within the trog+ cells generated under TH1polarizing conditions. Thus, the data in Fig. 3.7 supports the possibility that
trogocytosis-mediated signaling is capable of inducing TH1 to TH2 conversion.
That a greater frequency of TH2 polarized trog+ cells produced IL-4 than Ab124

stimulated TH2 polarized cells at 72 hours (Fig. 3.7C, D), further supports the
hypothesis that trogocytosis-mediated signaling is potent in driving IL-4
expression. Taken together, the data presented here are consistent with the
concept that trogocytosis-mediated signaling can drive the differentiation of CD4+
T cells towards a TH2 phenotype.

The TH2 phenotype observed in vitro with trog+ cells was also apparent in in vivo
immune responses. Using TCR-transgenic or wild type cells, and with different
antigen sysTEMs, we observed that in vivo derived CD4+ trog+ cells expressed IL4 and GATA-3 at greater levels, and higher cell frequencies, compared to trog–
cells from the same animal (Fig. 3.8B, C). The observed TH2 phenotype of in vivo
trog+ cells was less robust than the phenotype developed in in vitro assays,
however, this is consistent with findings that in some cases, GATA-3 expression
in TH2 CD4+ T cells is less pronounced in vivo than in vitro [143]. The observed
phenotype may also be attributed to the inherent nature of the mice used in our
study towards TH1, which, consequently, further underscores the significance of
the TH2 phenotype developed by trog+ cells in this study. Further studies are
underway to characterize the TH2 phenotype of in vivo-generated trog+ cells at
additional time-points, and after immunization with TH1-inducing components.

It is interesting to speculate on the mechanisms leading to the observed
association between CD4+ trog+ cells and a TH2 phenotype. It has been found
that the strength, duration, and “summation” of TCR and costimulatory molecule
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signaling can substantially impact T helper differentiation [143, 157, 455, 456]. In
non-differentiated cells, it is possible that immune synapses that result in
trogocytosis may be of shorter duration and/or generate weaker TCR signaling.
This would be consistent with observations that weaker TCR signaling drives
early IL-4 production by T cells [156, 157, 173, 457]. Because only a fraction of
the APC molecules involved in the immunological synapse are transferred to the
T cell, trogocytosis-mediated signaling is likely weaker than signaling at the
synapse. This signaling could further promote IL-4 production, consistent with the
increased levels of IL-4 observed in trog+ cells over a 72-hour incubation (Figs.
3.2, 3.4, 3.7). The TH1 to TH2 conversion observed with TH1 polarized trog+ cells
(Fig. 3.7) further supports this model, as weak TCR-signaling drives TH2
differentiation, even under TH1- polarizing conditions [139]. In contrast, IFN
production and TH1 differentiation have been shown to require strong TCRsignaling [82, 140, 141].

The differences in trogocytosis efficiency between polarized TH1 and TH2 cells
may also be attributed to morphological differences in the immunological
synapse formed. We have previously shown that at low Ag concentrations, TH1
synapses form the classical “bull’s-eye” shape, while TH2 cells form multi-focal
synapses [83]. In separate live-cell imaging experiments, we have observed that
small “packets” of MHC:peptide are transferred from APC to non-polarized T
cells from the immunological synapse, before becoming localized to a punctate
spot at the distal pole of the T cell membrane [31]. It is inviting to speculate that
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the multi-focal synapses formed by TH2 cells facilitate trogocytosis much more
efficiently than the synapses formed by TH1 cells, although that was not directly
tested here.

There are many biological implications of trogocytosis-mediated signaling driving
and/or augmenting a TH2 phenotype, while also antagonizing a TH1 phenotype.
Such implications are amplified when considering that trog+ cells display
sustained survival, along with enhanced activation and effector cytokine
production (Figs. 3.1, 3.2, [81]). The TH2 phenotype itself may contribute to the
enhanced survival displayed by trog+ cells (Fig. 3.2C, [81]), as IL-4 has been
found to enhance CD4+ survival both in vitro and in vivo [458]. Additionally, a TH2
phenotype may aid in the heightened activation commonly observed in trog+
cells, as TH2, but not TH1 cells, have been shown to be able to revert from an
anergic state to resume effector functionality [459]. It is possible that trog+ TH2
cells may significantly aid in the generation of B cell germinal centers, and/or
increase the quality and duration of protective antibody generation when Ag is
limited. On the other hand, the low trogocytic potential of TH1 cells, and the TH2
phenotype induced by trogocytosis-mediated signaling, could act as checkpoint
to limit unwanted TH1-associated inflammation after Ag clearance.

In cases where a TH2 response is undesirable, excessive CD4+ trogocytosis may
play a role in exacerbating TH2-mediated autoimmune diseases such as SLE and
rheumatoid arthritis, heighten allergic reactions, or negatively impact protective
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cell-mediated responses. In a study by Brown et al., CD4+ T cells from patients
with multiple myeloma showed increased rates of trogocytosis and the trog+ cells
displayed inhibitory effects on proliferation of stimulated T cells [284]. The
authors proposed that trogocytosis might play a role in tumor-induced immune
suppression through T-cell fratricide and deletion in patients with multiple
myeloma. It is possible that in tumor environments where antigen is presumably
abundant, a high frequency of CD4+ trogocytosis and subsequent TH2differentiation/conversion could significantly suppress an anti-tumor response.
Such suppression may be attributed to the inhibition of anti-tumor promoting TH1
cell differentiation by trogocytosis-mediated signaling, and the high IL-4
production by trog+ cells, as IL-4 has been shown to both inhibit IFN production
and prevent activation of naïve T cells [460].

Beyond driving a TH2 phenotype, continual trogocytosis-mediated signaling may
aid in the generation of CD4+ memory and/or TFH cells, as both subsets require
sustained-TCR signaling through repeated Ag-encounter for their differentiation
[142, 143]. As TH2 to TFH conversion has been found to take between 5 to 7 days
to occur in vivo [238], examining the phenotype of trog+ cells at extended timepoints is likely necessary to determine this possibility. Studies are currently
underway in our lab to examine the potential role of trogocytosis-mediated
signaling in the generation of both TFH and memory CD4+ T cells.
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In conclusion, the results from this study provide further insight into the role of
trogocytosis and trogocytosis-mediated signaling in the activation, effector
cytokine production and differentiation of CD4+ T cells. We report a strong
association between CD4+ trogocytosis and a TH2 phenotype, which is twofold,
as TH2 cells are highly efficient at performing trogocytosis, while trogocytosismediated signaling induced TH2 differentiation in both non-polarized, and
polarized TH1 cells. We propose a model for trogocytosis-mediated CD4+
differentiation in which trogocytosed MHC:peptide complexes and costimulatory
molecules sustain intracellular signaling by engaging their cognate receptors on
the trog+ T cell. The relatively weak intensity of this signaling leads to early IL-4
production, which is sustained by trogocytosis-mediated signaling. In the
presence of IL-4, the sustained trogocytosis-mediated TCR-signaling drives
GATA-3 expression, and thus, TH2 differentiation [450]. Because trog+ CD4+
possess the unique ability to remain activated independently of further APC
encounter via trogocytosis-mediated signaling, results from this study raise the
possibility that CD4+ trogocytosis may play a role in augmenting, or inducing a
TH2-dominant immune response.
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Chapter 4.
Trogocytosis-Mediated Signaling Drives a TFH
Phenotype with High Memory-Potential
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Introduction
The adaptability of the immune response is largely defined by the differentiation
of CD4+ T cells into specialized subsets. Despite extensive research efforts, the
mechanisms which govern CD4+ T cell differentiation are not fully understood.
This is largely due to variability in events at the immunological synapse which
have been found to impact CD4+ differentiation such as TCR affinity [456, 461465], antigen density and dose [155, 157, 456, 462, 463], TCR dwell time [82,
466], and costimulatory molecule signaling [155, 156, 217, 467-475]. In addition,
TFH differentiation and effector-to-memory transition have been shown to require
multiple signaling events through subsequent cognate interactions [145, 213,
476, 477]. Further convoluting the process of deciphering pathways behind CD4+
differentiation is the growing evidence for plasticity between various CD4+
subsets [144-148, 178, 451, 452]. Due to the wide spread implications for CD4+ T
cell differentiation in infectious and autoimmune disease, allergy and asthma, as
well as vaccine and immunotherapy design, understanding the mechanisms
behind CD4+ differentiation is critical for public health.
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One notable but unappreciated deviation from the canonical model for T cell
activation has been the discovery that T cells may act as APC themselves. This
is accomplished through the acquisition, and subsequent presentation of APCderived signaling molecules including peptide:MHC (p:MHC) complexes, and
costimulatory molecules such as CD80 and CD86, via trogocytosis [81, 285, 287,
368-372]. Trogocytosed molecules may be fully functional and become properly
re-expressed on the surface of trogocytosis-positive (trog+) T cells [278, 411].
Numerous studies have found that trog+ cells are able to impact the activation of
responding T cells through the presentation of trogocytosed molecules [369, 371,
372, 415, 420-426]. In addition, we previously reported that trog+ CD4+ T cells
are able to perform cell-autonomous signaling through engagement of their
receptors with trogocytosed ligands, which we have termed trogocytosismediated signaling [81, 412]. In T cell blasts recovered from APC after a 90 min
incubation, and cultured without additional stimuli, TCR signaling and a
heightened state of activation was maintained for >72 hours in trog+, but not
trog─, cells [81, 412]. The trog+ cells subsequently developed a TH2-phenotype
and increased expression of IL-4, while the trog─ cells produced IFNγ shortly
after removal of APC, but dramatically decreased IFNγ expression until reaching
levels comparable to unstimulated cells [412]. These results are consistent with
models of TCR signal strength in TH2 differentiation, in which the presumably
weaker signal from trogocytosis-mediated signaling had induced IL-4 expression
[139, 449, 457, 478]. It was also observed that IL-4 was directed towards
trogocytosed molecules in a manner reminiscent of T H2 help of B cells [48]. As
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both TH2 and TFH specialize in providing B cell help [21, 179, 479-481], TH2
readily differentiate to TFH [238], and TFH differentiation requires multiple TCR
signaling events [213, 214, 231, 479, 482]; it was possible that the observed
sustained trogocytosis-mediated signaling could further promote the
differentiation of trog+ cells towards TFH. Here, we researched this possibility
using naïve, and activated TCR-transgenic MCC-specific 5C.C7 CD4+ T cell
blasts and APC expressing CD80, and I-Ek with covalently attached MCC, or
peptide-pulsed BMDC expressing high levels of CD80, ICOS, CD86, and I-Ek.
We also examined the phenotype of trog+ cells in vivo using adoptively
transferred 5C.C7 cells, and pigeon cytochrome c (PCC) or (ovalbumin) OVA in
wild type animals.

Our results suggest that trogocytosis-mediated signaling drives a phenotype
consistent with TFH (CD69+ PD-1+ CXCR5+ ICOS+ IL-21+) in vitro, between 3-5
days post removal from APC. Inhibiting signaling through trogocytosed I-Ek and
CD80 with neutralizing antibodies, or removal of antigenic peptide from
trogocytosed MHCII, significantly reduced the TFH phenotype. In vivo-generated
trog+ cells developed a TFH phenotype more rapidly than trog─ cells following
immunization with PCC in Sigma Adjuvant System (SAS). The trog+ cells also
showed increased expression of IL-6, IL-21, and Bcl-6 compared to similarly
activated trog─ cells 5 days post-immunization of WT mice with OVA.
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At later time-points the trog+ cells in immunized mice contained a major
population that resembled T central memory cells (TCM) [483, 484]. Interestingly,
early TCM-precursors and TFH often share a similar phenotype including increased
levels of CXCR5 and Bcl-6 [483, 485], and IL-21 has been found to be critical for
T cell memory formation [440, 486-489]. In addition, repeat cognate-Ag
interactions that are required for TFH also promote effector-to-memory transition
[490]. These similarities raise the possibility that trogocytosis-mediated signaling
may promote the formation of memory CD4+ cells, and is supported by the
enhanced survival of trog+ cells in absence of APC [81, 412].
Our results suggested that trogocytosis-mediated signaling enhances IL2 production, proliferation, and survival of trog+ cells after APC removal. The
trog+ cells also showed higher expression of the anti-apoptotic protein Bcl-2, and
CD127. Interestingly, proliferating trog+ cells appeared to unequally distribute
trogocytosed molecules amongst progeny to produce a trog+ and a trogdaughter cell. The daughter cell that retained the trogocytosed molecules also
expressed levels of Tcf1, reminiscent of memory-precursors formed through
asymmetric division [491].

Results from this study show that extended trogocytosis-mediated signaling is
capable of driving CD4+ T cells to develop a phenotype consistent with TFH after
separation from APC. We also report a strong correlation between trogocytosis
and memory precursor cells and propose a model in which trogocytosis-mediated
signaling maintains the survival of CD4+ T cells which have received weaker
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signals from APC. These findings provide additional insights into both TFH, and
memory generation in the absence of APC, through the non-conventional
mechanism of trogocytosis-mediated signaling.

Results
Trog+, but not trog-, cells maintain a heightened state of activation after
APC removal.
While multiple studies have suggested that repeated cognate interactions with B
cells are required for full TFH-differentiation, [209, 221-224], it been demonstrated
that sustained TCR signaling can drive TFH differentiation independently of B
cells [213]. As a critical component in TFH differentiation is sustained
TCR/costimulatory signaling, we hypothesized that sustained trogocytosismediated signaling may drive and/or augment TFH differentiation after separation
from APC. To examine this possibility, in vitro trogocytosis assays were
performed using T cell blasts from 5C.C7 TCR-Tg mice. Following the
trogocytosis-assay, APC were removed resulting in cultures >95% CD4+ T cells
and <0.1% APC [412]. Recovered T cells were analyzed immediately (day 0), or
cultured at low density 104 cells/ml to minimize cell:cell interactions and analyzed
3, and 7 days post-recovery, at 24 h intervals. We previously have shown that
both trog+ and trog─ cells downmodulate TCR levels and increase CD69 levels,
suggesting that both populations were similarly activated by APC during the
trogocytosis assay [412]. Consistent with those findings; Figure 4.1 shows that
the trog─ and trog+ cells have similar CD69 levels immediately after recovery
from the trogocytosis assay with either MCC:FKPB APC or BMDC (Fig. 4.1).
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As with previous results, the trog+, but not trog─, cells retained high CD69
expression at 3 days and 7 days post recovery (Fig. 4.1). This supports the
model of trog+ cells retaining active TCR-signaling and subsequent activation in
the absence of APC. A notable difference in the activation state of cells
recovered from BMDC or MCC:FKPB APC was observed at day 0. Both the trog+
and trog─ cells recovered from MCC:FKPB fibroblasts had significantly lower
levels of CD69 compared to respective populations recovered from BMDC. This
is likely due to substantially higher expression of both I-Ek and CD86, and slightly
higher levels of CD80 and ICOS-L on BMDC compared to MCC:FKBP (Fig.
S4.1). The trog+ cells recovered from MCC:FKPB APC increased CD69
expression between Day 0 and Day 7, while the median CD69 expression of the
trog─ cells decreased, by 43% on Day 3, and was only 30% higher than resting
cells 5 days after removal of APC. In contrast, trog+ and trog- cells recovered
from BMDC decreased in CD69 expression between Day 0 and Day 3, by 61%
or 81% respectively. However, at 7 days post-recovery, the CD69 expression in
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trog─ cells was unchanged, while on the remaining trog+ cells CD69 expression
increased by 40% (Fig. 4.1).
In vitro-generated trog+, but not trog─ cells, develop a TFH-like phenotype
after separation from APC.
Signaling from the inducible T cell costimulator (ICOS) has been found to play a
major role in TFH differentiation, [209, 217, 242, 492, 493]. Immediately after
recovery from APC, the trog+ cells showed moderately higher levels of ICOS
compared to the trog─ cells (65% in cells recovered from BMDC, and 34% in cells
recovered from MCC:FKBP) (Fig. 4.2, top). At 7 days post-recovery, there was a
clear difference in expression in ICOS expression with the trog+ cells recovered
from BMDC showing a 3.2-fold increase in ICOS levels over trog─ cells, and a
2.2-fold increase in cells recovered from MCC:FKBP APC (Fig. 4.2, bottom).

TFH cells are largely identified by high expression of CXCR5 and PD-1 [494-496],
as well as CD69 [497], which was maintained in trog+, but not trog─ cells (Fig
4.1). Consistent with the ICOS expression levels (Fig. 4.2), and the kinetics of
TFH-differentiation [498], figure 4.3 shows that immediately post-recovery (Day 0),
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a TFH-like phenotype, (PD-1+ CXCR5+), was apparent in 9.2% of trog+ cells, but
only 3% of trog─ cells recovered from BMDC (Fig. 4.3, left). Similar levels were
observed in cells recovered from MCC:FKBP (7.04% of trog+ and 3.54% of trog─
cells) (Fig. 4.3, right), suggesting that the higher activation induced by BMDC did
not immediately impact CXCR5 and PD-1 surface expression levels. In cells
recovered from BMDC, the trog+ cells maintained CXCR5 expression at both 3
days and 7 days post recovery, while the frequency of the CXCR5 + PD-1+
population increased to 15%, and 19% of trog+ cells, respectively (Fig. 4.3, left,
red). In contrast, the trog─ cells initially had lower CXCR5 levels at 3 days
compared to trog+ cells, and by 7 days, CXCR5 expression was similar to
unstimulated cells (Fig. 4.3 left, blue). Accordingly, only 2.23%, and 0.3% of the
trog─ cells were PD-1+ CXCR5+ at 3 and 7 days post-recovery.
The trog+ cells recovered from MCC:FKBP APC showed markedly
different expression patterns compared to those recovered from BMDC. High
CXCR5 expression was maintained in the trog+ cells at 3 and 7 days postrecovery, and the frequency of PD-1+ CXCR5+ cells increased to 26.2% by Day 3
and had reached 57.5% on day 7 (Fig. 4.3, right, red). The trog─ cells showed a
very slight increase from 3.5% at Day 0 to 5.0% by Day 3. By Day 7 the CXCRS +
PD-1+ cells were only 4.4% of trog- cells (Fig. 4.3, bottom, blue).
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Consistent with a TFH phenotype, the trog+ cells from either APC cultures
expressed higher levels of Bcl-6 and IL-21 compared to trog─ cells 7 days postrecovery (Fig. 4.4). Consistent with the surface phenotype data (Fig 4.1-3), when
trog+ cells from the two different APC cultures were compared, the cells recovered
from MCC:FKPB APC expressed higher levels of Bcl-6 and IL-21 (Fig. 4.4A,
right), compared to trog+ cells recovered from BMDC (Fig. 4.4A, left). When
BMDC-stimulated populations were compared, a significantly higher frequency of
trog+ cells were IL-21+ at days 2, 3, 5, and 7. IL-21 expression by trog+ cells
peaked on Day 5, when 29% of the cells were IL-21+ (Fig. 4.4B, top). Similarly,
when cells recovered from MCC:FKPB APC were compared, a significantly higher
percentage of trog+ cells were IL-21+ at each time-point observed from 1 to 7 days
post-recovery (Fig. 4.4B, bottom).
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Collectively, the data in Figs. 4.1 to 4.4 show that trog+, but not trog─, cells are
highly efficient at developing a CXCR5+ PD-1+ BCl-6+, IL-21+ phenotype
consistent with TFH, after APC removal. When trog+ cells recovered from both
BMDC and MCC:FKPB APC were compared, cells recovered from MCC:FKPB
showed a more robust TFH-like phenotype. Regardless of the APC type, these
data strongly suggest that trogocytosis-mediated signaling promotes TFH
differentiation in trog+ cells.
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Trogocytosis-mediated signaling drives a TFH phenotype
The data in Figs. 4.2-4.2 show that after removal of APC, a substantial
percentage of trog+ cells developed a phenotype consistent with TFH, while the
trog─ cells do not. However, initial priming of CD4+ T cells by DC may result in a
pre-TFH phenotype including the upregulation of CXCR5 to promote T cell
migration towards B cell follicles/GC [218]. Therefore, the observed TFH-like
phenotype in the trog+ cells may be due to signals from APC promoting TFH
differentiation, and not a direct result of trogocytosis-mediated signaling. To
address the impact of trogocytosis-mediated signaling on development of the
observed TFH phenotype, CD4+ T cell blasts were used in an in vitro trogocytosis
assay with MCC-loaded BMDC or MCC:FKPB APC. Immediately following
recovery from BMDC, peptide was removed from trogocytosed MHC by mild acid
elution. Aliquots of acid-stripped cells were then cultured with 10 µM cognate
MCC peptide or 10 µM irrelevant hemoglobin (Hb) peptide as a negative control.
With cells recovered from MCC: FKPB APC, trogocytosed TCR and CD28
signaling was neutralized using 20 µM anti-I-Ek and/or 20 µM anti-CD80 purified
antibodies. Because the MCC: FKPB APC do not express CD86 (Fig. S4.1A),
antibodies against CD86 were not included.

After recovery on Day 0, cells recovered from BMDC and MCC:FKPB APC
exhibited minimal difference in PD-1 and CXCR5 expression on trog+ and trogcells, similar to the Day 0 in figure 4.1 (data not shown). As the TFH-phenotype
peaked at 5 days post-recovery (Fig. 4.4B) cells were examined at this time-
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point. The acid-stripped cells cultured with Hb peptide had substantially
decreased TCR signaling as determined by pZAP-70 signaling, compared to
non-treated or acid-stripped cells cultured in the presence of MCC (Fig. S4.1B).
Similarly, neutralization of I-Ek and CD80 in MCC:I-Ek-recovered cultures greatly
decreased TCR signaling (Fig. S4.1B).

Figure 4.5 shows that removal of antigenic-peptide had a drastic impact on the
phenotype of the trog+ cells, on Day 5, reducing the frequency of PD-1+ CXCR5+
trog+ cells by nearly 50% (15.2% PD-1+ CXCR5+) compared to untreated controls
(29.7% PD-1+ CXCR5+) (Fig. 4.5, left). On the other hand, addition of MCC to
peptide-stripped cells increased the frequency of PD-1+ CXCR5+ cells by 87%,
with 55.6% of these cells displaying the TFH-like phenotype (Fig. 4.5, left). Similar
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results were obtained with antibody neutralization as anti-I-Ek and anti-CD80
reduced the frequency of trog+ PD-1+ CXCR5+ cells by 71% to 20.4% PD-1+
CXCR5+ compared to the untreated trog+ cells (70.5% PD-1+ CXCR5+) (Fig. 4.5,
right). The frequency of PD-1+ CXCR5+ was very low in trog─ cells across the
board, ranging from 2.91% in untreated BMDC cultures to 1.07% in Hbsupplemented cultures, to 3.15% in MCC-supplemented cultures. Similarly, of
cells stimulated with MCC:FKPB, the frequency of CXCR5+ PD-1+ trog- cells was
2.91% in untreated cultures and 1.07% in Ab-neutralized cultures (Fig. 4.5,
middle).

In parallel cultures, T cell blasts were stimulated for 6 hours each day during a 5
day incubation as a control. These cells did not develop a robust PD-1+ CXCR5+
population, consistent with the requirement for IL-21 or IL-6, and costimulatory
molecules such as ICOS for TFH differentiation. It also suggests that the TFH-like
phenotype displayed by the trog+ cells was not simply a result of sustainedsignaling TCR and CD28 signaling.

Trogocytosis-mediated signaling drives a TFH phenotype in naïve T cells in
absence of APC
We next examined whether trogocytosis-mediated signaling could
drive a TFH-phenotype in trog+ naïve CD4+ cells. Like the activated blasts, trog+
and trog- naïve cells displayed comparable levels of activation immediately after
recovery from the trogocytosis assay (as determined by CD69 expression) (Fig.
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4.6). As anticipated, naïve cells were more highly activated by MCC-loaded
BMDC compared to MCC:FKBP APC (Fig. 4.6).

Figure 4.6 shows that approximately 22.3% of the trog+ naïve T cells cultured for
5 days after removal from an 18 hour trogocytosis assay using MCC-loaded
BMDC were CXCR5+ ICOS+. In comparison, acid-stripped cells cultured in Hb
peptide had a 4.5% decrease in the frequency of trog+ CXCR5+ ICOS+ cells to
12.5% (Fig 4.6, left). Addition of MCC to acid-stripped cultures led to a 2.2-fold
increase to 49.8% of the trog+ CXCR5+ ICOS+ cells (Fig. 4.6, left). The trog─ cells
in Hb-supplemented peptide-stripped cultures showed a 78% decrease in the
frequency of CXCR5+ ICOS+ cells compared to untreated cultures, to 4.07%
CXCR5+ ICOS+. MCC-supplementation increased this frequency 2.5-fold to
10.2%, which, while substantially higher compared to trog─ cells from untreated
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cultures, was well below the frequency of trog+ cells displaying this phenotype
(Fig. 4.6, left)

To assess the individual roles of TCR and costimulatory signaling, neutralizing
Abs anti-CD3 and anti-CD28 or anti-CD3 alone or anti-CD28 alone, were added
to naïve cells recovered from MCC:FKBP APC as in Fig. 4.3. The data in Fig. 4.6
(right) suggests that TCR signaling through trogocytosed-p:MHC complexes and
CD80 signaling both played a role in development of the apparent TFH
phenotype. Compared to trog+ cells from untreated cultures, the trog+ cells from
cultures with only neutralizing CD80 Abs had a 42% decrease in CXCR5 + ICOS+
cells (Fig. 4.6, second from left). The trog+ cells from cultures containing
neutralizing anti-I-Ek Abs showed a 61.5% decrease in this population (Fig. 4.6,
second from right), while the trog+ cells from cultures containing both anti-I-Ek
and anti-CD80 showed a further 83% reduction in the phenotype to 9.58% (Fig.
4.6, far right), compared to trog+ cells from untreated cultures (Fig. 4.6, far left).

Trog- cells can develop a TFH phenotype in the presence of APC
It was apparent that trogocytosis-mediated signaling was playing a role in driving
a TFH-phenotype in the trog+ cells, however it was also possible that the cells that
performed trogocytosis were predisposed to developing the TFH phenotype, and
trogocytosis-mediated signaling was simply sustaining their survival. To examine
whether the trog+ cells inherently developed a TFH-like phenotype more readily
than trog─ cells in cases where Ag receptor signaling was not limited to
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trogocytosis-mediated signaling, unlabeled MCC:FKBP APC were added back at
a 1:10 APC:T cell ratio to stimulate cultures of CD4+ T cell blasts immediately
after recovery from an 90 min trogocytosis-assay with biotin-labeled MCC:I-Ek
APC. Figure 4.7 shows that addition of MCC:FKBP to cultures after recovery
from the trogocytosis assay, increased the frequency of PD-1+ CXCR5+ trog─
cells increased from 5.56% to 22.5%. Interestingly, in these same cultures the
frequency of PD-1+ CXCR5+ trog+ cells decreased from 63.7% in untreated
cultures, to 38.4% (Fig. 4.7, right). Consistent with previous data, neutralizing
antibodies against trogocytosed I-Ek and CD80 led to a 67.2% decrease in the
frequency of PD-1+ CXCR5+ trog+ cells compared to cells recovered from
untreated cultures (Fig. 4.7, middle).

IL-21 expression in trog+ cells is enhanced by trogocytosis-medited
signaling in vitro
In line with the observed decrease in PD1+ CXCR5+ trog+ cells, after acidstripping or Ab blockade of trog-mediated signaling (Fig. 4.5), the frequency of IL21+ trog+ cells at 5 days was significantly reduced by the same treatments (Fig.
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4.8). Significantly fewer trog+ cells from peptide-stripped cultures supplemented
with Hb were IL-21+ (22.8%) compared to untreated cultures (32.5%). In contrast,
the frequency of IL-21+ trog+ cells in acid-stripped and MCC-supplemented
cultures increased to 40.3% (Fig. 4.8, left). Similarly, neutralizing trogocytosismediated signaling with anti-I-Ek and anti-CD80 decreased the frequency of IL21+ trog+ by 55% (Fig. 4.8, right).

In absence of APC, the development of a TFH phenotype is dependent on
trogocytosis-mediated signaling
To confirm that the trog+ cells were developing a TFH-like phenotype in absence
of APC, naïve 5C.C7 cells recovered from a standard 18 h in vitro trogyctosisassay were FACS-sorted into trog+ and trog─ populations. These purified trog+
and trog- cells were cultured individually in vitro and analyzed 72 hours later. At
this early time-point, 11.2% of the trog+, but only 1.53% of the trog─ cells
recovered from MCC:APC were CXCR5+ PD-1+ (Fig. 4.9, top). Similarly 11.8% of
trog+ and 3.36% of trog- cells acid-stripped cells cultured in MCC peptide were
CXCR5+ PD-1+ (Fig. 4.9, middle). Culturing with irrelevant Hb peptide after acidstripping led to a massive decrease in the frequency of CXCR5+ PD-1+ cells to
only 2.72% of the trog+ and 1.75% of the trog─ cells (Fig. 4.9, bottom). Due to low
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recovery following the FACS sort, later time-points were not examined in these
experiments.

TFH-associated cytokines IL-21, IL-4 and IL-6 are polarized towards
trogocytosed molecules
We previously reported that IL-4+ trog─ cells, >80% of trog+ cells had IL-4
directed towards trogocytosed molecules, while there was no IL-4 polarization in
trog- cells. To expand those previous studies, here intracellular polarization of IL6 and IL-21 was examined. As seen in figure 4.9, 3 days post-recovery, IL-21 and
IL-6 were directed towards trogocytosed molecules. As TFH cells help cognate B
cells through directed secretion of these cytokines, this data strengthens the
case for development of a TFH-phenotype observed in the trog+ cells.
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In vivo-generated trog+ cells can rapidly display a TFH-like phenotype
The in-vitro data presented above suggests that trogocytosis-mediated signaling
drives development of a TFH phenotype in trog+ cells after separation from APC.
To examine whether a similar phenotype occurs in vivo, 105 naïve 5C.C7 CD4+ T
cells were adoptively transferred into naïve WT B10.A mice. Six hours later,
recipients were immunized S.C. with PCC protein emulsified in Sigma Adjuvant
System (SAS). Mice with adoptively transferred cells immunized with SAS alone
served as negative controls. Spleens were harvested 3, and 7 days postimmunization and Ag-specific CD4+ T cells were identified by MCC:pMHCII
tetramer staining (Fig. S4.1C). As murine CD4+ cells do not endogenously
express MHCII, trog+ cells were identified by the presence of trogocytosed
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MHCII. Three days post-immunization, 2.3% of MCC:MHCII+ CD44+ cells were
PD-1+ CXCR5+ (Fig. 4.11A, left) This number increased to 7.4% by 7 days postimmunization (Fig. 4.11A, middle). Transferred cells from mice immunized with
SAS alone did not develop a TFH-phenotype, as expected in absence of Ag (Fig.
4.11A, right). The data in Fig. 4.11B suggests that the transferred trog+ cells were
able to more rapidly express PD-1 and CXCR5 compared to transferred trogcells. Of the PD-1+ CXCR5+ cells recovered 3 days post-immunization, 78.4%
were trog+ (Fig. 4.11B, middle). However, by 7 days post-immunization, the
frequency of CXCR5+ PD-1+ cells that were trog+ had decreased to an average of
37.2% (Fig. 4.11B, right). These findings suggest that even in the presence of
APC, the trog+ cells were more proficient at rapidly developing a phenotype
consistent with TFH.
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Trog+ cells express higher levels of IL-21, IL-6, and Bcl-6 compared to trogcells in vivo
To further examine the in vivo relationship between trog+ cells and a TFH
phenotype protein, WT B10.a mice were immunized S.C. with OVA protein in
SAS, or SAS alone. Proximal draining lymph nodes were collected 5 days postimmunization and recovered cells were analyzed via flow cytometry. Figure
4.12A shows that of CD44+ similarly-activated (CD69High) CD4+ T cells, the trog+
cells (red) had increased expression levels of IL-21 (left), IL-6 (middle), and Bcl-6
(right), compared to trog─ cells (blue). Meanwhile, the trog- cells had only slightly
higher expression levels of IL-21, IL-6, and BCL-6 than CD4+ T cells from SASonly controls (shaded grey). A significantly greater frequency of trog+ cells were
IL-21+ (10.2%), IL-6+ (17.1%), and BCL-6+ (6.8%) compared to CD4+ cells from
SAS-control mice. The trog+ cells had significantly higher frequencies of IL-21+
(38.4%), IL-6+ (39.2%) and BCL-6+ (22.1%), compared to CD4+ cells recovered
from SAS-control mice (Fig. 4.12B).
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In vitro-generated trog+, but not trog─, cells develop a TFH phenotype in
vivo, in absence of exogenous antigen
While the phenotype was consistent between in vivo-generated and in vitrogenerated trog+ cells, the role of trogocytosis-mediated signaling in the
phenotype in vivo could not be determined above. To more directly examine the
role of trogocytosis-mediated signaling in vivo, an 18 hr trogocytosis assay using
naïve 5C.C7 T cells and MCC:FKBP APC was performed. Recovered T cells
were purified from APC and adoptively transferred into naïve WT B10.A mice.
trog+ cells were identified by the presence of biotinylated APC membrane-derived
proteins. Similar to the in vitro data (Fig. 4.2), neither the trog+ or trog─ cells
contained a substantial population of PD-1+ CXCR5+ cells 24 hrs post-adoptive
transfer (Fig. 4.13A, left). However, by 72 hrs post-transfer, 17% of the trog+ cells
were PD-1+ CXCR5+, while only 1.4% of the trog─ cells shared this phenotype
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(Fig. 4.13, right). Since the only source of stimulation in these animals was
trogocytosed pMHCII and other APC-derived proteins, the appearance of the
CXCR5+ PD-1+ population only in the trog+ cells strongly supports the hypothesis
that trogocytosis-mediated signaling can drive TFH differentiation both in vitro and
in vivo.

In vivo-generated trog+ cells display a TFH phenotype during an active
immune response, but resemble T central memory cells after contraction of
the immune response.
The data thus far suggested that trogocytosis-mediated signaling was playing a
critical role in the apparent TFH-like phenotype, however, the role of trogocytosismediated signaling in maintaining this phenotype was unknown. We observed
that 7 days following the adoptive transfer of naïve 5C.C7 cells into WT B10.A
mice, and immunization with MCC+SAS as in Fig. 4.11, a significantly greater
frequency of trog+ cells resembled PD-1+ CXCR5+ TFH-like cells at 25%,
compared to only 2.9% of trog─ cells. Although the total numbers of PD-1+
CXCR5+ cells from each population was similar, due to only 10% of responding
cells being trog+, and thus consistent with the data in Fig. 4.11. The TFH
phenotype was not maintained beyond the expected time for Ag-persistence in
trog+ or trog- cells, and by 28 days post-immunization the TFH-like PD-1+ CXCR5+
population had decreased by 95% and 68% in the trog+, and trog─ populations,
respectively. (Fig. 4.13A, left).
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We did however, observe a noticeable difference in the phenotype of the trog +
and trog- cell at this time-point, as a substantial percentage (57% on average) of
the trog+ cells were expressing CXCR5, but not PD-1, compared to only 6.8% of
trog─ cells. Interestingly, these results are consistent with a study by Pepper et
al., which showed that early in the immune response, CXCR5 + PD-1- cells
contain a high frequency of CCR7+ T central memory (T CM)-precursors which
displayed sustained-survival after Ag-clearance [484]. In contrast, CXCR5+ PD-1+
TFH population decreased in frequency after Ag-clearance until disappearing
altogether [484]. Looking back, a significantly higher frequency of the the trog+
cells were CXCR5+ PD-1- compared to trog- cells at 7 days post-immunization.
In addition the trog+ cells also expressed higher levels of CCR7 compared to
trog─ cells at D28 (Fig. 4.14B), consistent with a TCM-phenotype. Recent studies
have found many similarities between TFH and CD4+ memory precursors, and TFH
themselves are able to become memory cells. Thus the apparent TFH-like
phenotype displayed early by the trog+ cells did not exclude the possibility that
these cells were memory/memory-TFH precursors
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Trogocytosis-mediated signaling increases memory-potential in CD4+ T
cells
The results in Fig. 4.14 indicated that the while the trog+ cells displayed a
phenotype consistent with TFH, this phenotype was not observed at late timepoints. Rather, the phenotype of the trog+ cells 28 days post-immunization
resembled that of memory-precursors. Interestingly, a recent study by Kaji et al.,
found that while GC B cells were critical for full TFH differentiation, a population of
memory precursors that resembled TFH cells in CXCR5, PD-1, and BCL-6
expression developed in absence of GC B cells [499]. In addition, TFH cells
themselves are able to readily become memory TFH [222, 500, 501], and in human
studies, circulating CXCR5+ memory cells represent a distinct subset of memory
cells which are able to rapidly migrate to B cell follicles and promote secondary
memory responses [483]. Thus, the collective results from Fig. 4.2-4.14
substantiates the in vitro TFH data, while also raising the possibility that trog+ cells
may also contain a high frequency of TCM precursors.
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Trogocytosis-mediated signaling enhances CD4+ T cell survival.
A defining hallmark of memory T cells is their ability to survive for extended
durations after Ag clearance. [502-504]. While the exact mechanisms which
permit the survival of CD4+ memory cells in absence of Ag is currently unknown,
prolonged Ag exposure and sequential cognate T cells:APC interactions promote
the transition to memory [318, 499]. Consistent with this, our previous reports
show that after separation from APC, trog+, but not trog─ cells retain active
signaling and that trog+ enhanced survival compared to trog─ cells up to 5 days in
vitro [81, 412].

To investigate whether the frequency of trog+ cells also increased in vivo as Ag
became depleted, WT B10.A mice were immunized with PCC in SAS as in Fig.
412. Spleens were harvested and MCC:MHC tetramer+ (Fig. S4.1D) CD44+ CD4+
cells were analyzed for the presence of trogocytosed MHCII and CD80/CD86 at
5, 7, 15, 21, and 28 days post immunization. A sharp increase in the percentage
of trog+ cells was observed between 7 and 14 days post-immunizationn from an
average of 6.8% during the peak of the immune response (Day 7), to 22% 14
days post-immunization. The frequency of trog+ cells further increased on Day 21
to an average of 52% of cells being trog+, then decreased slightly to an average
of 42.2% on 28 days post-immunization (Fig. 4.15A).
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However, in this in vivo system, it was unclear when these cells performed
trogocytosis, and it was possible that cells present in later time-points had
recently performed trogocytosis from APC expressing residual Ag. To directly
assess the role of trogocytosis-mediated signaling in the enhanced survival
displayed by the trog+ cells, the frequency of trog+ cells was measured in cells
recovered from in vitro trogocytosis assays in the presence of neutralizing
antibodies or with MCC peptide removed as in Figs. 4.4 and 4.5. Figure 4.15B
shows that blocking trogocytosis-mediated signaling with neutralizing antibodies
clearly impacted the survival of T cell blasts at 3, and 5 days post-recovery from
a 90 min in vitro trogocytosis-assay with MCC:FKBP. While on average, 33.5% of
recovered CD4+ T cells were trog+ immediately after recovery from the
trogocytosis assay, by day 3, untreated cultures were on average, 61.4% trog +.
Antibody blockade of trogocytosis-mediated signaling resulted in a significantly
lower frequency of trog+ cells, and only 16.3% of cells from cultures containing
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anti-I-Ek + anti-CD80 Abs were trog+ (Fig. 4.15B, left). At 5 days post recovery,
the frequency of trog+ cells in cultures containing neutralizing Abs had dropped
further to 1.8%, while 54% of the cells from untreated cultures were trog+(Fig.
4.15B, left). Similar trends in survival were observed in cultures of T cell blasts
recovered from a 90 min trogocytosis assay with MCC-loaded BMDC. While the
frequencies of trog+ cells were nearly equal in untreated and peptide-stripped +
supplemented MCC, the cultures where peptide was removed and supplemented
with Hb showed a 79% reduction in trog+ cell frequencies to only 4.8% trog+,
compared to the 22.8% trog+ from cultures where MCC was replenished (Fig.
4.15B, left). By 5 days post-recovery, only 1.2% of CD4+ cells from peptidestripped cultures supplemented with Hb were trog+, which was significantly lower
than the 4.8%, and 5.5% of trog+ cells in untreated, or MCC-supplemented
cultures, respectively (Fig. 4.15B, right).
Trogocytosis-mediated signaling also appeared to be critical for the
survival of naïve T cells following activation. In cultures where naïve cells were
used in an 18-hr trogocytosis assay with MCC:FKBP APC, 33.6% of recovered
cells immediately after the trogocytosis assay were trog+ (Fig. 4.14C, left).
Blocking trogocytosed I-Ek led to a significant decrease in the frequency of trog+
cells at 3 days post-recovery as only 4.7% of cells from cultures containing
neutralizing Abs were trog+, compared to 16.5% of untreated cells (Fig. 4C, left).
By 5 days post-recovery only 0.9% of cells from cultures containing neutralizing
Abs were trog+, which was significantly lower than the 4.2% of cells from
untreated cultures (Fig. 4.15C, left). Finally, in cultures of naïve cells recovered
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from an 18-hr trogocytosis assay with MCC-loaded BMDC, 34.4% of CD4+ cells
were trog+ immediately following recovery from the trogocytosis assay. At 5 days
post-recovery, on average, 6.8% of cells from peptide-stripped cultures
supplemented with MCC were trog+, compared to 4.7% of CD4+ cells from
untreated cultures being trog+ (Fig. 4.15C, right). The removal of Ag-peptide
however, led to a significant decrease in the frequency of trog+ cells to only 0.8%
of cells from these cultures being trog+ cells (Fig. 4.15C, right). These results
suggest that trogocytosis-mediating is critical for the survival of trog+ cells in the
absence of exogenous Ag.

Trogocytosis-mediated signaling drives IL-2 expression in trog+ cells
To examine downstream effects of sustained trogocytosis-mediated signaling
that could impact the survival of trog+ cells, expression levels of IL-2 and CD25
(IL-2Rα) were examined, as early IL-2 signaling is critical for T cell activation,
survival, and proliferation [505-507]. Naïve 5C.C7 CD4+ T cells were used in an in
vitro 18 hr trogocytosis assay using either MCC-loaded BMDC, or MCC:FKPB
APC. Five days post-recovery, cells recovered from BMDC were, on average,
42.5% of the trog+ but only 18.2% of the trog─ cells were expressing both IL-2
and CD25 (Fig. 4D, left). In cultures where peptide was stripped following the
trogocytosis assay, the addition of irrelevant Hb peptide resulted in a significantly
lower frequency (15.2% average) of IL-2+ CD25+ trog+ cells, compared to the
59.6% average of trog+ cells recovered from MCC-supplemented cultures. While
the trog─ cells from cultures supplemented with Hb showed a 41% decrease in

163

IL-2+ CD25+ cells compared to untreated cultures, from 24.6% to 14.7% (Fig.
4.16, third from left). The addition of MCC appeared to have little impact on IL-2
expression in trog+ cells, leading to an increase from 24.6% in untreated cultures,
to 25.6% in MCC-supplemented cultures. The addition of MCC had substantial
impacts on the trog+ cells however, increasing the frequency of IL-2-expressing
CD25+ cells by 36% to 68.4% of trog+ cells (Fig. 4.16, third from left). Correlating
with the massive cell death observed in Fig. 4.15, neutralizing trogocytosismediated signaling with anti-I-Ek + anti-CD80 significantly resulted in an 80%
decrease in IL-2+ CD25+ trog+ cells. From 62.6% of trog+ cells from untreated
cultures, to only 12.5% of trog+ cells (Fig. 4.16, right). In addition to a decrease in
frequency, there were clearly lower numbers of trog+ cells in peptide-stripped+
Hb (Fig. 4.16D, second from left), and cultures containing neutralizing Abs (Fig.
4.16, far right), compared to untreated (Fig. 4.16, left), or peptide-stripped
cultures supplemented with MCC (Fig. 4.16, third from left).
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Consistent with the decrease in IL-2 expression, and survival, inhibiting
trogocytosis-mediated signaling by removing antigenic peptide or blocking the
signaling with neutralizing Abs led to decreased activation (as indicated by
CD69) (Fig. 4.17, top). The clear reduction in IL-2 expression resulting from the
inhibition of trogocytosis-mediated signaling is further made apparent in
histogram overlays (Fig. 4.17, bottom)
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In vivo-generated trog+ cells showed a similar phenotype. Ninety-six hours postimmunization with PCC+SAS, the trog+ adoptively transferred naïve 5C.C7 cells
expressed higher levels of IL-2 and CD25 compared to trog─ cells from the same
animals (Fig. 4.18).
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Trogocytosis-mediated signaling sustains the survival of trog+ cells in an
IL-2-independent manner
The inhibition of trogocytosis-mediated signaling led to a reduced expression of
pro-survival cytokines including IL-2 (Fig. 4.16) and IL-21 (Fig. 4.8) by the trog+
cells. While trogocytosis-mediated signaling appeared to clearly play a role in the
survival of the trog+ cells in the absence of APC, the direct impact of
trogocytosis-mediated signaling vs the presence of survival-associated cytokines
was unclear. To address this, exogenous recombinant IL-2 (100 U/mL) was
added to an aliquot of T cell blasts in cultures with, or without, anti-I-Ek/anti-CD80
neutralizing antibodies. In cultures supplemented with IL-2 alone, there was a
modest, but significant increase in the number of trog+ cells relative to input
compared to untreated cultures from 26.5%, to 32%, respectively. The trog─ cells
showed a greater response to IL-2, showing a survival rate of 23% compared to
only 9.5% of cells from untreated cultures (Fig. 4.19, left). In cultures where antiI-Ek/anti-CD80 neutralizing antibodies were added, addition of exogenous IL-2
led to significantly increased survival of both the trog- and trog+ cells. However,
the increased survival was most apparent in the trog- cells, which increased from
6.2% to 22% relative to input, which was similar to the trog- cell numbers in the
absence of neutralizing Abs + IL-2. On the other hand, the trog+ cell numbers
were only partially rescued by supplemented IL-2 in the presence of neutralizing
Abs, increasing the survival rate from 12% to 18.2%, which was significantly
lower than the survival rate of trog+ cells in cultures with IL-2 alone.
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The data in Fig. 4.15 show that trogocytosis-mediated signaling plays a major
role in the survival of both trog+ and trog─ cells after separation from APC, but
through different mechanisms. While it appeared that the survival of recovered
trog─ cells blasts was largely dependent upon exogenous IL-2, trogocytosismediated signaling appeared to be playing a distinct role in the survival of the
trog+ cells independently of IL-2 (Fig. 4.19).
Consistent with previous studies, the trog+ blasts recovered from
MCC:FKPB APC showed enhanced survival compared to the trog─ cells (Fig.
4.15, left). In contrast to this pattern, the frequency of naive trog+ cells recovered
from either MCC:FKBP, or BMDC decreased between 0 and 3 days postrecovery (Fig. 4.15C). Interestingly, at day 5 the frequency of trog+ cells
recovered from MCC:FKBP APC had rebounded, while the cells recovered from
BMDC continued to decrease (Fig. 4.15C). One explanation for these observed
differences is that the cells more highly activated by BMDC were proliferating at a
greater rate than the cells that were comparably less-activated by MCC:FKBP.
As the trogocytosed material was limited to what was acquired during the
trogocytosis assay, either trogocytosed molecules were being diluted or
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internalized by the trog+ cells resulting in undetectable levels, or unequal
distribution of trogocytosed molecules was occurring during the division of trog+
cells. It was also possible that the trog─ cells were showing greater rates of
proliferation.

Trog+ cells rapidly proliferate, and produce trog+ and trog─ progeny
To ascertain whether the discrepancies in the frequency of trog+ cells in cultures
where naïve cells were used in the trogocytosis-assay, or BMDC were used as
APC, a series of experiments was conducted to assess the proliferation, and
retaining of trogocytosed molecules on proliferating trog+ cells. First, we
examined the proliferation in trog+ and trog─ cells using CFSE-labeled naïve
5C.C7 T in an 18 h in vitro trogocytosis assay with MCC:I-Ek APC. For
comparison, an aliquot of the CFSE-labeled naïve cells was added to anti-CD3 +
anti-CD28 coated plates at the same time cells were added to the APC during
the trogocytosis-assay (t= -18 h). Figure 4.20A shows that at 24 hrs postrecovery, of CD44+ CD4+ cells, a small portion of the trog+ cells and nearly none
of the trog─ or Ab-stimulated cells had performed a single cells division (Fig.
4.20A, top). By 48 hrs the majority of the trog+ cells had performed at lest one
cell division. Meanwhile a noticeably lower frequency of the trog─ cells had
divided, and Ab-stimulated cells showed a similar proliferation pattern as the
trog─ cells had undergone one or two cell-divisions (Fig. 4.20A, middle gray).
Interestingly, at 72 hrs the majority of the trog+ cells remained at 1- 2 divisions,

169

while it appeared that the trog─ and Ab-stimulated cells had continued to divide
(Fig. 4.20A, bottom).

Antibody-blockade against I-Ek and CD80 dramatically reduced the proliferation,
and survival of trog+ and trog- cells (Fig. 4.20B), suggesting that trogocytosismediated signaling was necessary for the proliferation of the trog+ cells after APC
removal.

Compared to naïve cells recovered from MCC:FKPB APC, cells recovered from
BMDC showed markedly different proliferation patterns. The trog─ cells appeared
to undergo comparable, if not more rounds of cell division compared to trog+ cells
at 48 hrs, and similar levels to the trog+ cells by 72 hrs (Fig. 4.21, left). Removal
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of peptide and supplementation with Hb led to decreased survival of both trog +
and trog─ cells, consistent with the findings in Fig. 4.20 (Fig. 4.21A, left),
however, there was no substantial difference in the extent of proliferation in the
trog+ cells from Hb-supplemented cultures compared to MCC-supplemented
cultures (Fig. 4.21 left). Somewhat unexpectedly, at 72 hrs, a higher frequency of
the trog+ cells from Hb-supplemented cultures had undergone 4-5 rounds of cell
division compared to trog+ cells from MCC-supplemented cultures (Fig. 4.21B,
top right). However, in terms of cell numbers, the removal of Ag and
supplementation with Hb led to a decrease in cell numbers within all cellular
divisions (Fig. 4.21B, right bottom).

Trog+ cells show increased proliferative responses compared to trog- cells
The seemingly disproportionate increase in the number of trog─ cells that had
undergone 3-4 divisions between 48 and 72 hrs (Fig. 4.20) could be due to a
delay in the proliferation of these cells. Another possibility for this observation
could be that the proliferating trog+ cells were producing trog─ progeny. To test
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this, 5-ethynyl-2′-deoxyuridine (EdU)-incorporation was examined in proliferating
trog+ and trog─ cells. Using a combination of EdU incorporation and Ki-67 Gossel
et al. have reported a strategy to determine whether a cell is currently undergoing
cell division or has recently divided but it not actively proliferating. If a cell is
actively dividing, it will express both Ki-67 and have incorporated Edu. If a cell is
not expressing Ki-67 but has incorporated Edu, this suggests that the cell has
recently divided, but is no longer actively proliferating, or a progeny of an actively
dividing cell [508]. Therefore, if unequal distribution of the trogocytosed
molecules was occurring during cell division, it would be expected that the trog ─
cells would contain a high proportion of EdU+ Ki-67─ cells, while a higher
frequency of the trog+ cells would be both EdU+ and Ki-67+. The data in Fig.
4.22A show that 48 hrs after naïve 5C.C7 cells were recovered form a standard
in vitro trogocytosis assay, 25.6% of the trog+, but only 7.4% of the trog─ cells
were actively dividing, as determined by Ki-67 expression (Fig. 4.21A). At 72 hrs
post-recovery, 16.5% of the trog+ and 13.1% of the trog─ were expressing Ki-67.
In comparison, 21% and 12.2% of anti-CD3 + anti-CD28-stimulated cells were Ki67+ at 48 and 72 hours, respectively. Between 48 and 72 hrs, the frequency of
recently-divided (EdU+), Ki-67─ cells increased 3.13-fold in the Ab-stimulated
cells, and 3.13-fold in the trog+ cells (Fig. 4.22, right, left). The trog─ cells
however, showed a 5.79-fold increase in this population, which did not fit well
with the frequency of actively proliferating cells detected at 48 hrs (Fig. 4.22,
middle).
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Trogocytosis-mediated signaling enhances the cellular division of trog+
cells
As Ag-experienced CD4+ T cells require less stimulation compared to naïve cells
to induce proliferation [37, 509], trogocytosis-mediated signaling may differently
impact the proliferation of previously-activated and naïve cells. Due to the
variability in the size of activated blasts, it is difficult to assess proliferation
confidently with cell proliferation dyes. Ki-67 was instead used to identify activelyproliferating cells. It appeared that trogocytosis-mediated signaling was impacting
the proliferation of previously-activated trog+ cells, as antibody blockade against
trogocytosed I-Ek and CD80 led to a decrease in Ki-67 in the trog+ cells (Fig.
4.22B).
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Trogocytosed molecules are retained through early cell divisions
While trogocytosis-mediated signaling appeared to be playing a role in driving
proliferation of lesser activated cells in vitro (Fig. 4.21), it was unclear whether in
vivo-generated trog+ and trog─ cells would show similar patterns. To examine
this, naïve CellTrace-labeled 5C.C7 cells were adoptively transferred into naïve
WT B10.A mice. Six hours later, adoptive-transfer recipients were immunized
with SAS alone, or PCC+SAS. Spleens were harvested 96 hrs later and cell
proliferation was assessed by dilution of CellTrace dye. As expected, adoptively
transferred cells in SAS-only immunized controls did not proliferate in the
absence of Ag (Fig. 4.23A). In contrast, the transferred cells in SAS+PCCimmunized mice underwent massive expansion. Interestingly, trogocytosed I-Ek
and CD80 were clearly present on cells which had undergone fewer (1-5) rounds
of cell division, but was scarce on cells which had undergone >6 rounds of cell
division (Fig. 4.23A). Consistent with the phenotype of memory-precursors early
in the immune response [510, 511], of adoptively transferred CD44+ CD4+ T cells
that had performed 1-4 cell divisions, expression levels of the anti-apoptotic
protein Bcl-2 were higher in trog+ cells compared to trog─ cells (Fig. 4.23B, left).
However, this was not the case in the few trog+ cells that had performed 5+ cell
divisions, as they displayed similar expression patterns to the trog- cells of similar
cell divisions (Fig. 4.23B, right).
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The results in Figs. 4.20-4.23 suggest that trogocytosis-mediated signaling was
critical for the proliferation of weakly-activated cells, but the extent of proliferation
in highly activated cells was occurring independently of trogocytosis-mediated
signaling (Fig. 4.21). Although, it was apparent that trogocytosis-mediated
signaling was playing a role in the survival of the trog+ cells, particularly those
that had undergone fewer rounds of cell division (Fig. 4.21B). The
disproportionate frequency of trog- cells that had divided between 48 and 72
hours relative to the frequency of cells actively-dividing at 48 hrs (Fig. 4.22A)
could be due to the increased survival of recently-divided cells. When also
considering the maintained levels of trogocytosed material (as determined by
staining intensity), through multiple rounds of cell division, these results raised
the possibility that these molecules may be unequally distributed to daughter
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cells during the division of the trog+ cells. Thus, potentially accounting for the
increase of trog- cells which appeared to have divided multiple times at 72 hrs.

During asymmetric division of trog+ cells, daughter cells that retain
trogocytosed molecules resemble memory precursors.
In addition to the effector-to-memory transition model, it has been found that
naïve T cell progeny may become predestined for memory fate during the
immune synapse through subsequent asymmetric division [329, 491, 512, 513]. In
this model, the signaling molecules converged at the immune synapse, along
with high levels of localized TCR and costimulatory signaling, form a region of
polarity known as the proximal pole. Concurrent with the formation of the immune
synapse, surface molecules including CD43 and CD45 migrate, and localize at a
focal point opposite of the immune synapse to form the distal pole complex [70,
514]. As this axis of polarity is established during the immune synapse, it has
been proposed that asymmetric division occurs in the first few rounds of cell
division following activation [329]. In this model, the daughter cell containing the
proximal pole which received strong TCR and costimulatory signaling from the
APC becomes an effector cell which continues to proliferate at high rates.
Meanwhile, the cell containing the distal pole complex are more likely to be
memory-precursors, which are less terminally differentiated, and do not expand
as rapidly as the effector cell population [329, 330, 515]. Asymmetric division is
not limited to naïve T cells, as memory T cells have also been observed to
asymmetrically divide upon re-challenge [331]. Interestingly, we have previously
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observed that during the immune synapse, >82% of trog+ cells had trogocytosed
molecules localized to the distal pole [81] (Fig. 4.24).

To examine whether the cells with retained trogocytosed molecules resembled
memory precursors, we examined Tcf1 expression in trog+ and trog─ cells. In
asymmetrically dividing CD4+ T cells, Tcf1 has been observed to be retained at
high levels on the daughter cell resembling TCM precursors [516]. In an influenza
model, of CD4+ T cells which had undergone only several rounds of divisions,
Tcf1High cells retained the capacity to self-renew, producing Tcf1-silenced
daughter cells which resembled terminally-differentiated effector cells, and a
memory-like sibling cell which maintained high Tcf1 expression [491]. Consistent
with these findings and the possibility that trog+ cells resemble memory-precursor
cells, 48 hrs post-recovery from a trogocytosis assay using naïve 5C.C7 CD4+
cells, the trog+ cells recovered from MCC:FKBP APC largely maintained high
Tcf1 expression through 1-3 cell divisions, while the trog─ cells within equal
divisions expressed low levels of Tcf1 (Fig. 4.25A, top). This pattern was not
observed in the cells recovered from BMDC, and both trog+ and trog─ cells
showed lower levels of Tcf1 compared to trog+ cells recovered from MCC:FKBP
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APC (Fig. 4.25B). Intriguingly, the trog+ cells recovered from BMDC which were
peptide-stripped and supplemented with Hb, showed higher levels of Tcf1
compared to the trog+ cells from peptide-stripped cultures supplemented with
MCC (Fig. 4.25B).

A similar phenotype was observed in in vivo-generated trog+ cells. Of adoptively
transferred cells as in Fig. 4.23., in cells that had undergone 1-4 cell divisions
following immunization with PCC+SAS, the trog+ cells showed higher levels of
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Tcf1 compared to the trog─ cells (Fig. 4.26). Similar to the trends for Bcl-2
expression (Fig. 4.23), of adoptively transferred CD44+ cells which had
undergone >5 rounds of cell division, the difference between Tcf1 expression in
trog+ vs trog─ cells was less apparent and did not resemble asymmetric
distribution of Tcf1. However, the trog+ cells still showed 62% higher expression
of Tcf1 as determined by MFI, compared to the trog─ cells (Fig. 4.26, right).

To test the possibility that asymmetric distribution of trogocytosed molecules was
occurring, naïve 5C.C7 cells were used in an 18 h in vitro trogocytosis assay with
fluorescent NHS-Sulfo BODIPY-labeled MCC-loaded BMDC. Recovered cells
were FACS sorted into trog+ and trog─ populations, CFSE labeled, then cultured
separately in vitro for 72 h. While >95% of the trog+ cells were displaying
trogocytosed molecules immediately following the FACS sort, by the end of the
3-day incubation, the frequency of cells displaying trogocytosed molecules
decreased within each successive cell division (Fig. 4.27, middle). The trog─
sorted as expected, did not display trogocytosed molecules within cells of any
cell division. (Fig. 4.2, right),
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The above data suggest that the trog+ cells had undergone asymmetric division,
where one cell retained both the trogocytosed molecules and Tcf1. To confirm
this, immunofluorescent imaging was performed on naïve 5C.C7 cells 32 hrs
post-recovery from an in vitro trogocytosis assay with MCC:FKBP APC. Four
hours prior to fixation and staining, cells were treated with the actin
polymerization inhibitor cytochalasin D to inhibit cytokinesis. Consistent with the
data in Fig. 4.27, in >70% of the dividing cell conjugates, the cells with
trogocytosed molecules also had higher levels of Tcf1. Representative images
are shown in Fig. 4.28. Interestingly, it also appeared that unlike observations in
trog+ T cell blasts [412], the majority of naïve trog+ cells had multiple punctate
spots of trogocytosed molecules. Suggesting that it is possible for a trog+ cell to
produce more than one trog+ progeny throughout it’s proliferation cycle.
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Collectively, the data in above strongly suggest that during cell division, at least
in lesser activated naïve CD4+ T cells, trogocytosed molecules are unequally
distributed to daughter cells in a manner reminiscent of asymmetric division. In
this case, the daughter cells which retained the trogocytosed molecules
resembled memory precursors, while the trog─ progeny did not.

Trog+ cells rapidly increase expression of TFH-associated molecules PD-1,
CXCR5, and IL-21 upon in vitro re-stimulation
In addition to extended periods of survival, another important function of memory
cells is to display rapid recall responses. To test the recall responses of trog+ and
trog- cells, naïve 5C.C7 cells were used in an 18-hr in vitro trogocytosis assay
with MCC:FKBP APC. Recovered cells were cultured in vitro for 7 days and then
re-stimulated for 3 hrs at a 1:1 ratio with MCC:FKBP APC, followed by a 3-hr
incubation. Following this brief period of re-stimulation, the trog+ cells increased
in their frequency of PD-1+ CXCR5+ cells by 50%, (from 39.5% to 59.3%), while
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the trog- cells showed a 32% increase in the frequency of this population.
Although, at significantly lower overall frequencies compared to the trog+ cells,
the frequency of PD-1+ CXCR5+ trog- cells increased from 5.36% to 7.06%
following in vitro re-stimulation (Fig. 4.29). To examine IL-21 expression in the
context of a recall response, the trog+ cells generated in vivo from the experiment
in Fig. 4.14 were isolated from spleens of PCC+SAS-immunized mice 28 days
post-immunization, and were re-stimulated in vitro as in Fig. 4.29A. Here, the
trog+ cells also displayed rapid expression of IL-21 upon re-stimulation while the
trog- cells did not. Although, this may be an unfair comparison due to the overall
lack of a robust TFH-like phenotype displayed by the trog- cells. Regardless, these
results show that the trog+ cells were able to rapidly upregulate TFH-associated
markers upon re-stimulation, consistent with a memory-phenotype.
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In vitro-generated trog+ cells display prolonged survival in vivo, in absence
of antigen
The results thus far suggested that the trog+ cells displayed characteristics
consistent with memory-precursor cells. However, the results showing that the
trog+ cells can produce trog- progeny through asymmetric division, and the
uncertainty of when trogocytosis occurred in the trog+ cells in vivo made it difficult
to ascertain the long-term phenotype of the initial trog+ cell. To isolate the time
frame for trogocytosis to occur to a set duration, and limit Ag to trogocytosed
molecules, naïve 5C.C7 cells were used in an 18-hr in vitro trogocytosis assay
with MCC:FKPB.
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Immediately following recovery, cells were FACS sorted into CD4+ trog+ and
trog─ populations. Immediately following the FACS sort, 2 x 105 FACS-sorted
trog+, trog─, or unstimulated 5C.C7 cells were transferred into separate naïve WT
B10.A recipient mice. An experimental timeline is shown in Fig 4.30A. In line with
the in vitro data (Figs. 4.1, 4.5), 24 hrs after adoptive transfer, cells recovered
from the spleens of trog+ and trog─ adoptive transfer recipients showed a
similarly activated phenotype as indicated by CD69 levels (Fig. 4.30B), and high
expression of CD44 and low CD62L (Fig. 4.30C).
Five days post-adoptive transfer, the transferred (MCC:MHCII tetramer-positive
CD44+) cells that had migrated to the LN of trog─ recipients contained a higher
frequency of actively-proliferating cells (46.7% on average) as determined by Ki67 staining (Fig. 4.31), and had slightly increased numbers (Fig. 4.32) compared
to the cells from trog+ recipients.
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Consistent with the in vitro data, on average 73.4% of the transferred cells which
retained trogocytosed I-Ek and CD80 (which accounted for on average 11% of
CD44+ MC:MHCII+ cells in the spleen, and 8.5% in the lymph nodes) were
actively proliferating, compared to 35.4% of the cells without detectable I-Ek /
CD80 (Fig. 4.31). It also appeared that the trog+ had noticeably higher levels of
CD44 in the cells recovered from spleens compared to the transferred cells from
the trog─ recipients (based off of fluorescence intensity) (Fig. 4.31), suggesting
that the cells from the trog+ recipients had remained highly activated, and that
those from the trog- recipients were becoming less activated.

It appeared that the trog+ cells more rapidly exited circulation compared to trog+
cells, as 24 hours post-transfer, there was a significantly lower frequency of
transferred cells in trog+ recipients in circulation compared to trog─ recipients
(Fig. 4.32, left), while similar frequencies of transferred trog+ and trog─ cells were
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observed in cells recovered from the lymph nodes and spleen (Fig. 4.32, middle,
right). In support of the in vitro data, the transferred cells in the trog+ recipients
showed enhanced survival compared to the cells from trog─ recipients, and at 21
days post-adoptive transfer, there was a significantly higher frequency of
transferred cells in the spleens of trog+ recipients compared to trog─ recipients
(Fig. 4.32, right). In support of the in vitro data, the transferred cells from trog+
recipients which had retained trogocytosed I-Ek/CD80 also expressed high levels
of CXCR5, (Fig. 4.33, left) while neither the I-Ek/CD80─ cells in these animals, or
the transferred cells recovered from trog─ recipients expressed CXCR5 (Fig.
4.33, left). Similar to the transferred cells in immunized mice (Fig. 4.13), 21 days
post-transfer, the transferred cells from trog+ and trog─ recipients did express
high levels of PD-1, although the cells from trog+ recipients showed lower levels
of PD-1 expression compared to those from trog─ recipients (Fig. 4.33, middle).
Compared to transferred cells recovered from the trog─ recipients, the cells from
trog+ recipients expressed higher levels of CCR7, consistent with CD4+ TCM cells
(Fig. 4.33, right).
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Consistent with the frequency observed in the immunized WT mice, an average
of 61.5% of transferred cells in trog+ recipients had retained I-Ek and CD80
expression on day 21, compared to only 6.95% of the cells from trog─ recipients
(Fig. 4.34, left). To test the recall ability of the transferred cells, mice were
immunized with MCC peptide alone or PCC emulsified in SAS on day 21. Fortyeight hours later, spleens, proximal draining lymph nodes, and skin from the
injection site were collected. While immunization with peptide alone in the
absence of high costimulation typically leads to anergy in naïve CD4 + cells [33],
memory CD4+ cells have been found to respond to injection with a single peptide
epitope [517]. Interestingly, 47% of the MCC:MHCII+ cells recovered from the
spleens of trog+ recipients displaying trogocytosed I-Ek/CD80, expressed Ki-67
after immunization of peptide alone, while only 18% of the cells without
trogocytosed molecules were Ki-67+. In transferred cells recovered from trog─
recipients, only 8.7% of all transferred CD44+ CD4+ cells were Ki-67+. It appeared
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that proliferation in these cells was induced by peptide, as <1% of the cells from
either trog+ or trog─ recipients were Ki-67+ on day 21 prior to the immunization. In
the presence of adjuvant, the transferred cells from trog+ recipients showed only
a slight increase in the frequency of Ki-67+ cells (49.6% on average) compared to
MCC peptide-immunization (40.5% average Ki-67+). The I-Ek/CD80-negative
cells showed a substantial increase in the frequency of actively-dividing cells
however, from 18% in MCC-immunized animals, to an average of 44.3% in
PCC+SAS-immunized animals (Fig. 4.34A, middle). Meanwhile, the cells from
the trog─ recipients responded more robustly to immunization with MCC+SAS
compared to MCC alone, increasing the total frequency of Ki-67+ transferred cells
to an average of 15.5%.
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Notably, 59% of the Ki-67+ cells in trog─ recipients on day 23 had acquired I-Ek +
CD80, suggesting that these cells performed trogocytosis from APC in vivo and
more readily proliferated than cells which did not perform trogocytosis (Fig.
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4.34A, bottom right). This is supported by the fact that cells from trog─ recipients
on day 21, and those recovered from mice 48 hrs post-immunization with MCC
alone showed similar frequencies of I-Ek/CD80+ cells (6% and 6.9%,
respectively), however after immunization with PCC + SAS, 26.7% of cells in
trog- recipients had become trog+ (Fig. 4.34A, bottom).
Interestingly, the cells in the lymph nodes did not display the same pattern
as those in the spleen, as both I-Ek/CD80 positive, and negative cells from the
trog+ recipients response to peptide alone, and a lower frequency of the cells in
the draining LN were I-Ek/CD80+ compared to those in the spleen (Fig. 4.34B).
However, a noticeable difference was still observed between the cells recovered
from the trog+ (71% Ki-67+) and trog─ (29% Ki-67+) recipients after immunization
with MCC (Fig. 4.34B, right). The cells from the trog─ recipients responded to
immunization with PCC+SAS, and 61% of MCC:MHCII+ cells in these animals
were Ki-67+ 48 hours post-immunization (day 23), compared to 76% of cells from
trog+ recipients (Fig. 4.34, right). To address potential TRM cells, skin was
collected from the immunization site, as well as a portion of skin from the distal
side of the mouse. Very few MCC:MHCII+ cells were detected in a similar-sized
portion of the skin distal to the injection site (not shown). However, there was a
striking difference between the cells in the trog+ and trog─ recipients at the site of
the immunization (Fig. 4.34C). Using the markers CD69 and CD103 to identify
TRM cells, of the transferred CD44+ cells in the trog+ recipients, 22.3% of cells in
MCC-immunized mice, and 62.1% of cells in MCC+SAS-immunized mice
showed a TRM-phenotype (Fig. 4.34C, top). In contrast, only 6.98% of transferred
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CD44+ cells in trog─ recipients immunized with MCC, and 13.7% of SAS+PCCimmunized mice shared this phenotype (Fig. 4.34C, bottom).

To further assess the recall responses of transferred cells, the frequency of
MCC:MHC+ cells relative to all CD4+ T cells in the spleens of mice at day 21 and
48 hrs after immunization on day 21, was determined. Immunization with
PCC+SAS led to a significantly higher frequency of MCC:MHCII-tetramer+ cells in
naïve WT, trog+ and trog─ recipients compared to the frequencies on day 21. In
naïve WT animals however, this frequency remained below 0.15% (Fig. 4.35A,
left). Immunization with PCC+SAS also led to significantly higher frequencies of
MCC:MHCII+ cells compared to MCC-immunized mice in naïve WT, and trog─
recipients, while the difference between MCC:MHCII+ cell numbers in
PCC+SAS immunized trog+ recipients was found to be significantly greater
compared to day 21, but was not significantly different compared to MCCimmunized mice (Fig. 4.35A). This suggests that the response of the Ag-specific
cells in the trog+ recipients was consistent with memory cells.

Finally, IL-21 expression was examined in cells recovered from the spleens of
trog+ and trog─ recipients 48 hrs after immunization with MCC or PCC+SAS.
Despite the apparent increase in proliferation displayed by cells in the trog+
recipients after immunization with MCC alone, the IL-21 expression was similar in
cells from MCC-immunized trog+ and trog─ recipients (Fig. 4.35B, left). The
transferred cells from the trog+ recipients however displayed a 28% increase in
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IL-21 expression compared to transferred CD44+ cells from trog─ recipients after
immunization with PCC+SAS (Fig. 4.35B, right).

As the early-memory checkpoint in mouse models typically falls between 21-28
days after the start of the immune response [518], at 21 days it is difficult to
confirm that these cells were true-memory cells, which can persist for months to
years after infection. However, in typical models the early checkpoint has been
based off of immunization models, where Ag-reserves may persist for weeks,
and thus making it difficult to determine if the cells were true memory or were
activated by Ag-reserves. In this system, Ag was limited to the APC during the
trogocytosis assay, and trogocytosed molecules. Therefore, these results
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suggest that trog+ cells contain a population of initial cells, or produce progeny,
that show enhanced survival, and recall responses consistent with a memoryphenotype. Because in the absence of exogenous Ag the rate of trogocytosis is
expected to be low, that a substantial percentage of surviving cells in the trog +
recipients still displayed trogocytosed I-Ek / CD80 21 days post-transfer (Fig.
4.34), suggests that the original cells which performed trogocytosis made up a
major portion of the persisting early memory-like population.

Discussion
The ability of CD4+ T cells to differentiate into specialized TH subsets is a critical
component in generating protective immunity against a multitude of pathogens.
Despite the central role these cells play in generating adaptive immunity, the
mechanisms behind CD4+ differentiation are not completely understood. In
particular, the multi-step signaling process required for TFH differentiation, [519],
and the mechanisms governing memory T cell formation are largely unknown.
Here, we set out to investigate the potential role for trogocytosis-mediated
signaling in TFH differentiation. We hypothesized that, because TFH differentiation
requires repeat-cognate TCR+costimulatory signaling events, that sustained
trogocytosis-mediated signaling may promote TFH differentiation after APC
removal.
While it has been agreed on that TFH development requires repeat
cognate interactions, the required source of these interactions has not been
solidified. The proposed requirement for B cells in the development of T FH is most
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likely due to the fact that the B cells become the most abundant APC for
activated T cells in the lymph node following clonal expansion. This is supported
by the fact that repeated interactions with DC can also drive T FH differentiation
[213]. Irrespective of the APC type, TFH differentiation requires repeated TCR
signaling after initial activation [213, 228, 231, 244]. In this system, T cells were
cultured in absence of APC, but still developed a T FH-like phenotype. This
strongly suggests that trogocytosis-mediated signaling is capable of driving T FH
differentiation in the absence of APC. If there were contaminating residual APC
in the cultures, then it would be expected that a higher frequency of the trog─
cells would also be able to develop a TFH phenotype. This is supported by the
results that the addition of APC to cultures of recovered cells led to a significant
increase in the amount of CXCR5+ PD-1+ trog─ cells (Fig. 4.7). Somewhat
unexpectedly, the addition decreased the frequency of CXCR5 + PD-1+ trog─ cells
compared to cultures containing only recovered T cells. This could possibly be
due to hyporesponsiveness developed by the T cells, which can occur after
repeat exposure to APC [520].
The T cells recovered from the MCC:FKBP APC were highly efficient at
developing a TFH phenotype, consistent with the positive correlation between
TCR binding strength and TFH differentiation [521]. That trogocytosis-mediated
signaling was contributing to the apparent TFH phenotype developed in the trog+
cells was further supported by the findings that removal of MCC from
trogocytosed pMHCII complexes led to a dramatic decrease in CXCR5, PD-1,
and IL-21 expression.
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Following adoptive transfer of naïve 5C.C7 cells into naïve animals, and
immunization with PCC, 3 days -post immunization we found that nearly 80% of
the PD-1+ CXCR5+ cells were also trog+ (Fig. 4.11). However, the frequency of
trog+ cells decreased to 40% by 7 days post-immunization. This strongly
suggests that the trog+ cells are able to more rapidly become TFH compared to
trog─ cells, while trog─ cells are able to efficiently become TFH given extra time.
One explanation for these results could be that trogocytosis-mediated signaling
contributed to the signaling required for TFH differentiation after the trog+ cells
dissociated from APC. On the other hand, the trog─ cells would require reengaging APC to receive sequential TCR signaling, reflected by a delay in the
differentiation to TFH. The kinetics of the immune response and TFH differentiation
further support this theory. Because purified populations of CD4+ TCR-Tg T cells
were transferred into the naïve animal, at early time-points, the number of
responding B cells would be expected to be low. Therefore, due to the time it
takes for TFH differentiation to occur (at least 2-3 days in vivo), the trog+ cells
likely started developing a pre-TFH phenotype shortly after activation by DC
outside of the B cell follicles. Seven days post-immunization, the host B cells
would have had time to undergo clonal expansion, and thus effectively drive T FH
differentiation in the trog─ cells through increased B:T cell interactions. These
findings raise the possibility that trogocytosis-mediated signaling may have
significant impacts on the kinetics of GC formation and B cell activation.
Trogocytosis-mediated signaling appeared to enhance IL-21 expression in
the trog+ cells, as blocking signaling or removal of Ag from MHCII led to a
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significant decrease in the frequency of IL-21+ trog+ cells. These results,
combined with the observation that IL-21 was polarized towards trogocytosed
molecules, suggest that trogocytosis-mediated signaling may further promote TFH
differentiation by driving IL-21 expression. The IL-21 produced by the trog+ cells
may play a separate role in vivo, as IL-21 can impact multiple aspects of T cell
immunity including maintaining cell survival, proliferation, effector function, and
memory formation.
The observed proliferation of I-Ek/CD80- cells in the LN in response to
immunization with MCC alone could be due to residual activation in the LN
compared to the spleen, as a higher frequency of the LN cells were performing
active cell division, and displayed higher levels of CD44 compared to those in the
spleen 5 days post-transfer (Fig. 4.34B).
It also appeared that the cells from the trog+ recipients were able to
respond to immunization with PCC+SAS in the periphery more readily than the
cells in the trog─ recipients. This was indicated by a massive recruitment of these
cells to the site of injection in trog+ recipients compared to the trog─ recipients
(Fig. 4.34C). Interestingly, these cells resembled T RM, however they were not
largely present in the injection site of mice immunized with MCC peptide alone,
suggesting that the presence of these cells may be an artifact of the adjuvant.
However, it has been shown that human TRM are able to leave the tissue to enter
circulation and take up residency in other sites. Therefore, it is possible that the
trog+ cells also produce TRM. Without an initial site of Ag-delivery to induce a
primary response in this model, it was difficult to assess T RM responses. In the
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study shown in Fig. 4.14, skin from the injection site was collected at the time of
harvest (7 and 28 days post-immunization), and no substantial differences in
MCC:MHCII+ CD69+ CD103+ TRM cells were observed between cells isolated
from the skin proximal, or distal, to the injection site (data not shown).
From these experiments, the possibility for T:T presentation between the
trog+ cells after adoptive transfer into animals cannot be ruled out. However,
even with this possibility, the results suggest that the trog+ cells produce a more
robust memory-like population compared to the trog─ cells in absence of
exogenous Ag and is a novel finding.
Collectively the results from chapter 4 suggest that trogocytosis-mediated
signaling plays a role in the generation of cells resembling both TEM and TCM.
Importantly, the results suggest that trogocytosis-mediated signaling plays a
critical role early in the response by enhancing the survival and proliferation of
cells weakly-activated by APC. Such activation may promote Tcf1 expression
and enhance the differentiation to T FH, or transition to memory [522].
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Chapter 5
Discussion
Although trogocytosis was first observed nearly a half-century ago [362], the
biological implications of this event were not appreciated until recent decades
with the discovery that trog+ cells can act as functional APCs through the
presentation of trogocytosed molecules. T-T Ag presentation after trogocytosis
can significantly impact the activation state of the responding cell. The various
effector phenotypes and distinct migratory patterns of trog+ cells add additional
layers of complexity to models of canonical T cell activation and differentiation.
The biological implications of trogocytosis-mediated signaling are underscored by
the fact that trogocytosis occurs at significant frequencies (~10-20%) in
responding T cells during an active immune response. Collectively, the published
literature, and the results from this dissertation, demonstrate the clear
immunomodulatory potential of trogocytosis, and subsequent signaling events.
A largely-understudied component of trogocytosis is how this event
impacts the trog+ cell itself. Studies have shown that irrespective of the context,
the trog+ cells show enhanced effector ability compared to their trog─
counterparts [406][282, 374, 391, 400]. The authors in these studies suggested
that trogocytosis was the result of a highly activated state in the trog+ cells. While
the heightened state of activation likely contributed to trogocytosis, the findings
here suggest that trogocytosis-mediated signaling itself could have been
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responsible for the observed phenotype in trog+ cells. While activated cells
perform trogocytosis more efficiently than naïve cells [391], the activation kinetics
of trog+ cells are not consistent with those of trog- cells after removal of TCR
stimulation [81,406,412]. This suggests that the trogocytosed molecules impact
the activation and, potentially effector functions of the trog+ cell. We previously
reported that T cells can engage their surface receptors with trogocytosed
signaling molecules to achieve sustained TCR signaling [81]. This signaling
correlated with a heightened activation state, and enhanced survival of the trog+
cells. Because the duration and frequency of TCR signaling can significantly
impact T cell activation, effector function, and differentiation, it is possible that
trogocytosis-mediated signaling impacts the trog+ cells beyond allowing for
sustained survival. The objective of this dissertation was to examine how
trogocytosis-mediated signaling impacted CD4+ effector function and subset
differentiation in the context of the trog+ T cell.

Part I. The Mechanisms of CD4+ Trogocytosis
On the Requirement for Active Signaling in T cell Trogocytosis
T cell trogocytosis is largely dependent on active signaling, and primarily
involves the acquisition of molecules that are bound to ligands on APC. However,
the acquisition of “bystander” molecules such as MHC class-I have been
observed on trog+ CD4+ T cells [523]. It has been proposed that such acquisition
occurs due the proximity of the non-engaged molecules to recycling TCR bound
to ligands on the APC. Support for this come from the findings by Gu et al., who
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demonstrated that CTLA-4 knockout nTreg, or iTreg with CTLA-4 neutralized with
anti-CTLA-4 Abs, acquired their CD80 and CD86 from DC [277]. This
trogocytosis event was not due to CD28 engagement with CD80/CD86 as
neutralizing antibody blockade against CD28 did not affect the acquisition of
CD80 or CD86. Curiously, they also reported that the addition of an endocytosis
inhibitor (unnamed) to T cell:DC co-cultures did not impact CD80/CD86
acquisition by the Treg. Thus, they speculated that Treg acquire CD80/86 via an
unknown mechanism independently of CTLA-4, CD28, or PD-L1 binding, or
endocytosis. Why they did not examine MHC in this study was unclear. One
possible explanation for these results could be that CD80/CD86 were transferred
via APC-derived exosomes that were bound to T cell surface receptors.

APC-Derived Exosome Acquisition as a Mechanism for Trogocytosis
The acquisition of pMHC complexes by T cells through APC or tumorderived exosomes has been found to confer T cells with antigen-presenting
ability, and has been proposed as one mechanism of intercellular membraneprotein transfer [524]. APC-derived exosomes include signaling, and nonsignaling molecules, including lysosomal membrane protein-1 (Lamp-1), CD86,
CD37, MHC1, MHCII, and transferrin receptor (TfR) [525-528]. Thus, the
acquisition of these exosomes is consistent with the presence of non-engaged
molecules detected on trog+ T cells. In support of this theory, cognate T cell
interactions with DC or B cells increase the rate of MHCII-rich exosomal
formation by APC [529]. Furthermore, DC and B cell-derived exosomes can
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stimulate activated, but not naïve CD4+ T cells both in vitro, and in vivo [529].
However, evidence suggests that exosomal acquisition of APC-derived
molecules is distinct from trogocytosis. For example, pre-treatment of DC with
the ATPase inhibitor CMA (which also inhibits exosome formation) prior to coincubation with CD8+ T cells, led to only a minimal decrease in PD-L1 transfer to
T cells [375]. However, separation of co-incubated T and DC by a trans-well
membrane prevented transfer of PD-L1 to T cells [375], suggesting that the PDL1 trogocytosis was contact-dependent. In a similar study using human cells,
while co-cultured DC and T cells resulted in high levels of HLA-DR acquisition,
separation of T cells and DC by a trans-well membrane inhibited virtually all
transfer of HLA-DR to T cells [410]. These studies did not account, for the fact
that contact with T cells induces increased exosomal release by APC [529].
Interestingly, when exosomes containing p:MHCII complexes and costimulatory
molecules were added to cultures of naïve CD4+ T cells, Ag-specific activation
occurred only in the presence of DC CD80+/CD86+, but was independent of
MHCII expression by the DC [530]. These results suggest that MHC acquired via
APC-derived exosomes is only functional upon T cell:APC contact.
Additional evidence discounting the role of exosomes as the mechanism
for trogocytosis come from findings with DC whose membranes were labeled
with the extremely stable lipophilic dye PHK26. Levels of PHK26 on the T cell
decreased between 6 and 24 h of iTreg co-incubation with DC while, in contrast,
levels of CD80 and CD86 increased [277]. This suggests that receptor-mediated
transfer was occurring, rather than absorption of membrane-bound exosomes
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which would be expected to increase the levels of PHK26 similarly to CD80/86
[277]. Our previous data using APC-conditioned media also observed minimal
acquisition of APC-derived exosomes by T cells [287]. In addtion, unpublished
data from our lab using mild acid treatment of antibodies against trogocytosed
molecules did not alter the amount of troocytosed molecules associated with a
trog+ T cell. These data show that the trogoctosed molecules are integrated into
the T cell membrane, even at early time points, and were not on APC-derived
exosomes adsorbed to the T cell surface.
While exosomes may contribute to the amount of transferred material to T
cells, exosomal transfer alone is unlikely to result in intracellular trogoctosis
mediated signaling. We, and others have observed trogocytosed molecules in
distinct, punctate spots on the surface of the T cell. These spots are orders of
magnitude larger than exosomes (~30-100 nm). Thus, dramatic re-arrangment of
TCR/costimulatory molecules as well as APC-acquired molecules via exosomes
would have to occur to form clusters equivelant to those which have been
visualized. If the observed spots of trogocytosed molecule/TCR complexes were
formed by T cell signaling events, then abolishing T cell signaling should lead to
the dispersion of molecules and loss of these spots. Such dispersion was not
observed in experiments where ZAP-70 signaling was inhibited with the Srk
kinase inhibitor PP2 [81]. Taken together, the published data suggests that
intracellular trogocytosis-mediated signaling is not dependent on exosomal
transfer.
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Microclusters as a Mechanism for Trogocytosis
Another potential mechanism for trogocytosis is the transfer of APC
molecules to the T cell via microclusters. We, and others have observed small
clusters of MHC being transferred from APC to T cells during the immune
synapse [397] [81]. In live-cell imaging experiments, it has been observed that
clusters containing pMHC move away from the immunological synapse and
migrate to the distal pole upon T cell:APC contact (Fig. 1.15). This transfer event
is strikingly similar to the formation of the distal pole complex or, the
“antisynapse” [70, 76]. A perplexing characteristic of the antisynapse is that,
despite its location at the distal pole, it contains active TCR signaling molecules
ZAP-70, LAT, PCLy1, P-Tyr, and Lck [76]. It has been proposed that the
formation of the antisynapse likely involves TCR microclusters which were
activated by pMHC that move to the distal pole [70]. That microclusters may be
involved in the active TCR signaling at the anti-synapse is strengthened from the
fact that TCR microclusters form an adhesion ring composed of LFA-1, focal
adhesion molecules paxillin and Pyk2, and myosin II (MyoII) [71]. It has been
proposed that this structure allows microclusters to exclude the suppressive
molecule CD45 and thus are able to retain active TCR signaling [69, 72, 74].
However, even by exclusion of CD45, there is little evidence that the TCR
proximal signaling complex would be sustained for the duration that has been
observed at the antisynapse, in the absence of MHC binding and subsequent
TCR signaling. Coincidentally, we have observed that the clusters of MHC which
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transfer to the T cell and localize to the distal pole also co-localize with TCR and
active proximal TCR signaling molecules ZAP-70, Lck, P-Tyr [81]. In fact, the
images we previously reported are strikingly similar to those of antisynapses (Fig.
5.1).

Further support for microclusters as a mechanism for trogocytosis, is that
microcluster formation is found to be resistant to treatment with PP2 [73]. This
potentially explains how punctate signaling complexes, or what I will refer to as
“trogosomes”, were observed after treatment of trog+ cells with PP2 [81]. The
uncanny resemblance between the antisynapse and our studies on trogocytosis
in the context of location and active signaling events, is consistent with the
hypothesis that active-TCR signaling at the antisynapse is driven by pMHC
complexes bound to the TCR.
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The location of APC-signaling molecules on the distal pole of the T cell
could result in trogocytosis when the T cell dissociates from the APC. In this
model, the transfer of APC-derived molecules is highly dependent on active
signaling, consistent with current models for trogocytosis. This would also
provide an explanation for the observed punctate spots on trog+ cells, which
would be derived from pre-existing microclusters rather than having to
independently form from re-expressed trogocytosed molecules. Consistent with
this possibility is the data from Fig. 3.3 which shows that pre-polarized TH2 cells
perform trogocytosis at significantly higher frequencies compared to polarized
TH1, or non-polarized cells. As TH2 cells have been observed to form multi-focal
synapses which resemble microclusters [83] this morphology could facilitate
trogocytosis of pMHCII and costimulatory molecules.
In this proposed microcluster model, it is possible that the acquired
molecules are endocytosed with recycling TCR. However, if a focal point of
signaling is already pre-established by the signaling complex formed at the distal
pole this would promote the migration of newly-bound TCR:pMHC to the site of
active signaling. This could be an explanation for the observed punctate
trogosomes detected on trog+ cells days after APC removal (Fig. 3.5).
It is possible that highly activated cells are more efficient at tearing off
membrane from the immunological synapse, as they have higher migration
patterns and form shorter synapses. Perhaps trogocytosis through this
mechanism would be more likely to enhance activation and effector functions of
the trog+ cell. The live-cell imaging should also be further analyzed, as the data
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show that as the T cell dissociates, the T:APC molecules bound near the dSMAC
appear to get “pulled in” towards the central point of T:APC contact and torn
away from the APC by the T cell. This is suggestive that the acquisition of
microclusters may also occur upon T cell dissociation.
The current literature has referred to trogocytosis in the context of all of
the aforementioned mechanisms, however this broad categorization has led to
contrasting results in not only the mechanisms of trogocytosis, but its biological
outcomes as well. The microcluster model fits well with our previous results, and
those in this study, showing that trogocytosis-mediated signaling is sustained for
up to 72 hrs after APC removal, and leads to increased activation and effector
cytokine production. In contrast, the acquisition of APC molecules not engaged
with T cell receptors through bystander endocytosis or exosomes may lead to a
different phenotype in the context of the trog+ cell. Whether there is a difference
in the overall result between the different mechanisms of APC-derived signaling
molecules remains to be determined.

Part II
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T:T Antigen Presentation and TrogocytosisMediated Signaling in T cell Activation, and
Immuno-Regulation
The results in this study suggest that trogocytosis-mediated signaling enhances
the activation state of the trog+ cell independently from activation by APC.
However, other studies have reported T:T presentation of trogocytosed
molecules signaling to inhibit the activation of responding cells. The most likely
explanation for such conclusions is simply, that the trog+ cells which induce
repressive modes of action are actually Treg, which are highly efficient at
performing trogocytosis. In such a case, trogocytosis-mediated interactions
would enhance the trog+ Treg suppressive capabilities rather than provide
insufficient signaling to induce anergy in activated cells. While some studies
claim that the trog+ cells which showed repressive functions were “not Treg”, the
argument for this is questionable. For example, Helft et al. reported that when
trog+ CD4+ cells were mixed with previously-activated T cells, T:T presentation of
Ag to activated cells induced responder cell death, but stimulated naïve T cells to
proliferate. The authors proposed that this was likely due to insufficient levels of
costimulatory molecules upon p:MHC presentation by trog+ cells. Interestingly,
when DC were added to cultures containing a mixture of trog+ and either
activated or naïve T cells, the presence of trog+ cells inhibited the activation of
activated, but not naïve cells, compared to controls which did not contain trog+
cells [429]. Firstly, activated cells require less stimulation than naïve T cells to
maintain an activated state, thus the argument for insufficient stimulation for
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naïve vs activated cells is not sound. Second, if insufficient stimulation by
trogocytosis-mediated signaling was the reason for activated cells to become
inactive, the addition of APC to mixed trog+/trog─ cultures should have rescued at
least some of the phenotype. Rather than determining the phenotype of the trog+
cells, it was suggested that because the suppression of activated cells occurred
in an Ag-specific manner, the trog+ cells were not Treg, which function in an Agindependent manner. In complete contradiction to this reasoning, a study by
Bacheli et al found that Treg efficiently perform trogocytosis and formed contacts
with responding T cells leading to a contact-dependent mechanism for
immunosuppression by trog+ Treg. [432]. In addition, three years prior to the
publication by Helft et al. it was published that Treg perform contact-dependent
immunosuppression through granzyme B release onto ligated cells [296]. While
insufficient levels of trogocytosed costimulatory molecules are likely to induce
anergy, inadequate phenotyping of the trog+ cells in previous studies has
resulted in a convoluted consensus of the impacts of non-Treg T:T presentation.
Our results suggest that in effector CD4+ cells, trogocytosis-mediated
signaling enhances the activation of the trog+ cells (Figs. 3.1, 4.1). This is
consistent with a role for trogocytosis signaling in the heightened state of
activation observed in trog+ cells from other studies. The sustained activation
observed here occurred in the context of peptide bound to MHCII. This timing is
the average t-1/2 half-life for peptide binding to MHC is ~72-96 hours, which is
consistent with the kinetics of trogocytosis-mediated signaling we have observed
in the activation state of trog+ cells recovered from BMDC, or other APC with
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non-covalent peptide. At later time-points, as peptide dissociates from MHC,
engagement with a combination of empty MHC and pMHC complexes would be
insufficient to trigger T cell responses.
Trogocytosis-mediated signaling also involves costimulatory receptor
signaling, which could also contextually lead to differences in TH subset
differentiation, for example, the acquisition of ICOS-L, and OX40L and
subsequent trogocytosis-mediated signaling promoting a TFH phenotype.
Costimulatory signaling through CD28 in the absence of TCR signaling has been
found to be sufficient to induce the nuclear translocation of NF-κB [531]. Thus, as
peptide dissociates from the MHC and TCR signaling dcreases, co-stimulatory
signaling may be playing a larger role in the apparent phenotype at later time
points.

Part III
Biological Implications of Intracellular TrogocytosisMediated Signaling
Implications of Trogocytosis-Mediated Signaling and a TH2 Phenotype
The strong correlation between trogocytosis and the subsequent T H2 phenotype
observed in chapter 3 supports the hypothesis that trogocytosis-mediated
signaling plays a role in T cell effector function and subset differentiation. In cells
that are weakly activated by APC (which also promotes T H2 differentiation),
trogocytosis-mediated signaling could help overcome the threshold of signaling
required for T cell survival and activation. In recently activated cells, or T H2
effector cells, the production of IL-4 driven by trogocytosis-mediated signaling
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could enhance cell survival [458]. By driving TH2 differentiation, trogocytosismediated signaling could further promote the survival of the trog+ cells by
increasing their resistance to Treg suppression. It has been found that TH2 cells
are resistant to galectin-mediated apoptosis by Treg, while TH1 and TH17 are
susceptible [299]. The TH2 phenotype could also aid in preventing an exhausted
phenotype from sustained trogocytosis-mediated signaling as TH2 cells suppress
the expression of the apoptosis-inducing antigen FAS Ligand, making them less
susceptible to activation induced cell death (AICD) [532]. On the other hand, TH1
cells are highly susceptible to AICD [533]. Interestingly, TH2, but not TH1, cells
have been shown to be able to revert from an anergic state to resume effector
functionality [459], which may promote the transition of TH2 cells to memory.
These characteristics may be a reason for the observed bias for trogocytosismediated signaling to drive a TH2 phenotype, over a TH1 or TH17 phenotype. The
high susceptibility of TH1 cells to Treg suppression and AICD may also help
explain the extremely low frequency of TH1 trog+ cells at later time-points.
The implications of trogocytosis-mediated signaling and development of a
TH2 phenotype were discussed in detail at the end of chapter 3. One additional
point of emphasis should be made regarding this phenotype in the context of
solid tumors. Increasing evidence has been found from both animal studies and
samples from human patients that trogocytosis occurs at high rates in solid tumor
environments and by multiple cell types [388, 389, 399, 435, 534, 535]. In these
cases of a localized tumor environment, a TH2 phenotype driven by trogocytosismediated signaling could inhibit TH1 effector functions, and the activation of naïve
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CD4 T cells. TH1 responses are generally considered protective in tumor models.
As Ag is removed from tumor cells the responding T cells would receive weaker
TCR signals from tumor cells or APC, leading to imbalanced TH2 differentiation
and augmenting a localized TH2 environment. This could lead to generation of a
non-protective humoral response. Effective immunotherapy against solid tumors
has not yet been developed. The results from this study suggest that the
differentiation/effector cytokine production by CD4+ trog+ T cells in the tumor
microenvironment is worthy of consideration in future strategies to combat solid
tumors.

Trogocytosis-Mediated Signaling in the Apparent TFH Phenotype
The phenotype observed in the trog+ cells in chapters 3 (TH2) and 4 (TFH)
overlap in that both of these subsets specialize in providing B cell help. The
differentiation towards TH2 could ultimately promote TFH differentiation by
increasing the proximity of the T cell to the B cell and increasing the likelihood of
interactions with cognate B cells. In addition, TH2 cells have been shown to
readily become TFH themselves [148, 231, 238]. In these studies, trogocytosismediated signaling drives cells towards a TFH-like phenotype, while still retaining
qualities of TH2. This possibility is supported by observations that TFH-like cells
can concurrently express Bcl-6 and GATA3 [148], and both TH2 and TFH cells
commonly express IL-4 [234, 238, 448, 481, 536]. It is temping to conclude that
the early TH2 phenotype developed by the trog+ cells may act as a favorable
intermediate for the TFH phenotype observed at later time-points.

212

An interesting observation from the results in chapter 4 was, in vivo,
the trog+ cells developed a TFH-phenotype more readily than trog─ cells (Fig.
4.11). In addition, when cultures of cells recovered from the trogocytosis assay
were supplemented with APC, a greater frequency of the trog+ cells displayed a
TFH-like phenotype compared to the trog─ cells (Fig. 4.7). These results suggest
that the trog+ cells were more efficient at becoming TFH upon initial priming by
APC compared to trog─ cells. This also raises the possibility that trogocytosismediated signaling may have significant impacts on the kinetics of GC formation
and B cell activation. By rapidly upregulating high levels of CXCR5 and
producing high levels of IL-21 (Figs. 4.2-5), the trog+ cells could rapidly provide
help to the B cells to increase Ab production, affinity maturation, class switching
and proliferation to further increase the chances of B:T cell interactions early
during the effector phase of the immune response. This is an area of active
inquiry in the Wetzel lab.
It is also likely that trogocytosis-mediated signaling would have significant
impacts on TFH differentiation in cases of low Ag. If a low number of APC
displaying cognate-Ag were present, Ag-specific T cell:APC interactions would
be less likely to occur. The current models of TFH differentiation require 2 or more
distinct T-APC interactions. However, the necessity for additional APC could be
circumvented by sustained trogocytosis-mediated signaling after the first
interaction, thus making the trog+ cells more likely to differentiate to TFH than the
trog─ cells.
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Finally, trogocytosis-mediated signaling also resulted in the sustained
expression of IL-21, and IL-4 by the trog+ cells (Figs. 3.3, 4.5). This is important
because the initial T-DC interactions that result in pre-TFH cells do not induce IL21 expression, which has been proposed to occur only after subsequent
interactions with B cells. This implies the Trog-mediated signaling is contributing
to full TFH differentiation. It is possible that the trog+ cells would be more efficient
TFH early in response by secreting high amounts of these cytokines in the GC
without requiring cognate B cell interactions. Furthermore, if trogocytosismediated signaling can drive TFH differentiation in the absence of B cells, then
the trog+ cells could act also as extra-follicular TFH-like cells, that readily provide
help to B cells outside of B cell follicles/GCs.
The sustained activation and high production of IL-4 and IL-21 by trog+
cells could also play a major role in humoral autoimmunity. Hyperreactive TH2
and TFH responses play a major role in Ab-mediated autoimmune diseases such
as myasthenia gravis, autoimmune thyroiditis, Sjögren’s syndrome, rheumatoid
arthritis (RA), multiple sclerosis, SLE, ulcerative colitis, Crohn's disease,
ankylosing spondylitis (spinal arthritis), and type 1 diabetes [245, 246].
Interestingly, extrafollicular cells, which resemble TFH, have been found to be key
mediators in such autoimmune diseases by forming ectopic lymphoid structures
with B cells to induce class switching, affinity maturation, and high antibody
production [537]. These structures have been observed in patients with RA [538],
and have shown to play a major role in progression of SLE [539]. It is possible
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that trogocytosis-mediated signaling could be contributing to the TFH-like
phenotype of these cells outside of the GC.

IL-21 promotes T cell Activation, Survival, Effector Function, and Memory
Generation
The high production of IL-21 by trog+ cells has biological implications
beyond driving a TFH phenotype and providing B cell help. IL-21 may contribute
to the sustained survival displayed by the trog+ cells, as IL-21 has been shown to
be critical for the survival of activated CD4+ and CD8+ T cells in cases where IL-2
is limited [540]. Is it also possible that IL-21 production by trog+ cells aids in their
ability to sustain effector functionality, as addition of IL-21 has been shown to
protect T cells from suppression by Treg [541]. In CD8+ T cells, IL-21 has been
shown to preserve effector function in exhausted cells, and presence of IL-21producing CD4+ T cells has been shown to enhance Ag-presentation and the
generation functional anti-tumor CTL [499]. This raises the possibility that IL-21producing trog+ cells may also play an important role in anti-tumor immunity.
Consistent with the results in chapter 4, IL-21 production driven by trogocytosismediated signaling may aid in the transition of trog+ cells to memory, as IL-21 is
critical for the formation of CD4+ and CD8+ memory T cells [440, 489].

Tcf1 is a Common Feature in TH2, TFH, and Memory Cells
A shared feature between the TH2, TFH, and memory-precursor
phenotypes observed in the trog+ cells here is expression of the repressive
transcription factor T cell factor 1 (Tcf1). The results in chapter 4 show that the
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trog+ cells displayed higher levels of Tcf1 compared to trog─ counterparts, and it
is possible that Tcf1 was playing a central role in the observed differentiation
patterns.
Tcf1 likely contributed to the TH2 phenotype observed in chapter 3, as
Tcf1 suppresses IFNγ and IL-17 expression, and it enhances the expression of
GATA-3 [9, 244]. Consistent with the results from chapter 4, Tcf1 also is critical in
TFH differentiation by regulating Blimp1 expression and repressing IL-2 signaling
to promote the expression of Bcl-6 [227]. The high levels of Tcf1 expression in
the trog+ cells may explain their ability to develop a TFH-like phenotype in the
presence of high levels of IL-2. In addition, in a viral model Tcf1 had a critical role
in TFH development, and was required for memory T cell formation [542]. Human
lymph nodes have also been found to contain memory T cells which maintain
high expression of TCF1, and these cells show superior functional potential
compared to TCF1low memory cells [543]. Similar to the phenotype of the trog+
cells in chapter 4, during T cell asymmetric division Tcf1 is inherited by the distal
daughter cell and correlates with self-renewal and the transition to memory [491].
The regulation of Tcf1 is also consistent with a model in which
trogocytosis and trogocytosis-mediated signaling are correlated with weaker TCR
signaling. Strong TCR signaling has been shown to repress Tcf1 expression
through high levels of PKCθ activation [522]. In addition, inflammatory cytokines
such as IL-12 can suppress Tcf1 activation and drive effector differentiation
[544]. It is possible that the IL-4 expression driven by trogocytosis-mediated
signaling acts to shield the trog+ cells from inflammatory cytokines through a
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negative-feedback loop and aids in their progression to become a memory cell.
The compelling correlation between Tcf1 function in each of the phenotypes
observed in trog+ cells in this study suggest that Tcf1 plays a central role in T cell
differentiation via trogocytosis-mediated signaling.

Trogocytosis-Mediated Signaling in CD4+ Memory Generation
Trogocytosis-Mediated Signaling in Effector-to-Memory Transition
Our previous results [81], and results from this study, show that despite similar
activation by APC, the trog+ cells display superior survival compared to trog─
cells after APC removal (Fig. 2.1). Results in chapter 4 show that trogocytosismediated signaling was necessary for the high levels of IL-2 expression by the
trog+ cells, which was a major contributor the survival of both trog+ and trog─ cells
(Fig. 4.19). These results suggest that trogocytosis-mediated signaling can
promote effector-to-memory transition, as it has been found that autocrine IL2/IL-2R signaling induced by late-cognate interactions with APC are required for
memory transition [317]. As mentioned above, it is also likely that the IL-21
produced by the trog+ cells would aid in the transition to memory, as IL-21 has
been found to be critical in CD4+ memory formation [440].
The sustained TCR downmodulation by the trog+ cells also has
implications for memory transition. While trogocytosis-mediated signaling may be
sustained at a level which promotes survival and licensing to become memory,
subsequent interactions with APC may drive terminal effector differentiation of
the trog+ cell. By maintaining low levels of surface TCR, the chances of
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subsequent interactions between the trog+ cells and APC would be decreased,
thus favoring memory formation over terminal-effector differentiation.
Currently, the mechanisms which allow memory cells to persist after Ag
clearance are not well defined. The data presented here raise the possibility that
trogocytosis-mediated signaling plays a role in the sustained survival of the trog+
cells and subsequent effector-to-memory transition.

Trogocytosis-Mediated Signaling in T cell Memory Generation via
Asymmetric Division
The results in chapter 4 show a strong correlation for trogocytosis and
asymmetric division. The presence of trogocytosed molecules on the cell
resembling the distal daughter cell during asymmetric division could be
established during the immunological synapse. However, our results showed that
it was apparent that trogocytosis-mediated signaling enhanced the survival of
trog+ cells and was critical for the proliferation, and survival of the lesser
activated cells. The initial description of asymmetric division and memory
development suggested differential signaling at the synapse and the distal region
of the cell set up the asymmetry. Our imaging experiments show reduced, but
present, signaling at the distal pole associated with trogocytosed molecules. This
may have major biological implications in the context of memory formation, as
cells which receive stronger signaling develop terminally-differentiated effector
cells, while the cells which receive less intense signaling upon activation retain
high memory-potential.
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In addition to promoting the survival of cells which received weaker
signals from APC, it is possible that trogocytosis-mediated signaling plays a role
in the asymmetric division of cells. An unknown variable in the model for
asymmetric division is how a T cell which has been separated from an APC for
several rounds of cell division is able to maintain its axis of polarity established at
the immune synapse. One proposed mechanism is strong PI3K signaling and the
formation of the proximal TCR signaling complex established this polarity [513].
However, this still does not explain how the polarity is maintained long after the T
cell separates from the APC and has undergone multiple rounds of cell division.
It is possible that the sustained trogocytosis-mediated signaling at the distal pole
complex/antisynapse is responsible for maintaining this polarity.

Proposed Model for the Presented Results
The phenotypes displayed by the trog+ cells in this study can be centered
around a few common mechanisms, all of which can enhance the survival of the
trog+ cell. In the context of trogocytosis-mediated signaling, the most obvious
factor is the signaling itself. The results in this dissertation show that
trogocytosis-mediated signaling can influence the activation, proliferation, and
survival of the trog+ cell after APC removal. In addition, the primary cytokines we
found trogocytosis-mediated signaling to promote were IL-2, IL-4, and IL-21.
These cytokines are all able to promote CD4+ T cell survival, and depending on
the context of TCR/costimulatory signaling, could differently impact the effector
functions and differentiation of the trog+ cell. For example, strong trogocytosis219

mediated signaling in the presence of IL-21 could lead to TFH differentiation, while
weaker signaling would further promote IL-4 production. IL-4 in the context of
trogocytosis-mediated signaling could then drive GATA-3 expression and TH2
differentiation. Trogocytosis-mediated signaling could also enhance the T cell
memory pool through the survival of memory-precursors formed through
asymmetric division. By rapidly, and sustainably, producing high levels of IL-2 the
trog+ cells could aid in the proliferation of not only the trog+ cell, but the
surrounding trog─ cells as well. Later in the immune response IL-2 and IL-21
have been found to be critical in generating a stable memory T cell population
from effector cells, again, in the context of TCR signaling. The common theme in
these potential outcomes, is these are all mechanisms that could enhance the
survival of the trog+ cell through potentially self-sustainable mechanisms.
Throughout this dissertation I have also proposed that trogocytosismediated signaling of relatively weak strength, at least when compared to
signaling from interaction with APC. This hypothesis is supported in that, weak
TCR signaling can drive TH2-differentiation, and promote memory formation,
which is consistent with the phenotypes observed in trog+ cells in this study. TH2
cells display superior survival mechanisms compared to inflammatory subsets
such as TH1 and TH17. It is possible that the survival of the individual cell would
be enhanced through phenotypic changes towards a less inflammatoryassociated subset such as the TH1 to TH2 conversion seen in Fig. 3.7 or become
a memory T cell as proposed in chapter 4. Weak signaling also promotes Tcf1
expression, which as mentioned above, can drive TFH, TH2, and memory T cell
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formation. In addition, it is likely that strong trogocytosis-mediated signaling
would lead to T cell exhaustion. Thus, the surviving trog+ cells are primarily those
receiving a sustainable level of continual signaling.
This raises the question of whether the weak signaling by trogocytosismediated signaling drives phenotypes, or simply maintains the survival of cells
programmed towards a particular subset by APC. Both of these possibilities are
likely scenarios.
In an in vitro system where transgenic cells display uniform TCR and APC
which display the same peptide antigen, if all T cells encounter Ag and are
similarly activated, why do some cells perform trogocytosis while others do not?
In this scenario, a major variable is the duration of contact between T cell and
APC. If this is the case, then why did the trog+ cells display a phenotype
associated with weaker T cell signaling (TH2), while the trog─ cells displayed a
phenotype associated with stronger signaling (TH1)? These data are seemingly
contradictory to the published data showing that T cell trogocytosis is associated
with a heightened state of activation, which is also what was observed here, as
indicated by CD69 levels in the trog+ and trog─ cells (Figs. 3.1, 4.1).
One possible example is that the acquisition of pMHC/costimulatory
molecules occurs via microclusters. Microclusters can localize to the distal pole
rapidly upon T:APC contact, but become recruited to the immunological synapse
within minutes. Therefore, if a T cell were to form a short-lived synapse and
spontaneously dissociate before the microclusters integrate into the SMAC, this
would result in the transfer of pMHC/costimulatory molecules to the T cell.
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Consequently, in the in vitro system used here, it is likely that a shorter synapse
would also be associated with weaker TCR signaling events. The weaker
signaling would allow the trog+ cells to retain high Tcf1 levels which could
promote a TH2 and/or TFH phenotype, effector-to-memory transition, or memoryprecursor formation through asymmetric division. In contrast, longer-lived
synapses would allow extra time for pMHC complexes in these microclusters to
migrate back towards the immune synapse and thus would be less likely to be
acquired by the T cell. The extended duration of the synapse would likely also
subsequently lead to stronger signaling, providing an explanation for the
predominant TH1 phenotype and nearly exclusive IFNγ expression by the trog─
cells observed in chapter 3.
In addition, the morphology of microclusters granting them ability to
exclude regulatory molecules allows them to sustain active signaling for longer
durations compared to TCR in the sMAC. This could also play a significant role in
the sustained trogocytosis-mediated signaling observed in this study.
If a weaker signal promotes TH2 and memory generation, then why do
the trog+ display equal, if not greater levels of CD69 compared to the trog─ cells
immediately after recovery from APC? Figures 3.1 and 4.1 show that the trog+
cells not only maintained high CD69 expression after APC removal, but levels of
CD69 increased over subsequent incubation. This strongly suggests that
trogocytosis-mediated signaling was driving CD69 expression, as in absence of
stimulation, CD69 levels peak within 24 hours of stimulation. Therefore, it is
possible that compared to the trog─ cells, the trog+ cells were not as activated by
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the APC, but this was not reflected in their activation state due to trogocytosismediated signaling augmenting CD69 expression in the trog+ cells.
This proposed models is intended to serve as an explanation for the
results obtained in this study, however as described in earlier sections, the broad
consequences of trogocytosis-mediated signaling are likely context dependent.

Outro
As the number of identified TH subsets continues to grow, and plasticity
between differentiated subsets is becoming more apparent, determining the
exact mechanisms governing TH differentiation has become a challenging topic
of research. In particular, the multi-step processes involved in the generation of
TFH comes with extra layers of complexity. In addition to TH differentiation, the
mechanisms which drive memory formation are largely unknown. This combined
lack of knowledge has been a major roadblock in vaccine design and efficacy,
and anti-tumor immunotherapy. Therefore, improving our understanding of the
mechanisms governing the differentiation of effector subsets, and memory cells
are of paramount importance in human health. The results here provide insight
into a novel mechanism for CD4+ T cells to differentiate towards TH2 and/or TFH
in the absence of further interaction with APC. They also provide compelling
evidence for trogocytosis-mediated signaling to play a role in the generation of
CD4+ memory cells through effector-to-memory transition, and asymmetric
division.
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I will end with a few questions for speculation. Could there be a distinct
phenotype of T cell which displays all of these characteristics? Is trogocytosis
simply a common, but understudied mechanism in the differentiation of these
subsets? And finally, does weak TCR signaling itself promote a TH2 phenotype
and memory formation, or does weak TCR signaling actually promote
trogocytosis?

Future Directions
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To address whether a shortened T cell:APC contact leads to increased
trogocytosis via microclusters, additional live-imaging experiments should be
conducted over a wider time-course to observe the rate of dissociation in
comparison to the MHC that remains on the T cell microclusters. Additionally,
collecting the cells which spontaneously dissociate from APC at different time
points for immediate analysis, and assessment of the downstream phenotype will
help address the hypothesis that shorter T cell:APC contact duration favors
trogocytosis and memory cell generation.

While the differentiation of previously-activated trog+ cells in chapter 3 was
towards a TH2 phenotype, this could be an artifact of the APC used in the
system. While a greater frequency of the trog+ cells from BMDC produced IL-4
compared to the trog─ cells, the frequency of IL-4+ trog+ cells was substantially
lower in cultures from BMDC vs MCC:FKPC APC. This is likely due to the
weaker activation state induced by the FKPB:APC compared to BMDC which has
been shown to promote TH2 differentiation. In addition, other model systems
should be utilized with pathogen-associated antigenic proteins in in vivo studies,
or the addition of different agonists which trigger separate TLR/RLR (PRR
receptors) to observe whether the TH2 phenotype of trog+ cells holds true in
inflammatory settings which promote a TH1 phenotype.

While we observed a phenotype in the trog+ cells consistent with TFH, it was not
actually demonstrated that the trog+ cells were indeed TFH, as defined by their
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ability to help B cells. Further studies to examine the functional role of trog+ cells
in the help of B cells should therefore be conducted to confirm this phenotype.
Assays should include B cell help assays containing mixtures of trog+ and trog─
FACS sorted cells to assess B cell activation, class switching, and proliferation.
To assess the migratory location, FACS-sorted trog+ and trog─ cells may be
labeled with different dyes and adoptively transferred in to mice 3-5 days
following immunization with either a cognate or irrelevant Ag. Histology on the
lymph nodes to observe the proximity of the trog+ cells and trog─ cells to B cell
follicles can be assessed 12-24 hours post-transfer, and 48-72h post-transfer to
also stain for Ig class switching proximal to the trog+ or trog─ cells. If the trog+, but
not trog─ cells migrate to the B cell follicle/GC in animals immunized with
irrelevant Ag, this would suggest that the trog+ cells are able to home towards B
cell follicles independently of cognate B cell interactions. The role of trogocytosismediated signaling through costimulatory molecules shown to be involved in TFH
differentiation such as ICOS:ICOS-L and OX40:OX40-L interactions, should also
be assessed. The acquisition of these molecules is likely to impact IL-21 and Bcl6 expression through trogocytosis-mediated signaling.

It is also possible that trogocytosis-mediated signaling could lead to the
generation of extrafollicular cells displaying a TFH-like phenotype, including IL-21
secretion, which have been observed in other studies [242]. This is a possibility
that should be examined further, as this would be an area where trogocytosismediated signaling would be most influential on the immune response, as
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opposed to GCs where the all of the CD4+ T cells in proximity would have access
to APC contact.

In the context of asymmetric division, it is possible that the axis of polarity are
maintained by trogocytosis-mediated signaling at the distal pole. This is an
intriguing hypothesis that should be explored further. While it was difficult to
ascertain whether this possibility was true due to the massive cell death and
decreased proliferation of the trog+ cells when trogocytosis-mediated signaling
was neutralized with anti-I-Ek/CD80 antibodies, it is possible that the
supplementation of sufficient survival cytokines would allow the T cells to survive
and proliferate long enough to examine this possibility. I did find some evidence
for reduced asymmetric distribution in the few cells which divided in cases where
trogocytosis-mediated signaling was neutralized (data not shown). However, due
to extremely low cell numbers, I cannot conclude with confidence that
trogocytosis-mediated signaling promotes asymmetric division.

Following up with the asymmetric division model, another interesting possibility is
the potential role for the molecule CD43. Thought to be due to its repressive
activity and physically large size, CD43 has been observed to become excluded
from the immunological synapse, and travel to the distal pole complex during the
immune synapse. Interestingly, anti-CD43 Ab-induced CD43 signaling alone in
TH2 cells led to IL-4 production, increased proliferation, and CD69 and CD25
upregulation [545]. CD43 signaling has also been found to act as a costimulatory
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molecule, acting independently of CD28 to enhance T cell activation, particularly
in low levels of TCR signaling. High levels of CD43 signaling have been shown to
inhibit TCR/CD3-mediated apoptosis, which may aid in the survival of trog+ cells
expressing pMHC. Due to its physical size, CD43 has also been proposed to
inhibit cell:cell interactions, and thus could prevent MHC-recognition and killing of
trog+ by CTL. The role of CD43 in the activation, differentiation, and survival in
the context of trog+ cells is worth examining further.

Signaling through Notch proteins may also play a role in trogocytosis. These
previously overlooked molecules have been shown to play significant roles in T,
and other cell development and activation. Interestingly Notch signaling has been
found to be important in activating the long isoforms of Tcf1, which promote TFH
differentiation and are critical for memory formation, at least in the context of a
viral model [542]. Therefore, the presence of these molecules should be
assessed on trog+ cells, as well as determining whether they play a role in
trogocytosis, and/or trogocytosis-mediated signaling.

In the context of Tcf1, the Wnt/-catenin pathway is an important regulator of
Tcf1 and should be further examined in the context of trogocytosis-mediated
signaling.
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